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ABSTRACT

Thermodynamically-Constrained Computational Modeling of
Lung Tissue Bioenergetics and the Effect of
Hyperoxia-Induced Acute Lung Injury
Xiao Zhang, B.S.
Marquette University, 2019
Altered lung tissue bioenergetics is an important and early step in the
pathogenesis of acute lung injury (ALI), one of the most common causes of admission to
medical ICUs. A wealth of information exists regarding the effect of ALI on specific
mitochondrial and cytosolic processes in isolated mitochondria, cultured endothelial cell,
and intact lungs. However, the interdependence of lung cellular processes makes it
difficult to quantify the impact of a change in a single or multiple cellular process(es) on
overall lung tissue bioenergetics. Integrating bioenergetics data from isolated
mitochondria and intact lung is necessary for determining the functional significance of
targeting a specific cellular process for prognostic and/or therapeutic purposes. Thus, the
main objective of my dissertation was to develop and validate comprehensive,
thermodynamically-constrained models of mitochondrial and lung tissue bioenergetics,
and to use these models to predict the impact of ALI-induced changes in mitochondrial
and cytosolic processes on lung tissue bioenergetics. For Aim 1, I developed an
integrated model of the bioenergetics of mitochondria isolated from rat lungs, which
incorporates the major biochemical reactions and transport processes in lung
mitochondria. The model was validated by assessing its ability to predict experimental
data not used for parameter estimation. The model provides important insights into the
bioenergetics of lung mitochondria and how they differ from those of mitochondria from
other organs. For Aim 2, I developed and validated an integrated computational model of
lung tissue bioenergetics. The model expanded the computational model developed under
Aim 1 by accounting for glucose uptake and phosphorylation, glycolysis, and the pentose
phosphate pathway. The model was then used to gain novel insights into how lung tissue
glycolytic rate is regulated by exogenous substrates, and assess differences in the
bioenergetics of isolated mitochondria isolated from lung tissue and those of
mitochondria in intact lungs. For Aim 3, the models developed under Aims 1 and 2 were
used to quantify the impact of previously measured changes in specific mitochondrial
processes in a rat model of clinical ALI on lung mitochondrial and tissue bioenergetics.
To the best of our knowledge, the two computational models are the first for lung
mitochondrial and tissue bioenergetics. These models provide a mechanistic and
quantitative framework for integrating available lung tissue bioenergetics data, for testing
novel hypotheses regarding the role of different cytosolic and mitochondrial processes in
lung tissue bioenergetics and the pathogenesis of ALI, and for identifying potential
therapeutic targets for ALI.
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Chapter 1 : Introduction and background
1.1 Clinical motivation
Acute lung injury (ALI) and its most severe form acute respiratory distress
syndrome (ARDS) are a major cause of morbidity and mortality in medical intensive care
units (ICU) [1, 2]. ARDS occurs in ~200,000 patients in the U.S. per year and carries a
mortality rate of 30-40% despite the best supportive care [3].
One reason for this high mortality rate is the lack of a clinical means for early
detection of ALI/ARDS [2]. For instance, Herasevich et al. revealed that bedside
providers are unable to detect ALI early enough in 70% of ALI patients [4], which delays
the administration of available treatments at a time when interventions are most effective.
Another reason for the high mortality rate is the lack of effective therapies. Several
potential pharmacologic therapies have been evaluated in clinical trials for the treatment
of ALI/ARDS [1]. These treatments include glucocorticoids, surfactants, inhaled nitric
oxide, antioxidants, protease inhibitors, and a variety of other anti-inflammatory
treatments. Unfortunately, to date none of these pharmacologic treatments has proven to
be effective. As a result, existing treatments are mostly supportive. For example, one
essential therapy is lung-protective mechanical ventilation with high oxygen (O2)
concentrations to reverse hypoxemia (i.e. low blood O2) and hypoxia (low tissue
oxygenation) associated with ALI/ARDS. Even though this therapy can help restore
blood O2 level to close to its normal level, it has serious side effects [1, 2]. For instance,
exposure to O2 at high concentrations for extended periods is known to cause lung injury
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due to oxidative stress [5], and exacerbates lung injury associated with common causes of
clinical ALI/ARDS [6, 7]. Furthermore, the positive pressure used in mechanical
ventilation may lead to over-distention of the alveoli and as a result may cause
mechanical injury to the epithelial cells and exacerbate lung injury. Recent advances
including PEEP (positive end-expiratory pressure) and lung-protective ventilation have
significantly reduced the risk of mechanical injury [8, 9] and improved outcomes.
Thus, there is an urgent need for a clinical means for early detection of
ALI/ARDS and novel treatments options for ALI/ARDS. As such, the long-term goal of
this work is to develop a mechanistic and quantitative approach to identify novel cellular
targets for therapeutic and/or prognostic purposes in patients with ALI/ARDS.

1.2 Etiology, pathophysiology, and pathogenesis of clinical ALI/ARDS
Clinical ALI/ARDS can be due to a direct or indirect insult to the lung [2, 3]. The
most common direct insult is pneumonia. Less common direct insults include inhalation
injury, pulmonary contusions, reperfusion injury, fat emboli, and near drowning. The
most common indirect insults include sepsis, severe trauma, and shock. Less common
indirect insults include multiple blood transfusions, burns, head injury, drug overdose,
and cardiopulmonary bypass.
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Figure 1.1: Pathogenesis of ALI/ARDS. Reproduced from reference [2].

As shown in Figure 1.1 and Figure 1.2 [2, 3], cardinal features of clinical
ALI/ARDS include compromised lung alveolar-capillary barrier and pulmonary edema,
which leads to impaired gas exchange and hypoxemia, multi-organ failure, and often
death. Clinical criteria for ALI/ARDS include bilateral pulmonary infiltrate on chest
radiographs reflective non-cardiogenic pulmonary edema, and hypoxemia as measured by
the ratio of partial pressure of arterial O2 (PaO2) and fraction of inspired O2 (FiO2).
Normal PaO2/FiO2 is ~500 mmHg as compared to PaO2/FiO2 ≤ 300 mmHg for ALI and ≤
200 mmHg for ARDS [1].
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Figure 1.2: The injured alveolus in the acute phase of ALI (right) compared to normal
alveolus (left). Reproduced with permission from [3], Copyright Massachusetts Medical
Society.

There is sufficient evidence that enhanced reactive oxygen species (ROS)
generation and inflammation play a key role in the pathogenesis of ALI/ARDS [2].
Neutrophils accumulate in lung microvasculature in response to the pulmonary insult and
become activated. As a result, a number of toxic mediators are released from neutrophils,
including oxidants, leukotrienes and proteases (Figure 1.2). These mediators can cause
damage to lung endothelial and epithelial cells and eventually lead to cell death including
apoptosis and necrosis [10].
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1.3 Hyperoxia-induced ALI/ARDS
Several animal models of clinical ALI/ARDS have been developed to further
understand the pathogenesis of ALI/ARDS [11, 12]. As mentioned above, prolonged
exposure to high O2 (hyperoxia) can lead to lung injury consistent with clinical ALI.
Crapo et al. [12, 13] demonstrated that the extent of hyperoxia-induced ALI is dependent
on O2 concentration and exposure duration. They provided a detailed description of
histologic and morphometric changes in lungs of rats exposed to 100% O2 hyperoxia.
Specifically, they observed no structural or functional changes in lungs of rats exposed to
100% O2 for up to 40 hours. However, the lungs of rats exposed to 100% O2 for 60 hours
showed significant cellular and functional changes, including loss of capillary endothelial
cells and cell surface, infiltration of phagocytic leukocytes, and an increase in the
thickness of air-blood barrier. Longer exposure periods resulted in additional loss of
endothelial cells, compromised microvascular capillary permeability, severe hypoxemia
and death within 64 to 72 hours.
Although the mechanisms that lead to pulmonary hyperoxic injury are not fully
understood, there is ample evidence that the deleterious effects of high O2 are the result
of increased formation of ROS such as superoxide (O•2 ) , hydrogen peroxide ( H 2O2 ) and
hydroxyl radical ( OH • ). Excessive ROS can readily react with tissue structures and
macromolecules (e.g. DNA, proteins, lipids) and cause damage to the lung endothelial
and epithelial cells.
Cellular antioxidant mechanisms can detoxify ROS via enzymatic (e.g.
superoxide dismutase, SOD (MnSOD and CuZnSOD); catalase, CAT; glutathione (GSH)
system; thioredoxin (TRX) system) and non-enzymatic (e.g. vitamins C and E) processes.
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Superoxide can be efficiently catalyzed into H2O2 by intra- and extra-matrix SODs [14],
and the resulting H2O2 can then be reduced to water by CAT, the GSH system, or the
TRX system. GSH is one of the most abundant cellular antioxidants. It exists in both
cytosol and mitochondria. The pentose phosphate pathway and the GSH redox cycle are
the major sites for GSH synthesis [15]. Up-regulation of the cytosolic GSH redox cycle
has been shown to protect the lung cells from oxidant injury, including key mitochondrial
enzymes [13, 16]. However, during the pathogenesis of ALI/ARDS, uncontrolled
increase of ROS production is suggested to overwhelm the capacity of antioxidant
mechanisms, resulting in oxidative stress with damage to lipids, proteins and DNA [17].

1.4 Lung mitochondrial and tissue bioenergetics
Altered lung tissue bioenergetics (i.e. cellular capacity for ATP production) play a
key role in the pathogenesis of hyperoxia induced ALI/ARDS. The following is a brief
summary of the key substrates and cellular processes that affect lung mitochondrial and
tissue bioenergetics.
Glucose is the major energy substrate for lung. Even though fatty acids and amino
acids can also be oxidized by lung, their contributions for the lung energy metabolism are
relatively small compared to that for glucose [18]. Gluconeogenesis does not occur in
lung, and glycogen stores are limited so that glycogenolysis is not prevalent, and the lung
depends primarily on the circulation for its glucose needs for energy production [18].
Mitochondria are the major site of energy production in lung, accounting for 85%
of ATP production in the whole organ, while glycolysis accounts for the other 15% of
ATP production [18]. Glycolysis and the pentose phosphate pathway (PPP) are two key
pathways for glucose catabolism in cytosol. Around 11% of consumed glucose enters the
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PPP, with some of the generated ribose 5-phosphate (R5P) subsequently used for the
synthesis of nucleotides [18]. Unused R5P reenters the carbohydrate pool [18, 19]. In
glycolysis, glucose is broken down to pyruvate and lactate through a series of enzymatic
reaction processes with two ATP molecules consumed at hexokinase (HK) and
phosphofructokinase (PFK) catalyzed reaction processes, and subsequently four ATP
molecules are generated at phosphoglycerate kinase (PGK) and pyruvate kinase (PK)
catalyzed reaction processes. Therefore, there is a net production of two ATP molecules
for each glucose that is consumed via glycolysis. All the generated lactate and some of
the pyruvate are released into the blood from the cytosol [18]. Most of the generated
pyruvate enters the mitochondria to generate the majority of lung tissue ATP via the
coupled processes of pyruvate oxidation and the reactions of tricarboxylic acid (TCA)
cycle, electron transport chain (ETC) and oxidative phosphorylation (OxPhos).
Specifically, in mitochondria, pyruvate is oxidized by pyruvate dehydrogenase
(PDH) to produce acetyl-CoA (ACoA), which enters the TCA cycle to generate the
reducing equivalents or the coenzyme electron donors NADH and FADH2 (reduced
forms of pyridine nucleotide and flavin adenine dinucleotide). NADH and FADH2 then
enter the ETC at complex I and complex II, respectively, passing electrons to UQ to form
UQH2. At complex III, UQH2 passes two electrons to cytochrome c (UQH2 oxidized,
cytochrome c reduced). Cytochrome c is then oxidized by O2 at complex IV to form
water. At the same time, protons are pumped from the mitochondrial matrix into the
intermembrane space at complexes I, III and IV, generating proton gradient (ΔpH) and
membrane potential (ΔΨ) across the inner membrane. Using the energy provided by the
proton motive force (membrane potential and proton gradient), ADP is phosphorylated to
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ATP at complex V. Mitochondrial membrane potential (ΔΨ) is a key component in the
bioenergetics that controls ATP production and mitochondrial redox status, and is
associated with apoptosis (programmed cell death). A change in ΔΨ is indicative of
mitochondrial dysfunction, and the collapse of ΔΨ is an early sign of apoptosis.
The outer mitochondrial membrane (OMM) has the voltage-dependent anion
channels (VDACs) that allow free passage of ions and metabolites (respiratory substrates,
phosphates, and adenine nucleotides) into and out of the mitochondrion, while the inner
mitochondrial membrane (IMM) is impermeable to most ions and metabolites. Several
transporters, including metabolite carriers, inorganic phosphate carrier (PIC) and adenine
nucleotide translocase (ANT), exist in the IMM to facilitate the transport of specific ions
and metabolites into and out of the mitochondrial matrix.

1.5 Role of lung mitochondrial dysfunction in the pathogenesis of
hyperoxia-induced ALI/ARDS
As mentioned above, prolonged exposure to hyperoxia leads to ALI/ARDS [2].
Rats exposed to > 95% O2 environment develop ALI and die within 64-72 hours from
lung injury [5]. Rat exposure to hyperoxia is a well-established animal model of human
ALI/ARDS that can reproduce the cardinal features of clinical ALI/ARDS, including
epithelial injury, neutrophilic infiltration and edema accumulation. There is ample
evidence that oxidative injury causes an increase in the rate of ROS production plays a
key role in the pathogenesis of hyperoxia-induced lung injury [5, 17]. The mitochondrial
ETC is the main source of ROS under hyperoxic conditions [17]. As shown in Figure 1.3,
excess mitochondria ROS cause damage to mitochondrial proteins, membranes and
DNA, and impair ATP production. In addition, mitochondria ROS cause damage to

9
cardiolipin and increase the release of cytochrome c, and initiate mitochondria
permeability transition pore (PTP) opening, mitochondria swelling, outer-membrane
rupture, and eventually cell death [14].

Figure 1.3: Overview of the diverse roles of mitochondrial ROS [17]. Figure reproduced
from [17] with permission from Portland Press.

A wealth of information exists regarding bioenergetic cellular processes measured
in mitochondria isolated from rat lungs, cultured pulmonary endothelial cells, and intact
rat lungs, and the effects of prolonged exposure to hyperoxia on these processes [7, 18,
20-24]. Audi et al. demonstrated 50% decrease in complex I activity in lungs of rats
exposed to 85% O2 for 48 hrs [25]. Sepehr et al. demonstrated a decrease in complex I
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(77%) and complex II (63%) activities in lung homogenates of rats exposed to >95% O2
for 48 hrs [26]. The decrease in complex I activity could be attributed to the oxidation of
cardiolipin [10], which is important for electron transfer in the ETC. Besides, 7 out of the
45 complex I subunits are encoded by mtDNA, which is known to be highly sensitive to
mitochondrial ROS damage [26].
Mitochondrial dysfunction is associated with energy deficiency since
mitochondria are the major site of ATP production, accounting for 80-85% of ATP in
lung tissue [18]. Even though cytosolic glycolysis can partially compensate for the lost
ATP production in mitochondria, it is not enough to maintain the lung ATP level [16].
Bongard et al. [16] demonstrated that inhibition of mitochondria complex I decreased the
whole lung tissue ATP level by ~60% and compromised microvascular permeability as
measured by an increase in pulmonary vascular endothelial filtration coefficient (Kf, a
sensitive measure of endothelial barrier function) by 262%, consistent with the need for
ATP to maintain the barrier function of endothelial cells. Moreover, they demonstrated
that the decrease in lung tissue ATP and the increase in Kf can be reversed by adding
coenzyme Q1 (CoQ1). The oxidized form of CoQ1 can be reduced to CoQ1H2 by cytosolic
enzyme NADPH-quinone oxidoreductase 1 (NQO1) and by complex I. CoQ1H2 then
enters mitochondria, passes electrons to complex III, and hence bypass complex I to
restore mitochondrial bioenergetics [16]. These results suggest that altering mitochondrial
bioenergetics can reproduce one of the cardinal features of ALI, and hence are consistent
with an important role for mitochondrial bioenergetics in the pathogenesis of ALI.
Furthermore, the results suggest that manipulation of mitochondrial pathways are
potential therapeutic targets for ALI/ARDS.
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Pulmonary edema formation and clearance are regulated by changes in osmotic
pressure [27]. For edema clearance processes, Na+ is transported from lung alveolar fluid
into pulmonary circulation, and as result an osmotic gradient is created. The alveolar
fluid can then be reabsorbed by this osmotic gradient. The active transport of Na+
requires energy, and hence is ATP dependent via the Na,K-ATPase. The Na,K-ATPase
pump is a key transporter of Na+ and thus is important for lung edema clearance. For
instance, Lecuona et al. demonstrated that Na,K-ATPase activity is significantly inhibited
in acute lung injury, resulting in edema in interstitial space [28]. Moreover, a study by
Factor et al. suggested that over-expression of Na,K-ATPase in rats improved alveolar
fluid clearance and protected rats against hyperoxia-induced ALI as measured by the
increase in the time these rats survived in >95% O2 environment [29]. Overall, the
requirement of ATP for edema clearance underscores the importance of bioenergetics in
the progression of lung diseases, including ALI.

1.6 Computational models of lung and other tissue mitochondrial
bioenergetics
There is a wealth of data on the bioenergetics of lung tissue at the molecular,
cellular and whole organ levels, and on the impact of lung injury on mitochondrial
enzymes, transporters and macromolecules [7, 16, 18, 20-24]. However, quantitative
integration of such data is difficult, and the interdependence of lung cellular processes
makes it difficult to quantify the impact of a change in a single or multiple cellular
process(es) on overall lung tissue bioenergetics. Integrated computational modeling has
been used to describe mitochondrial and tissue bioenergetics of other organs, including
heart, liver and skeletal muscle under physiological and pathophysiological conditions
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[30-34]. However, to the best of our knowledge, no such model exists for bioenergetics
of lung tissue or isolated lung mitochondria.
The first computational model of energy metabolism was developed by Garfinkel
et al. in 1960s for Ehrlich ascites tumor cells, and was subsequently used to model energy
metabolism in dog and rat hearts [30, 35, 36]. Figure 1.4 shows a block diagram of their
energy metabolism model, which incorporates key reactions in glycolysis and key
mitochondrial pathways. Each enzyme was formulated in the simplest terms that can
explain their in situ kinetics [30]. Their model was able to provide regulatory insights of
anoxic perfused rat heart [30] and ischemic metabolism in dog heart [35].

Figure 1.4: Block diagram of the metabolic processes included in the first model of
energy metabolism. Arrow indicates direction of metabolic flux. BOH: NAD-linked
substrate. Figure was reproduced from reference [37] with permission from Elsevier.

Subsequently, with the development of fast computing platforms, more detailed
computational models of mitochondrial function with complex kinetics were developed
(reviews in [38]). For instance, in 1985, Holzhütter et al. [39] included more detailed
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kinetics of electron transfer and proton translocation by ETC, ATP synthesis by complex
V, and passive proton leak in their model. Later, Ca2+ and Na+ were included in a model
by Magnus et al. to study their interactions with cellular energy metabolism in pancreatic
beta cells [40]. Their model simulations agreed well with experimental data of
mitochondrial Ca2+ uptake and the influence of Ca2+ alterations on mitochondrial oxygen
consumption and ATP synthesis in pancreatic beta cells. A series of models of oxidative
phosphorylation (OxPhos) were developed by Korzeniewski et al. to study the control
mechanisms of OxPhos and energy production in skeletal muscle during exercise (change
in energy demand) [34, 41-44].

Figure 1.5: Scheme of the mitochondrial model structure by Holzhütter et al. [39].
Left: Schematic representation of the reactions in whole model. Right: Reaction scheme
of the respiration chain. Reproduced with permission from Elsevier.

In 2003, Cortassa et al. introduced a detailed computational model of the TCA
cycle and OxPhos to quantitatively test the contribution of feed-forward control of
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mitochondria respiration and energy balance in cardiomyocytes mediated by Ca2+
regulations of mitochondrial dehydrogenase enzymes [38, 45]. In another study, Cortassa
et al. integrated cardiac electrophysiology (electrical activity of the cardiomyocyte and
the molecular and cellular processes that govern their signaling) and cardiac contraction
into a model of the mitochondrial bioenergetics of cardiomyocytes to study how energy
demand is matched by mitochondria in response to increased workload [33].
Beard and coworkers improved the fidelity of computational models of
mitochondrial bioenergetics by applying thermodynamic principles in the modeling of
reaction and transport fluxes [32, 46, 47]. Using experimental data of isolated enzymes
and transporters, Beard and coworkers developed detailed mechanistic models for key
enzymes and transporters accounting for the effects of pH, ionic strength, and cation
binding and buffering. For example, detailed mechanistic models have been developed
for citrate synthase [48], isocitrate dehydrogenase [49] and succinyl-CoA synthetase [50]
and key transporters such as monocarboxylate transporter [51]. Recently, Dash and
colleagues developed and parameterized detailed kinetic models for mitochondrial cation
transporters, including Ca2+ uniporter (CU), Na+/Ca2+ exchanger (NCE) and Na+/H+
exchanger to study regulations of mitochondrial cation homeostasis [47, 52-55]. These
models not only provide foundation for integrated computational models at the cellular
level, but also facilitate understanding of how OxPhos and ATP synthesis is regulated in
skeletal muscle and heart during ischemia and exercise, and how energy metabolism
breaks down under pathophysiological conditions [56-61]
Critical bioenergetics regulation questions have been addressed using integrated
computational modeling of mitochondrial bioenergetics. Many of the existing models
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have focused on the question of how mitochondrial ATP synthesis is controlled. Potential
mechanisms such as feed-forward control and feedback control were tested (see above).
Moreover, models were developed to explain metabolic oscillation during heart ischemia
[62-64]. Mitochondrial ROS production and scavenging have been incorporated into
mitochondrial bioenergetics models to study the role of ROS in the progression of
diseases [65, 66]. Recently, electron microscopy showed that mitochondria are not
uniformly distributed in cardiomyocytes [67], some mitochondria are aggregated into
different sizes of columns. The impact of this mitochondrial heterogeneity on
bioenergetics was investigated using a mitochondrial computational model that accounts
for mitochondrial heterogeneous arrangement [67].
Computational models of mitochondrial and tissue bioenergetics have been
developed for organs such as heart, liver and skeletal muscle [33, 34, 40-44, 56-61, 68].
However, such computational models are not available for lung bioenergetics. In contrast
with skeletal muscle, heart and liver cells which utilize fatty acids as the main oxidative
fuel, rat lung cells use glucose as the main energy source. In addition, lung cells are
mostly non-excitable, and thus are postulated to behave very differently from excitable
cells such as cardiac and skeletal muscle cells [69]. Therefore, new computational models
of lung mitochondrial and tissue bioenergetics are needed. Such models would provide
new insights into lung energy production under physiological and pathological
conditions, including ALI/ARDS.

1.7 Objective and specific aims
There is ample evidence that altered lung tissue bioenergetics is an important and
early step in the pathogenesis of hyperoxia-induced ALI/ARDS [1, 10, 16]. Previous
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studies in lung isolated mitochondrial, cultured endothelial cell, lung tissue homogenate,
and intact lung have demonstrated ALI/ARDS-induced changes in multiple lung tissue
mitochondrial and cytosolic metabolic processes that are pertinent to overall lung tissue
bioenergetics [1, 18].

Sample data
Isolated enzyme
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Isolated mitochondria
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Complexity

Cell
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(> 40 cell types)
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Figure 1.6: Sample data on different levels of biological complexities

However, it is difficult to integrate bioenergetics data from different levels of
biological complexities and infer functional outcome relying on experiments alone.
Integrating bioenergetics data from isolated mitochondria, cultured endothelial cells, and
whole-organ through computational modeling (Figure 1.6) is necessary for determining
the functional significance of targeting a specific cellular process for prognostic and/or
therapeutic purposes. To that end, the key objective of my dissertation work is to develop
integrated computational models of lung mitochondrial and tissue bioenergetics. This is
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achieved through the following specific aims:
Specific Aim 1: Develop and validate an integrated computational model of
the bioenergetics of mitochondria isolated from rat lungs.
Rationale: The isolated mitochondrial preparation is widely used for evaluating
lung tissue mitochondrial bioenergetics under physiological conditions and the impact of
ALI/ARDS on specific mitochondrial enzymes, including mitochondrial ETC complexes
and TCA cycle enzymes. Such a preparation is important for studying the lung tissue
mitochondrial bioenergetics independent of cytosolic changes, including glucose uptake,
glycolysis, and substrate availability. However, interpretation of the data is not straight
forward since the transport processes and reaction processes are interdependent. Also,
substrate availability and experimental environment such as buffer pH and temperature
affect experimental results. Therefore, a computational model of lung mitochondrial
bioenergetics is essential to interprete the isolated mitochondria experimental data.
Objective: To develop and validate a model of lung mitochondrial TCA cycle and
electron transport system that governs oxidative phosphorylation. The proposed model
will provide a mechanistic and quantitative framework for 1) integrating new and existing
data regarding lung tissue mitochondrial bioenergetics, 2) assessing the impact of a
change in one or more mitochondrial processes on overall mitochondrial bioenergetics,
and 3) predicting the ability to counter the effects of hyperoxia-induced ALI/ARDS on
lung tissue mitochondrial bioenergetics by targeting specific mitochondrial processes.
Furthermore, the proposed model is an important step towards the development and
validation of a comprehensive thermodynamically-constrained computational model of
isolated perfused rat lung tissue bioenergetics (Aim 2).
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Specific Aim 2: Develop and validate an integrated computational model of
lung tissue bioenergetics.
Rationale: Even though mitochondria have been identified as a primary and early
target of hyperoxia-induced ALI/ARDS, there are other potential contributing factors in
the cytosol that may be associated with the progression of hyperoxia-induced ALI/ARDS.
For instance, although ~85% of cellular ATP is produced in mitochondria [18], glycolysis
is important for tissue bioenergetics since it can partially compensate for the decrease in
lung mitochondrial ATP generation. Furthermore, the pentose phosphate pathway in the
cytosol is important for defending against oxidative stress by generation of NADPH,
which is a required electron donor for regeneration of the antioxidant GSH. The isolated
perfused rat lung preparation allows us to control composition of lung perfusate and
ventilation gas, and to directly manipulate specific key pathways pertinent to lung tissue
bioenergetics. Previous studies [18, 21, 70, 71] using isolated perfused rat lung
preparation, provide a wealth of information regarding lung tissue bioenergetics, such as
glucose uptake, lactate and pyruvate production rate, ATP content, surface NADH and
FAD, oximetry, etc.
Objective: To develop and validate a computational model of rat lung tissue
glucose utilization and intermediary metabolism using existing and new data. The model
will account for the major processes that determine lung tissue bioenergetics, including
glucose uptake and phosphorylation, glycolysis, the pentose phosphate pathway, pyruvate
oxidation, the Krebs cycle, and oxidative phosphorylation. The model developed under
Aim 1 will be the foundation of this lung model. The model will then be used to evaluate
the impact of hyperoxia-induced changes in key mitochondrial and cytosolic processes
(Aim 3) on overall lung tissue bioenergetics.
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Specific Aim 3: Quantify the impact of hyperoxia-induced changes in specific
mitochondrial processes on lung mitochondrial and tissue bioenergetics.
Rationale: Published data suggest that specific mitochondrial and cytosolic
processes pertinent to lung tissue bioenergetics, such as mitochondria complexes I and II,
are significantly impaired in hyperoxia-exposed rats, and that these processes are
important to lung hyperoxic lung injury and protection from this injury. The
computational models will be important for determining the potential of these processes
as targets for therapeutic purpose.
Objective: To use the computational models under Aims 1 and 2 for quantitative
integration and interpretation of data from isolated mitochondria and isolated perfused
lungs of rats exposed to hyperoxia for 48 hrs as a model of clinical ALI/ARDS. To this
end, published data about specific cytosolic and mitochondrial processes pertinent to lung
tissue and mitochondrial bioenergetics (e.g., complexes I, II, IV, mitochondrial
membrane potential, oximetry, lactate and pyruvate production, etc.) collected from
isolated rat lung mitochondria, lung tissue homogenate, and isolated perfused lungs of
rats exposed to >95% O2 for 48 hrs as a model of clinical ALI/ARDS will be used. The
expected outcomes will allow us to determine the functional impact (e.g. effect on lung
tissue bioenergetics) of changes in each of these processes. This would help in
determining the potential of these processes as targets for therapeutic proposes.
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Chapter 2 : Computational Model of the Bioenergetics of
Isolated Lung Mitochondria
2.1 Introduction
Mitochondrial respiration accounts for 80–85% of total lung ATP, and
mitochondrial dysfunction plays a key role in the pathogenesis of acute and chronic lung
diseases. There is ample information regarding the impact of lung injury on
mitochondrial enzymes, transporters, and other macromolecules. The objective of Aim 1
was to develop and validate an integrated computational model of the bioenergetics of
isolated lung mitochondria. The model incorporates the major biochemical reactions and
transport processes in lung mitochondria. A general framework was developed to model
those biochemical reactions and transport processes. Intrinsic model parameters such as
binding constants were estimated using previously published isolated enzymes and
transporters experimental data describing their kinetics. Extrinsic model parameters such
as maximal reaction and transport velocities were estimated by fitting the integrated
bioenergetics model to published and new tricarboxylic acid cycle and respirometry data
measured in isolated rat lung mitochondria. The integrated model was then validated by
assessing its ability to predict experimental data not used for the estimation of the
extrinsic model parameters. For example, the integrated bioenergetics model was able to
predict reasonably well the substrate and temperature dependency of mitochondrial
oxygen consumption, kinetics of the NADH redox status, and the kinetics of
mitochondrial accumulation of the cationic dye rhodamine 123 (R123), driven by
mitochondrial membrane potential, under different respiratory states. The latter required
the coupling of the integrated bioenergetics model to a pharmacokinetic model for the
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mitochondrial uptake and release of R123 from buffer under different respiratory states.
The integrated bioenergetics model provides important insights into the bioenergetics of
lung mitochondria and how they differ from those of mitochondria from other organs for
which similar models have been developed. To the best of our knowledge, this model is
the first for the bioenergetics of isolated lung mitochondria. The results of this Aim,
including model development and validation, are published in the journal PLoS One
(Zhang et al. Jun 11;13(6):e0197921, 2018).

2.2 Experimental Methods
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated
otherwise. All treatment protocols and procedures for animals were approved by the
Institutional Animal Care and Use Committees of the Zablocki Veterans Affairs Medical
Center, the Medical College of Wisconsin, and Marquette University.
2.2.1 Isolation of rat lung mitochondria:
Adult male Sprague-Dawley rats (320-360g) were anesthetized (pentobarbital
sodium 50-100 mg/kg, ip) and the lungs were rapidly exposed and cleared of residual
blood with 50 ml cold perfusion solution (physiologic saline buffered with 10 mM
HEPES, pH 7.4, and containing 5.5 mM glucose) via the right ventricle. The lungs were
then removed from the chest, and the trachea, large airways and large vessels were
removed, after which the peripheral lung was placed in an ice-cold homogenization
buffer (pH 7.4) containing 10 mM HEPES, 200 mM mannitol, 70 mM sucrose, 1 mM
EGTA, 2% fatty acid-free BSA, and protease inhibitor cocktail Set III (50 μl/g lung
tissue; Calbiochem, San Diego, CA) and minced over ice. Lung tissue was then
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homogenized using a Teflon pestle. The resulting homogenate was then centrifuged
(Sorvall Superspeed RC-5B, Norwalk, CT) at 2,000 × g and 4°C for 15 minutes. The
supernatant was transferred to a clean tube and centrifuged at 17,800 × g at 4°C for 15
minutes. The resulting supernatant was discarded and the remaining pellet was
resuspended in 5 ml ice-cold homogenization solution and centrifuged at 17,800 × g at
4°C for 15 minutes. The supernatant was discarded and the final pellet was resuspended
in 0.3-4 ml ice-cold buffer (same as the homogenization buffer without BSA or the
protease inhibitor cocktail) and stored on ice to be used for the respirometry and
membrane potential studies described below. Mitochondrial protein was determined
using the Pierce BCA protein assay with bovine serum albumin as the standard.
Mitochondrial yield was ~2 mg/rat lung.
2.2.2 Mitochondrial oxygen consumption:
Mitochondrial oxygen consumption (respiration) was measured polarographically
at 23°C with a Strathkelvin 782 2-Channel Oxygen System (Strathkelvin Instrument).
Briefly, 0.55 ml respiration buffer (130 mM KCL, 5 mM K2HPO4, 20 mM MOPS, 0.1
mM EDTA, 0.001 mM Na4P2O7 and 0.1% BSA, pH 7.2) was transferred to the reaction
chamber. After 2 minutes, 0.55 mg mitochondrial protein (1 mg/ml) was transferred to
the 0.55 ml reaction chamber. Stock solution containing respiratory substrates (pyruvate
(10 mM) + malate (5 mM), glutamate (10 mM) + malate (5 mM), or succinate (7 mM) at
pH 7.2) was introduced into the reaction chamber using a Hamilton syringe. Once the
oxygen consumption rate reached steady state (state 2), ADP (100 M or 50 M) was
added to stimulate the rate of oxygen utilization (state 3). State 4 was measured as the
rate of oxygen consumption following depletion of ADP in the reaction chamber. The
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respiratory control index (RCI) for pyruvate + malate, malate + glutamate, or succinate
was then calculated as the ratio of state 3 and state 4 respiratory rates. The rate of
uncoupled oxygen consumption was measured in the presence of the uncoupler carbonyl
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 2 µM).
For a subset of experiments, maximal complex IV activity was measured at 30°C
using the complex IV substrate tetramethyl-p-phenylenediamine (TMPD, 0.3 mM) as a
direct artificial electron donor in the presence of antimycin A (1 M, complex III
inhibitor). Ascorbate (1.3 mM) was also added to the medium to maintain TMPD in its
reduced form. Furthermore, the integrity of the mitochondrial outer-membrane was
assessed by evaluating the ability of exogenous cytochrome c (10 M) added to the
medium to stimulate oxygen consumption.
2.2.3 Mitochondrial membrane potential:
As previously described [72], mitochondrial membrane potential (m) studies
were performed at room temperature (23°C) using a Photon Technology International
(PTI) QuantaMaster spectrofluorometer (HORIBA Scientific, Edison, New Jersey) that
monitored and recorded the R123 fluorescent signal (503/527 nm excitation/emission
wavelength) continuously over time. Briefly, a cuvette containing 1 ml of the buffer (pH
7.2), R123 (200 nM), and either pyruvate (10 mM) + malate (5 mM) or succinate (7 mM)
as respiratory substrate was placed in the cuvette holder of the spectrofluorometer. After
2 minutes, mitochondrial protein (1 mg/ml) was added, and then once the R123
fluorescent signal had reached steady-state (state 2), ADP (100 M or 50 M) was added
to evaluate the ADP-stimulated depolarization of m. The maximum uncoupled m
was then determined by adding FCCP (2 M). Since the R123 medium concentrations
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are low (≤ 200 nM), quenching effects are negligible [73]. Hence, the R123 fluorescent
signal was converted to R123 concentration by assuming a linear relationship between
R123 medium concentration and fluorescent signal.

2.3 Model Development
2.3.1 Model Structure
The integrated model of bioenergetics of isolated lung mitochondria was
developed based on the thermodynamic and kinetic properties of the mitochondrial
metabolic reactions and transporters [46, 56, 68]. As shown in Figure 2.1, the model
consists of three regions: the extra-mitochondrial region (buffer), the mitochondrial
matrix region, and the inter-membrane space (IMS) region. Moreover, the model
accounts for the dynamics of forty state variables, including thirty-seven metabolite
concentrations in the matrix and buffer regions, two ion concentrations (matrix H+ and
buffer H+ concentrations), and mitochondrial membrane potential (m). Volumes of the
three regions along with initial concentrations of metabolites are given in Table 2.1.

Table 2.1: General model parameter values for isolated mitochondria model
Parameter
Value
Source
Mitochondria matrix volume (Vm)
Mitochondria IMS volume (Vims)
Total cytochrome c content
Total pyridine nucleotide content
(NAD+NADH)
Total flavin adenine dinucleotide
concentration (FAD+FADH2)
Total adenine nucleotide content (ATP
and ADP)
Total coenzyme A content
(SCoA+ACoA+CoA)

1 l/mg mitochondria protein
Assume to be 10% of Vm
0.33 nmol/mg mitochondria
1.73 nmol/mg mitochondria

[46, 74, 75]

0.7 mM

[66]

6.4 nmol/mg mitochondria

[76]

0.93 nmol/mg mitochondria

[76]

[76]
[76]
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Aspartate + glutamate concentration in
mitochondria matrix
Total ubiquinone concentration
(UQ+UQH2)

12 mM

[77]

0.52 mM
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Figure 2.1: Structure of the isolated lung mitochondrial bioenergetics model.
The model consists of three regions (extra-mitochondrial buffer, mitochondrial matrix,
and inter-membrane space (IMS)). Major reactions include TCA cycle reactions and
electron transport chain reactions. Transport exists between mitochondrial matrix and
IMS. Most of the metabolites are assumed to be freely permeable across mitochondria
outer-membrane. The major biochemical species included in this model are: PYR:
pyruvate, CoA: coenzyme-A, ACoA: acetyl-CoA, OXA: oxaloacetate, CIT: citrate, AKG:
a-ketogluterate, SCoA: succinyl-CoA, SUC: succinate, FUM: fumarate, MAL: malate,
GLU: glutamate, and ASP: aspartate, NAD and NADH: oxidized and reduced form of
nicotinamide adenine dinucleotide, respectively, FAD and FADH2: oxidized and reduced
form of Flavin adenine dinucleotide, respectively, ADP and ATP: adenosine triphosphate
and adenosine diphosphate, respectively, UQ and UQH2: oxidized and reduced form of
ubiquinone, respectively, CtyC3+ and CytC2+: oxidized and reduced form of cytochrome
c, respectively.

26

Fifteen reaction fluxes are included in this integrated model, including ten
reactions in the tricarboxylic acid cycle (TCA or Krebs cycle) and five reactions in the
respiratory system (complex I-complex V). Unlike liver and kidney mitochondria, which
can produce oxaloacetate (OXA) from pyruvate, pyruvate carboxylase activity is
extremely low in lung mitochondria [78]. Thus, pyruvate carboxylase is not included in
this model. In isolated mitochondria experiments, bovine serum albumin (BSA) was used
to bind free fatty acids and their esters [79]. Therefore, fatty acid oxidation was not
considered in this isolated mitochondrial model. All the reactions in the integrated
bioenergetics model are listed in Table 2.2.

Table 2.2: Enzymatic reaction in the mitochondria bioenergetics model
Reaction
Enzyme
Enzyme reaction
number
name
PDH
1
PYRm+CoAm+NADm ⇌
ACoAm+CO2+NADHm+Hm
CITS
2
ACoAm+OXAm ⇌ CITm+CoAm+ 2Hm
CITDH
3
CITm+NADm ⇌ AKGm+NADHm+CO2
AKGDH
4
AKGm+CoAm+NADm ⇌ SCoAm+NADHm+CO2
SCAS
5
SCoAm+GDPm+Pim ⇌ SUCm+GTPm+CoAm+Hm
NDK
6
GTPm+ADPm ⇌ GDPm+ATPm
SDH
7
SUCm+FADm⇌ FUMm+FADH2m
FH
FUMm = MALm
8
MDH
9
MALm+NADm ⇌ OXAm+NADHm+ Hm
GOT
10
ASPm+AKGm ⇌ GLUm+OXAm
CI
11
NADHm+UQm+Hm ⇌ NADm+UQH2m+ 4∆H
CII
12
FADH2+UQm ⇌ FADm+UQH2m
CIII
13
UQH2m+2CytCo ⇌ UQm+2CytCr+ 2∆H+ 2𝐻𝑖
CIV
14
2CytCr+0.5O2+2Hm ⇌ 2CytCo+H2O+2∆H
CV
15
ADPm+Pim+Hm⇌ ATPm+3∆H
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Additionally, the model includes ten transport processes to account for the
exchange of key metabolic species between the mitochondrial matrix and IMS regions.
The mitochondrial inner membrane is impermeable to most metabolites. Therefore,
except for proton leak, the exchange of species between the mitochondrial matrix and
IMS regions is assumed to be catalyzed by specific transporters, such as inorganic
phosphate carrier (PIC) and adenine nucleotide translocase (ANT). The proton leak
between the IMS and mitochondrial matrix regions is modeled using modified GoldmanHodgkin-Katz equation [46]. All the transporters in the model are listed in Table 2.3.

Table 2.3: Metabolite transporters in the mitochondrial bioenergetics model
Transporter
Transporter
Transporter reaction
number
name
PYRH
1
PYRe + He ⇌ PYRm + Hm
GLUH
2
GLUe+ He ⇌ GLUm+ Hm
DCC (MAL)
3
MALe+Pim ⇌MALm+Pie
DCC (SUC)
4
SUCe+Pim ⇌ SUCm+Pie
TCC
5
MALe+ CITm ⇌ MALm+ CITe
OME
6
MALe+AKGm ⇌ MALm+AKGe
GAE
7
ASPe+ HGLUm ⇌ ASPm + HGLUe
ANT
8
ADPe + ATPm ⇌ ADPm + ATPe
PIC
9
Pie + He ⇌ Pim + Hm
Hleak
10
Hi ⇌ Hm

The mitochondrial outer membrane (OMM) has VDACs that allow the transport
of small molecules in and out of mitochondria [46]. Therefore, we assumed that the
concentration differences of most of the metabolic species between the IMS and extramitochondrial space to be negligible. However, cytochrome c, which has a molecular
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weight of about 12 KD, and hence too large to pass through the mitochondrial outer
membrane under normal conditions, was assumed to exist only in the IMS region.
2.3.2 Reaction and transport flux expressions:
In the proposed integrated bioenergetics model, all enzymatic reactions are
assumed to follow a generalized random-ordered rapid-equilibrium kinetic mechanism
[80], which encompass all possible kinetic mechanisms as special cases. Thus, for each
reaction, all pertinent substrates must bind to the enzyme together before the catalysis can
take place. For a general multi-substrate and multi-product enzymatic reaction:
Ns

NP

i 1

j 1

i Si   j Pj

(2.1)

where Si is ith substrate, Pj is jth product, Ns and Np are the number of substrates and
products, respectively, and αi and βj are the corresponding stoichiometric coefficients.
The general form of the reaction flux, J, accounting for the thermodynamic (Haldane)
constraint is given by:
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where KSi and KPj are binding constants corresponding to substrates and products,
respectively;

[ Si ] and [ Pj ] are concentrations of substrate i and product j, respectively;

Vmaxf is the maximum forward reaction rate; and Keq is the apparent equilibrium constant
for the reaction, which is the value of the equilibrium-state reaction quotient (i.e. ratio of
product of product concentrations over product of substrate concentrations) at specified
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thermodynamic conditions (i.e. temperature, ionic strength and pH). Detailed derivations
of this general reaction flux equation and its various special cases are included in the
Appendix.
In the presence of cofactor pairs (e.g. NADH and NAD+, ATP and ADP, GTP and
GDP, CoA and ACoA, or CoA and SCoA), the generalized reaction flux equation (2.2)
can be modified appropriately so as to not include any interactive cofactor product terms
[80]. The assumption is that the substrate and product represented as a cofactor pair bind
with a given enzyme at the same binding site, in which case the resulting reaction flux
equation does not include the corresponding substrate and product multiplication terms in
the denominator of equation (2.2). Equation (2.2) can also be suitably modified to
account for other reaction kinetic mechanisms (e.g. sequential-ordered mechanisms, pingpong mechanisms). The flux expressions of all the enzymatic reactions are included in
Appendix.
In this integrated bioenergetics model, all the transport processes across the
mitochondrial inner membrane, with the exception of the proton leak, are catalyzed by
specific metabolite transporters involving two different species (co-transporters and antiporters). For generality, a random-ordered rapid-equilibrium binding mechanism is
assumed for all the transporters, i.e., the transporter can bind to the two species in an
arbitrary order, similar to that described for a reversible two-substrate two-product
enzymatic reaction. Thus, the general form of the transport flux expression is assumed to
be the same as that for the reaction flux expression. The flux expressions for all the
metabolite transporters are included in the appendix.
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2.3.3 Accounting for the effect of pH on equilibrium constants:
The proposed integrated bioenergetics model accounts for the pH dependence of
the apparent equilibrium constants for proton-releasing reactions (2.3) and for protonconsumption reactions (2.4) [68, 75, 81]:
  Keq
0 10 pH 7  eΔr G
Keq

/ RT

10 pH 7

(2.3)

  Keq
0 107 pH  eΔr G
Keq

/ RT

107 pH

(2.4)

0

0

0 is the reaction apparent equilibrium constant ( K eq ) at pH of 7, and  r G  R
where K eq
0

and T are the standard Gibbs free energy of the reaction at pH = 7, gas constant, and
temperature, respectively.
2.3.4 Accounting for the effect of temperature on enzymatic reaction and transport
rates:
To allow for model simulations at different temperatures, we account for the
temperature effects on the maximal reaction and transport rates (Vmax’s and Tmax’s) using
the Q10 temperature coefficient [75].

R2 R1  Q10(T2 T1 )/10

(2.5)

where T is the temperature, R2/R1 is the correction coefficient (i.e. the ratio of maximal
reaction and transport velocities at temperature T2 and T1), and Q10 is the temperature
coefficient which was set to 2.5.
2.3.5 Dynamic mass balance equations
The governing ordinary differential equations describing the dynamic changes in
the concentrations (C) of the forty biochemical species were derived based on the
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principle of mass balance. The change in the concentration of a given species within the
mitochondria matrix region and extra-mitochondria (buffer) region are given by:

Vm

dCm, j
dt

   m , j J m , j   J m e , j

Ve

dCe, j
dt

(2.6)

  J m e , j

(2.7)

where J m, j is the jth reaction flux in the mitochondrial matrix and J me, j is the jth transport
flux between mitochondria matrix region and extra-mitochondria buffer region,

Vm and

Ve are the volumes of the mitochondrial matrix region and the extra-mitochondria region,
respectively. For the extra-mitochondria region which does not include chemical
reactions, the right hand side of (2.7) contains just transport fluxes. Detailed mass balance
equations are included in Appendix IV.
The rate of change of mitochondrial membrane potential (m) is given by
equation (2.8) [46]:

d Ψm
1

 4 J CI  2 J CIII  4 J CIV  3J CV  J Hleak  J ANT 
dt
Cimm
where

(2.8)

Cimm is the capacitance of the inner mitochondrial membrane; J CI , J CIII , J CIV and

J CV are the reaction fluxes of complex I, complex III, complex IV and complex V,
respectively; J Hleak is the proton leak between the IMS and mitochondria matrix regions;
and

J ANT is the transport flux characterizing ATP/ADP exchange via the ANT.
MATLAB function ‘ode15s’ (MathWorks Inc.) was used to solve the system of

governing differential equations. The ode solver ‘ode15s’ is suitable for solving stiff
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ordinary differential equations, where solution components vary on drastically different
time scales [82]. Non-stiff ode solvers, such as ‘ode45’ and ‘ode23’, are unable to solve
stiff problems, or are extremely slow. For a stiff system, ‘ode15s’ is more efficient than
the non-stiff ode solvers.

2.4 Model Parameter Estimation
As described below, some model parameters were set at published values, while
others were estimated from new and published data, including isolated enzyme and
transporter kinetics (See Appendix), TCA cycle kinetics [78], and respirometry [76, 78].
2.4.1 Estimation of the intrinsic model parameters:
The binding constants (K’s) of various substrates and products for enzymes and
transporters were either set to published values [46, 83] or estimated using published
kinetic data from isolated mitochondrial enzymes and transporters. Some of the isolated
enzyme and transporter kinetic data were from heart, kidney or liver mitochondria due to
the scarcity of such data from lungs. The assumption is that the binding constants are
intrinsic model parameters, and hence their values should be organ-independent.
For a given enzyme or transporter, the MATLAB function ‘fmincon’, a nonlinear
program solver, was used with a least-squares objective function to estimate the values of
the K’s from the published kinetic data for the enzyme or transporter by fitting the flux
equation for a given enzyme or transporter reaction to pertinent kinetic data.
Models of reaction and transport fluxes for various enzymatic reactions and
metabolite transporters, parameter estimation results, as well as the kinetic data are
included in Appendix III.
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2.4.2 Estimation of the extrinsic model parameters:
With the binding constants (K’s) of the various enzymes and transporters known,
a genetic algorithm (GA, MATLAB function ‘ga’) was then used to estimate the values
of the extrinsic model parameters (i.e. Vmaxfs and Tmaxfs) of the integrated bioenergetics
model that best fit new and published dynamic kinetic data (Figure 2.3-Figure 2.5)
obtained from isolated lung mitochondria, including TCA cycle kinetics data [78], and
respirometry data at different respiratory states [76, 78]. Thus, the resulting values of
extrinsic model parameters are specific to isolated rat lung mitochondria.
GA is a global parameter estimation algorithm that mimics the process of natural
selection and can escape local minima [84]. In each iteration of GA, a population of
parameters is generated, the fitness of each ‘individual’ (parameter) is evaluated based on
the objective function, and ‘parents’ are selected at random to produce offspring for the
next generation. Generally, the “parents” with better fitness have more probability to
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reproduce, thus the population evolves towards the optimal solution.

Initialize a population of
parameter sets and evaluate their
fitness functions
Select parents, use cross-over
and mutation to generate
offspring

Fitness
function

Evaluate the fitness function of
individuals

Check if the
fittest individual
meets criterion

Local minimum

Global minimum

No

Variables

Yes
STOP

Figure 2.2 Flow chart of genetic algorithm.

GA is suitable for optimization problems with a relatively large number (>10) of
unknown parameters. For such optimization problems, GA can usually find better
estimation of the best fit than ‘fmincon’ because of its ability to find global minimum.
However, GA is usually more time-consuming than ‘fmincon’. For a simple parameter
estimation problem with less than 5 unknown parameters, fmincon is usually more
efficient in finding the optimal values for the model parameters. Therefore, fmincon was
used for estimation of the intrinsic parameters for the flux of an enzymatic or transport
reaction (Section 2.4.1), and GA was used for extrinsic parameter estimation at the
mitochondrial level.
For the integrated model extrinsic parameter estimation, the objective function ƒ
used is:
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(2.9)

where xi,j and Xi,j are the model solutions and the corresponding experimental data at the
ith time point and jth data set, respectively. N is number of data points and M is the
number of data sets used for the parameter estimation.

2.5 Experimental and computational results
2.5.1 Oxygen consumption
Respirometry data were collected at room temperature (23o C). In order to collect
enough information for parameter estimation of different substrate tranporters and
enzymes, different combinations of metabolic substrates were used in experiments. For
example, two combinations of complex I substrates (pyruvate + malate and malate +
glutamate) were used to get enough information for relevent enzymes/transproters, such
as pyruvate tranportor (PYRT), malate-pi exchanger (DCC) and glutamate-aspartate
exchanger (GAE). Results are shown in Figure 2.3. Averaged time-course respirometry
data (mean ± SE) are shown in the presence of complex I substrates pyruvate + malate
(Figure 2.3A, n = 4), complex I substrates malate + glutamate (Figure 2.3B, n = 1), and
complex II substrate succinate (Figure 2.3C, n = 4). A summary of the oxygen
consumption rates (OCR, nmol/min/mg) show higher states 2, 3 and 4 respiratory rates
with complex II substrate (Figure 2.3F) compared to those with complex I substrates
(Figure 2.3D and Figure 2.3E). Furthermore, the results show smaller respiratory rates,
but higher respiratory control index (RCI, defined as the ratio of state 3 OCR to state 4
OCR) than those in Figure 2.4 (at 30o C) for pyruvate + malate and succinate. Figure 2.4
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also shows fits of the integrated bioenergetics model to the measured oxygen
consumption kinetic data (solid lines, upper panels) and oxygen consumption rates (red
bars, lower panels) generated using the values of the model parameters in Table 2.4,
except for the value of the Tmaxf parameter describing the proton leak process (Tmaxf, LEAK),
which was set at 40% of the value in Table 2.4. This is consistent with a less “leaky” and
more coupled isolated rat lung mitochondria for the data in Figure 2.3 as compared to the
data in Figure 2.4. Figure 2.10A and D, which provide a summary of the states 2 and 3
oxygen consumption rates in Figure 2.4 and Figure 2.3, show the expected dependency of
those rates on buffer temperature.

A.

B.

C.

ADP
ADP

FCCP

FCCP

ADP
FCCP

D.

E.

F.

Figure 2.3: Respirometry data at room temperature (23˚C).
Rat lung mitochondria were incubated in 0.55 ml buffer containing 2 mM Pi, and 0.55
mg mitochondria protein, buffer pH=7.2. Average oxygen concentrations in buffer are
shown under state 2, state 3, state 4 and uncoupled state 3 using pyruvate (PYR) + malate
(MAL) (n = 4, panel A), MAL + glutamate (GLU) (n = 1, panel B), or succinate (SUC) (n
= 4, panel C) as substrates. ADP and FCCP was added to buffer at 3.5 min and 6.5 min,
respectively. Symbols are experimental data (mean ± SE) and solid lines are integrated
model fits to the data. For the integrated model fits to the uncoupled state 3 data, the
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estimated value of the proton leak parameter Tmaxf, LEAK in Table 1 was increased by seven
folds. Panels D, E, and F show average oxygen consumption rates (OCR, nmol/min/mg)
under states 2, 3 and 4 using PYR + MAL (n = 4), MAL + GLU (n = 1), or SUC (n = 1)
as substrates. Blue bars are experimental data (mean ± SE) and red bars are integrated
model fits to the data.

2.5.2 Estimated values of the unknown model parameters
In what follows, all Figure and Table numbers with prefix “A” are found in the
Appendix. Most of the intrinsic parameters of the integrated bioenergetics model, such as
the binding constants (K’s) of the enzymatic reactions and transport processes, were
estimated based on previously published isolated enzyme or transporter kinetic data
shown in appendix using the MATLAB function “fmincon”. The solid lines
superimposed on the data in the Figures are fits of corresponding enzyme/transporter
models to the data in Appendix. Since the binding constants of the enzymatic reactions
and transport processes are intrinsic model parameters, they are assumed to be tissueindependent [75] . It is worth noting that the extrinsic model parameter Tmaxfs and Vmaxfs
values estimated from the isolated enzyme and transporter kinetic data were not used in
the integrated bioenergetics model since those parameters are expected to be dependent
on the tissue source of mitochondria.
With the K’s of the various enzymes and transporters known, the next step was to
estimate the extrinsic parameters (i.e. Tmaxfs and Vmaxfs) of the integrated bioenergetics
model using kinetic data from isolated rat lung mitochondria. Multiple datasets from
isolated rat lung mitochondria were used, including previously published TCA cycle
o

metabolite uptake/release dynamic data (Figure 2.5) and respirometry data at 30 C
(Figure 2.4) by Evans et al. [78], and newly measured respirometry data at room
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temperature (23 C, Figure 2.3).

A.

B.

ADP ADP

ADP

C.

D.
ADP

ADP
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Figure 2.4: Respirometry data (30˚C) (Evans et al. [78]).
Rat lung mitochondria were incubated at 30˚C in 1.9 ml buffer containing 4 mM Pi, and
0.7 mg mitochondria protein, buffer pH=7.4. Oxygen consumption rates (OCR,
nmol/min/mg) were calculated under state 2 and state 3 conditions. Different metabolic
substrates were used: (A) PYR + MAL, (B) SUC, (C) CIT + PYR and (D) PYR + AKG.
Shaded areas are experimental data (mean ± SE) and solid lines are integrated model fits
to the data. In the inset figures, the same experimental data are plotted as blue bars (mean
± SE) and the integrated model fits are plotted as red bars.
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Figure 2.5: Substrate-dependent responses of pyruvate (PYR) uptake, malate (MAL)
uptake and citrate (CIT) production (Evans et al. [78]).
Rat lung mitochondria were incubated at 30ºC in 1.0 ml buffer containing 4 mM Pi, and
0.7 mg mitochondria protein, buffer pH = 7.4. Mitochondria were incubated in the
presence of different substrate concentrations. Panel A, B and C: (A) mitochondria were
incubated with 5 mM MAL ([MAL] = 5 mM) and different concentrations of PYR:
[PYR] = 0 mM (red circle), [PYR] = 0.5 mM (green star), [PYR] = 1 mM (blue triangle),
[PYR] = 5 mM (purple plus sign), [PYR] = 10 mM (cyan triangle). Panel D, E and F:
mitochondria were incubated with fixed PYR concentration ([PYR] = 5 mM) and
different concentrations of MAL: [MAL] = 0 mM (red circle), [MAL] = 0.5 mM (green
star), [MAL] = 1 mM (blue triangle), [MAL] = 5 mM (purple plus sign), [MAL] = 10
mM (cyan triangle). PYR uptake rate (A, D), MAL uptake rate (B, E) and CIT production
rate (C, F) were measured over a 10-minute incubation period. Symbols are experimental
data and lines are integrated model fits.

As shown in Figure 2.5, mitochondrial pyruvate uptake, malate uptake, and citrate
production/release were measured in isolated rat lung mitochondria by Evans et al. in the
presence of 5 mM malate and varying pyruvate concentrations (top panel) or 5 mM
pyruvate and varying malate concentrations (bottom panel) in buffer [78]. Results show
that pyruvate uptake, malate uptake, and citrate release increased with increasing buffer
pyruvate concentration at 5 mM of malate (top panel) and increasing malate
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concentration at 5 mM of pyruvate (bottom panel), and that those flux rates saturated
when pyruvate and malate concentrations were greater than 5 mM.
In addition to the TCA cycle metabolite uptake/release data, the study by Evans et al.
also provided mitochondrial oxygen consumption rates using different metabolic
substrates [78]. As shown in Figure 2.4, mitochondria oxygen consumption rates under
states 2 and 3 were measured in the presence of different complex I substrates (pyruvate
+ malate, -ketoglutarate (AKG) + pyruvate, and citrate + pyruvate) and complex II
o

(succinate) substrates, with the buffer temperature set at 30 C [78]. The data show that
states 2 and 3 oxygen consumption rates tended to be higher in the presence of complex
II substrate as compared to those in the presence of complex I substrates. However, only
oxygen consumption rates are provided in this study, whereas key information such as
length of state 3 and oxygen dynamic changes under state 3 conditions are lacking. Thus
for additional information on rat lung mitochondria ETC for the estimation of pertinent
extrinsic model parameters, we measured oxygen consumption (Figure 2.3) at 23 oC
using pyruvate + malate or glutamate + malate as complex I substrates or succinate as
complex II substrate. The resulting average oxygen concentration kinetic data under
states 2, 3 and 4 were used along with the data in Figure 2.3 for estimating the extrinsic
parameters of the integrated bioenergetics model. The uncoupled state 3 kinetic data in
Figure 2.3 were simulated by increasing the estimated value of the proton leak parameter
Tmaxf, LEAK by seven fold.
Figure 2.3 and Figure 2.4 show different state 2 respiration rates. Since state 2
respiration rates in Figure 2.3 are ~40% (after accounting for temperature effect) of those
in Figure 2.4 (Evans et al. data), the maximum rate of proton leak (Tmaxf, LEAK) was
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adjusted to account for those differences. Therefore, for the data in Figure 2.3, Tmaxf, LEAK
was set at 40% of the value used to fit the data in Figure 2.4 (Table 2.4). However, for
experimental data from the same study (Figure 2.4 and Figure 2.5), Tmaxf, LEAK was set to
the same value.
All of the extrinsic parameters (Table 2.4) of the integrated bioenergetics model
were estimated by simultaneously fitting the integrated model solution to kinetic data
from isolated rat lung mitochondria (Figure 2.3 -Figure 2.5) using genetic algorithm
(MATLAB function “ga”). The estimated values of the extrinsic parameters of the
integrated bioenergetics model are shown in Table 2.4.

Table 2.4: Estimated value of the extrinsic parameters of the mitochondria model (30°C)
Parameters
Definition
Value
(nmol/min/mg)
Vmaxf, PDH
Maximum forward reaction rate of PDH
307
Vmaxf, CITS
Maximum forward reaction rate of CITS
4631
Vmaxf, CITDH
Maximum forward reaction rate of CITDH
531
Vmaxf, AKGDH
Maximum forward reaction rate of AKGDH 780
Vmaxf, SCAS
Maximum forward reaction rate of SCAS
5816
Vmaxf, NDK
Maximum forward reaction rate of NDK
4.33×106
Vmaxf, SUCDH
Maximum forward reaction rate of SDH
1.08×104
Vmaxf, FH
Maximum forward reaction rate of FH
6.4×103
Vmaxf, MDH
Maximum forward reaction rate of MDH
3.3×103
Vmaxf, GOT
Maximum forward reaction rate of GOT
975
Vmaxf, CI
Maximum forward reaction rate of CI
11
Vmaxf, CII
Maximum forward reaction rate of CII
220
Vmaxf, CIII
Maximum forward reaction rate of CIII
2.23×104
Vmaxf, CIV
Maximum forward reaction rate of CIV
0.27
Vmaxf, CV
Maximum forward reaction rate of CV
589
Tmaxf, DCC(SUC)
Maximum transport rate of DCC(SUC)
1699
Tmaxf, DCC(MAL)
Maximum transport rate of DCC(MAL)
22
Tmaxf, OME
Maximum transport rate of OME
1
Tmaxf, TCC
Maximum transport rate of TCC
81.3
Tmaxf, PYRH
Maximum transport rate of PYRH
96.6
Tmaxf, PIC
Maximum transport rate of PIC
2.4×104
Tmaxf, ANT
Maximum transport rate of ANT
523.9
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Tmaxf, GLUH
Tmaxf, GAE
Tmaxf, LEAK

Maximum transport rate of GLUH
Maximum transport rate of GAE
Maximum rate of proton leak

5
646
36

2.6 Model validation
2.6.1 Measures of identifiability and estimatility of the extrinic parameters of the
integrated model
To assess the estimability (existence of model parameters to fit available
experimental data) and identifiability (uniqueness of the model parameters to fit available
experimental data) of the extrinsic parameters of the integrated bioenergetics model
(Table 2.4), we estimated the parameters’ normalized sensitivity coefficients and a matrix
of correlation coefficients between the model parameters. The normalized sensitivity
coefficients provide information about the contribution of each of the extrinsic model
parameters to the overall model solution. If a given model parameter is identifiable, its
sensitivity coefficient should be relatively large. In addition, a parameter that has a
relatively larger sensitivity coefficient indicates the parameter has more influence on
model outputs. While the correlation coefficient matrix provides information about the
degree of interdependence between the various model parameters. For a given extrinsic
parameter, the normalized sensitivity coefficient was determined using equation (2.10)
[57]:
Si 

i  E 


E  i 

(2.10)

where E is the sum of squared difference between experimental data (Figures 1-3) and the
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integrated bioenergetics model fit, and θi is the estimated value of ith intrinsic parameter.

E
was approximated using the central difference method with 0.1% change in  i .
 i
The matrix of correlation coefficients between the model parameters was
evaluated at the values in Table 1 that best fit the integrated model to the data (Figure
2.5–Figure 2.3). The correlation coefficient (CCij) between the ith parameter and jth
parameter was determined using equation (2.11) [85]:
CCij 

HH ij
HH ii HH jj

for i, j 1, , np

(2.11)

where np is the number of model parameters, HH is the inverse of the product of the
transpose of the Jacobian matrix and the Jacobian matrix evaluated at the values of the
model parameters in Table 2.4 that best fit the integrated bioenergetics model to the data
in Figure 2.3–Figure 2.5.
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Figure 2.6: Normalized sensitivity coefficients of the integrated model extrinsic
parameters. A parameter contribution to the model solution is proportional to its
normalized sensitivity coefficient estimated using equation (2.10)

Figure 2.6 and Figure 2.7 show the respective normalized sensitivity coefficients
and matrix of correlation coefficients for the intrinsic parameters of the integrated model.
For most of the intrinsic model parameters, the normalized sensitivity functions are
relatively high, and the correlation coefficients are relatively low, consistent with a tight
range of values for those parameters that provide a good fit to the data in Figure 2.3–
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Figure 2.5.

Correlation Coefficient
-1

Figure 2.7: Matrix of correlation coefficients between the extrinsic parameters of the
integrated model.
Correlation coefficients range between -1 (perfect negative correlation) and +1 (perfect
positive correlation) and are estimated using equation (2.11). A small positive or negative
correlation coefficient between two parameters suggests small interdependence between
those parameters.

2.6.2 Model validation using Pharmacokinetic model for the cationic dye rhodamine
123 (R123)
To validate the integrated bioenergetics model, we assessed its ability to predict
experimental data that were not used for estimating the values of the unknown model
parameters. To that end, we measured mitochondrial membrane potential (m) using the
fluorescent cationic dye R123 in isolated rat lung mitochondria. R123 fluorescence
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intensity increases linearly with dye concentration at low concentrations (<1 µM) in the
buffer [73]. Thus, we converted the R123 fluorescence intensity to R123 concentration to
compare with model simulated R123 concentration in the buffer.
To simulate R123 dye disposition in isolated mitochondria, the integrated
bioenergetics model was coupled with a modified version of a pharmacokinetic model by
Gan et al. for the cellular uptake and mitochondrial accumulation of R123 [86]. Two
additional state variables were needed, namely R123 concentrations in the mitochondria
matrix  R123m and in the extra-mitochondrial buffer  R123e . The process which
accounted for the transport of R123 from the buffer to the matrix driven by an
electrochemical gradient was modeled using the Goldman-Hodgkin-Katz equation [73].
zF Ψ /RT
zF   R123e e m   R123m 
J R123  p


RT 
e zF Ψm /RT  1


(2.12)

where F is Faraday’ s constant, z is R123 valence, R is the gas constant, T is temperature,
Ψm is the membrane potential and p is the permeability coefficient of the membrane
which was set to 1.38 mol/(liter mitochondria)/s/M.
The ordinary differential equations that describe the change in the concentrations
of R123 in the matrix and buffer are:

VmAPP
APP

where Vm

and Ve

APP

d  R123m
dt

 VeAPP

d  R123e
dt

 J R123

(2.13)

are the apparent volumes of mitochondrial matrix region (Vm) and

extra-mitochondria buffer region (Ve), respectively [86]. For the model predictions in
APP

Figure 2.8, Vm
Ve = 1 ml.

was set to 2.25 µl/mg mitochondria protein and Ve

APP

was set to that for

47

A.

Mito

B.

PYR+MAL

ADP
0.1 mM

ADP
0.05 mM

FCCP

SUC

ADP
0.1 mM

ADP
0.05 mM

FCCP

Figure 2.8: Model validation using membrane potential data.
Experiments were performed under the same experimental condition as in Figure 2.3.
R123 buffer concentrations are shown (symbols). Either pyruvate + malate (PYR+MAL,
blue, n = 4) or succinate (SUC, red, n = 4) was used as the metabolic substrate. Values are
mean ± SE. Black lines in Panel A are model predictions using the estimated values of the
model parameters in Table 2.4. Panel B shows integrated model predictions of the
mitochondrial membrane potential with either PYR + MAL or SUC as the metabolic
substrates and with the values of the model parameters set to those in Table 2.4.

2.6.3 Model validation using ACoA and CoA steady state data (Evans et al. [78]) and
dynamic NADH redox status data [76].
In addition to membrane potential data, we evaluated the ability of the integrated
model to predict steady-state ACoA and CoA fractions at different malate concentrations
[78], and kinetic NADH redox status data under different respiratory states [76]. Figure
2.9A and B show the ability of the integrated bioenergetics model to predict quite well
both sets of data using the values of the model parameters in Table 2.4.

48

A.
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ADP

Figure 2.9: Model validation using ACoA and CoA steady state (Evans et al. [78]) and
dynamic NADH redox status data [76].
Panel A. Rat lung mitochondria were incubated with fixed pyruvate concentration (5
mM), and without or with 5 mM malate. Mitochondria density = 2.5 mg/ml. Other
experimental conditions are the same as in Figure 2.3. ACoA and CoA steady-state
concentrations were measured at the end of 10-min incubation time. Symbols are
experimental data and solid lines are integrated model predictions under the same
experimental conditions with the values of the model parameters set to those in Table 2.4.
Panel B. Fluorescence of pyridine nucleotides (NADH) in isolated rat lung mitochondria.
Mitochondrial density was 2.5 mg/ml. 2.5 mM MAL and 0.2 mM ADP were added to the
buffer at 1 min and 2.2 min, respectively. Symbols are experimental data and solid lines
are integrated model predictions under the same experimental conditions with the values
of the model parameters set to those in Table 2.4.

2.7 Discussion
We have developed and validated the first integrated mechanistic computational
model of the bioenergetics of isolated lung mitochondria using new and previously
published experimental data. As described below, this integrated model provides
important insights into the bioenergetics of isolated lung mitochondria and how they
differ from those of mitochondria from other organs.
Similar computational models of mitochondrial bioenergetics have been
developed for mitochondria isolated from other organs, including the heart and skeletal
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muscles [41, 46, 56, 68, 75]. Such models differ from the current integrated model in
many aspects, in part because of differences in mitochondrial bioenergetics and energy
demand of lung tissue as compared to those of the heart and skeletal muscle. It is well
known that mitochondrial content, major metabolic substrates, and control mechanisms
vary widely between different organs. For instance, β-oxidation of fatty acids has been
identified as the primary source of energy for heart under physiological conditions
accounting for 70% of ATP production [87-89], whereas glucose is the primary source of
energy for lung tissue and accounts for 80–85% of the total lung tissue ATP production
under physiological conditions [18].
Moreover, lung cells are mostly non-excitable, and thus are postulated to behave
very differently from excitable cells such as cardiac and skeletal muscle cells [69]. For
instance, the ATP demand for cardiac cells between resting state and maximal exercise
state could increase by ~4 fold, while that for skeletal muscle cells could increase by as
much as ~100 fold between resting state and maximal exercise state [61, 90]. Thus, key
enzymes in existing computational models are modeled to be modulated by metabolic
controllers, such as inorganic phosphate (Pi), ADP/ATP ratio, NADH/NAD+ ratio, etc.
However, in lung mitochondria where the energy requirement is much more stable, such
control mechanisms may not be as important. Furthermore, most existing computational
models place emphasis on complex I substrate-dependent respiration [46, 75]. These
differences were one of the reasons for the development and validation of an integrated
model specific for the bioenergetics of isolated lung mitochondria.
Another reason for developing a comprehensive integrated model for
bioenergetics of isolated lung mitochondria is the relatively complex flux equations for
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enzymes and transporters used in the existing heart and skeletal muscle models [41, 46,
68]. Those equations are not feasible for an isolated lung mitochondrial model due to the
scarcity of experimental data needed to estimate the values of the large number of
unknown parameters in the individual flux expressions and in the integrated
mitochondrial model [78]. In the present study, a simplified general flux equation that
accounts for apparent binding constants was developed and utilized for all enzymatic
reactions and metabolite transporters. As such, the number of unknown model parameters
was minimized for the individual flux expressions as well as for the integrated
bioenergetics model. Yet, the model incorporated major pathways associated with lung
mitochondrial bioenergetics, including metabolite transports and oxidations, TCA cycle
reactions, ETC reactions, and oxidative phosphorylation.
2.7.1 Estimation of unknown model parameters, and integrated model predictions
For intrinsic model parameters, such as binding constants, for major enzyme
reactions and transport processes, their values were estimated using experimental data
measured in isolated enzymes or fixed to published values, mostly from organs other than
lungs due to lack of such data from lungs. The assumption is that for a given
mitochondrial enzyme or transporter, intrinsic properties, such as binding constants, are
organ-independent [46].
With intrinsic model parameters known, a challenging aspect of the integrated
bioenergetics model development was estimation of the values of the extrinsic
parameters. To that end, we relied on previously published experimental data from
multiple studies in isolated rat lung mitochondria as well as new data that were obtained
in the present study for further validation and corroboration of the model. As shown in
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Figure 2.3–Figure 2.5 and Figure 2.8-Figure 2.10, the model is capable of fitting (Figure
2.3–Figure 2.5) and predicting (Figure 2.8–Figure 2.10) quite well all the data from
isolated rat lung mitochondria with the same set of values for the extrinsic model
parameters (Table 2.4).
A genetic algorithm was used to estimate the values of the extrinsic model
parameters that best fit the kinetic data in Figure 2.3–Figure 2.5. Even though GA is a
global parameter estimation algorithm that does not require initial estimates for the model
parameters, good initial estimates can significantly reduce the computational time needed
to identify optimal values of the model parameters. Good initial estimates can be obtained
from boundary conditions such as pyruvate uptake rate, citrate production rate, and
malate production rate.
For the TCA cycle experimental data measured by Evans et al. [78] and used for
estimating the values of some of the model parameters, citrate formation was reported
even when no exogenous pyruvate was added to the buffer medium (Figure 2.5C, F). In
our integrated bioenergetics model, both pyruvate and malate are required to generate
citrate. This resulted in a difference between model fits and experimental data when the
pyruvate buffer concentration is zero. One possible explanation for this apparent
inconsistency is that citrate measured at zero pyruvate buffer concentration, in the
experiments by Evans et al., was from endogenous substrates, such as ACoA [78].
However, reported endogenous ACoA of ~1 nmol/mg mitochondria [78] is too small to
account for the measured 40 nmol citrate. Since citrate formation was observed only after
4 min of incubation time (as shown in Figure 2.5C, F), it is more likely that the source of
citrate was other metabolic pathways that are not included in this model such as amino

52
acids from mitochondrial proteins [23]. Another potential source of medium pyruvate is
the presence of some endogenous pyruvate in the isolated mitochondria.
2.7.2 Identifiability and estimability of the extrinsic parameters
Figure 2.6 shows that proton leak extrinsic parameter Tmaxf, LEAK has the largest
normalized sensitivity coefficient among the 25 extrinsic model parameters of the
integrated model. This could be because mitochondrial membrane leakiness not only
affects oxygen consumption rate, RCI, and membrane potential, but also substrate
consumption rate at state 2 since proton leak is the only pathway in this model for
consumption of the energy provided by substrate oxidation under state 2 conditions (in
the absence of ADP).
The intrinsic model parameters for glutamate-hydrogen or glutamate-hydroxyl
antiporter (GLUH), nucleoside diphosphokinase (NDK), fumarate hydratase (FH), and αketoglutarate (2-oxoglutarate) malate exchanger (OME) reactions have the smallest
normalized sensitivities coefficients (Figure 2.7). GLUH exists in rat liver mitochondria
and heart mitochondria [91], but does not exist in rat brain mitochondria [91]. The
existence of GLUH in rat lung mitochondria has not been confirmed, even though it was
proposed that GLUH might be an important process for the replenishment of TCA cycle
metabolites in the rat lung [92]. In the present study, the estimated GLUH activity and
sensitivity are very low, indicating that GLUH is not required to fit the data in Figure
2.3–Figure 2.5 or to predict the data in Figure 2.8-Figure 2.10. In contrast, glutamate
oxaloacetate (GOT) is the major pathway for glutamate + malate-driven respiration. The
GOT enzyme activity reported by Evans et al. [78, 92] (975 nmol/min/mg protein) is both
necessary and sufficient to reproduce the glutamate + malate respirometry data in Figure
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2.3B. Since the NDK and FH reactions are running at near equilibrium, their
corresponding extrinsic parameters are not identifiable without additional data.
We also estimated the matrix of correlation coefficients between the extrinsic
parameters (Figure 5) of the integrated bioenergetics model for the estimated parameters.
The extrinsic parameter pairs with the highest positive correlation are those for
PDH/PYRH and DCC (SUC)/SDH reactions. The extrinsic parameter pair with the
highest negative correlation is that for TCC/CITDH reactions. Extrinsic parameters for
equilibrium reactions such as NDH and FH have virtually no correlation with the
extrinsic parameters of other reactions.
2.7.3 Membrane integrity of isolated mitochondria
Isolation of mitochondria from rat lung tissue is challenging due to the high lipid
content and low mitochondria content [93]. For instance, cardiac myocyte mitochondria
account for ~35% of cell volume, compared to 1–2% in pulmonary endothelial cells,
which account for 50% of the cells in the lung [93]. Thus, a relatively high concentration
of bovine serum albumin is required in the isolation buffer to bind free fatty acid and
lipids. In addition, the integrity of lung mitochondrial membrane in the isolated
mitochondria is highly dependent on the isolation protocol used. For the data from Evans
et al. (Figure 2.4), the measured state 2 oxygen consumption rate was higher than that
measured in the present study (Figure 2.3). This could be due to differences in the
mitochondria isolation protocols used. Thus for the model fit to the data in Figure 2.4–
Figure 2.5, the value of the leak parameter (Tmaxf, LEAK, which accounts for state 2
respiratory rate) was adjusted to account for differences in the measured state 2
respiratory rate.
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State 3

State 2
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Figure 2.10: Effect of temperature and/or proton leak activity on mitochondrial
respiration, membrane potential, and NADH concentration.
Panel A (PYR+MAL) and Panel D (SUC) show integrated bioenergetics model
simulation of the state 2 and 3 oxygen consumption rates (OCR) with different proton
o
leak activities at different temperatures. Temperature was varied from 25 to 37 C and
leak activities were varied from 40% to 170% of Tmaxf, LEAK value in Table 2.4. Symbols
are experimental data (mean ± SE) of Figure 2.3 and Figure 2.4. Panel B (PYR + MAL)
and E (SUC) show corresponding simulated RCIs, which were calculated as the ratio of
state OCR and state 2 OCR. Panel C and F show model predictions of membrane
potential and NADH dynamic responses at different temperatures.

Simulations in Figure 2.10 show the effect of temperature and proton leak activity
(Tmaxf, LEAK) on mitochondrial oxygen consumption. With pyruvate + malate as metabolic
substrates, both state 2 and state 3 oxygen consumption rates increase (Figure 2.10A),
although the % increase in state 2 appears to be larger than that for state 3. As a result,
there is an inverse relationship between proton leak activity and RCI (Figure 2.10B). In
contrast, with succinate as the metabolic substrate, the state 3 oxygen consumption rate
decreases as proton leak activity increases (Figure 2.10D) due to the collapse of
membrane potential. Therefore, membrane leakiness has a higher impact on RCI when
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using succinate as substrate.
By altering the proton leak activity (Tmaxf, LEAK), the integrated model was capable
of simulating a wide range of mitochondrial experimental data performed under different
experimental conditions (temperature, mitochondria density, pH, etc.) with the same set
of values for the other model parameters (adjusted for temperature and pH effects).
Figure 2.10C and F show the effect of temperature on dynamic responses of membrane
potential and NADH redox states at state 3. Figure 2.10C also shows that ADP is
consumed faster at higher temperature. As a result, the length of state 3 decreases as
temperature increases.
2.7.4 Apparent functionally incomplete TCA cycle in isolated lung mitochondria
Isolated rat lung mitochondria and heart mitochondria show different behavior
under similar experimental conditions. For instance, isolated rat lung mitochondria with
pyruvate + malate as respiratory substrates produce significantly higher citrate than
isolated cardiac mitochondria [77]. For lung mitochondria with pyruvate + malate as
substrates, citrate production rate accounts for ~80% of the pyruvate and malate uptake
rate. In contrast, for heart mitochondria, the consumed pyruvate and malate rate is
approximately equal to amounts of citrate, α-ketoglutarate, succinate, and fumarate
production rates [77].
The large citrate production rate in isolated rat lung mitochondria is consistent
with an apparent functionally incomplete TCA cycle since most of the consumed carbon
from pyruvate and malate is converted to citrate and released into the extra-mitochondrial
buffer medium. Therefore, not enough substrate is left for the reaction to proceed beyond
citrate in the TCA cycle. This might also be due to high NADH significantly inhibiting
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the CITDH reaction under physiological conditions, based on isolated enzyme
experiments (KNADH = 4.7 M). Model predicted simulations (Figure 2.11) also show that
the reaction fluxes of CITDH and AKGDH are very low compared with those for
PYRDH and MALDH.

Key Metabolite Transporters

Key Enzymatic Reactions

Figure 2.11: Model predicted substrate-dependent responses of the steady state reaction
and transport fluxes.
3-Dimensional surface plots of key metabolic fluxes at steady-state as a function of buffer
pyruvate (PYR) and malate (MAL) concentrations ranging from 0.5 mM to 10 mM
obtained at the end of a 10-minute incubation period in isolated lung mitochondria.
Simulations were performed under the same experimental conditions as in Figure 2.5 and
Figure 2.4 with the values of the extrinsic model parameters set to those in Table 2.4.

Additional evidence of the apparent functionally incomplete TCA cycle in
isolated rat lung mitochondria is the relatively high pyruvate/oxygen ratio since pyruvate
consumption rate (10 nmol/min/mg mitochondria protein, as shown in Figure 2.5) is
comparable to oxygen consumption rate (12 nmol/min/mg mitochondria protein, as
shown Figure 2.4) under the same experimental conditions with pyruvate + malate as
metabolic substrates. If all the TCA cycle reactions are active, one would expect 4
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NADH to be generated from each pyruvate (PYRDH, ICDH, MALDH and AKGDH),
and 8 electrons to transfer to complex IV and reduce two molecules of oxygen. However,
the data from Evans et al. (Figure 2.4 and Figure 2.5) show that only 1.2 oxygen
molecules are consumed for each pyruvate molecule. The high pyruvate/oxygen ratio in
experiments suggests that only around 2.4 molecules of NADH are produced for each
pyruvate consumed, consistent with only two of the four dehydrogenases being
functional.
The observed large citrate production and the release to extra-mitochondrial
buffer in isolated lung mitochondria with complex I substrate (pyruvate + malate) could
be a means to ensure the availability of enough lipid synthesis for lung surfactant since
citrate is an important source of acetyl units for ATP citrate lyase, an important step in
fatty acid biosynthesis. The lung is an active organ that produces fatty acid to maintain
lung surfactant balance, which is composed of approximately 90% lipids [94].
It is well known that calcium ions (Ca2+) have a stimulating effect on key
dehydrogenase enzymes in mitochondria [90]. Considering that not all of the
dehydrogenase enzymes are active in isolated mitochondrial experiments (Figure 2.11),
the effect of Ca2+ control on the TCA cycle and bioenergetics might be underestimated in
isolated mitochondrial experiments. For example, Vinnakota et al. [90] showed that
physiological and supra-physiological Ca2+ levels have no or only modest stimulatory
effect on cardiac mitochondrial oxidative phosphorylation, respectively, in isolated
mitochondria respiring on complex I substrates (pyruvate + malate), which is insufficient
to explain the Ca2+ stimulating effect on oxidative phosphorylation in vivo in the heart.
The apparent functionally incomplete TCA cycle in isolated lung mitochondria due to
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excess citrate production and release to buffer (Figure 2.5 and Figure 2.11) could provide
an explanation for why the stimulating effect of Ca2+ on mitochondrial bioenergetics with
pyruvate + malate as respiratory substrate is less evident in isolated cardiac mitochondria
than mitochondria in vivo. In addition, significant NADH inhibition of the CITDH
reaction at physiological conditions could be another mechanism behind the nonstimulating effects of Ca2+ on mitochondrial bioenergetics in isolated cardiac
mitochondria with pyruvate + malate as respiratory substrates.
2.7.5 Rate-limiting steps in rat lung mitochondrial electron transport chain (ETC)
In the present study, experimental data and model sensitivity analysis reveal key
information regarding the limiting step(s) in the rat lung mitochondrial ETC. Consistent
with a previous report [76, 78], states 2 and 3 oxygen consumption rates in the presence
of succinate were higher than those measured in the presence of pyruvate + malate.
In isolated heart mitochondria, simultaneous addition of complex I and complex II
substrates increased state 3 oxygen consumption rate by up to 2-fold relative to that
following the addition of complex I or complex II substrates alone [95]. In contrast to
heart and liver mitochondria [95], our data show that convergent electron flow from both
complex I and complex II substrates is not additive (i.e. oxygen consumption rate with
pyruvate + malate + succinate did not increase relative to that with succinate alone),
indicating that in isolated rat lung mitochondria the rate limiting step(s) for the flow of
electrons in the ETC is downstream from complexes I and II (sum of CI and CII reaction
fluxes exceeded maximum reaction fluxes downstream CI and CII). Therefore,
complexes III, IV, V and/or ANT could be the potential rate limiting step.
At the end of each isolated rat lung mitochondrial experiment in Figure 2.3, the
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uncoupler FCCP was added to the extra-mitochondrial buffer to increase proton leak
from the inter-membrane space to the mitochondria matrix. In agreement with a previous
rat lung mitochondria study [76], our data (Figure 2.3 and Table 2.5) show that the
oxygen consumption rate at uncoupled state 3 did not increase relative to that of ADPstimulated state 3, suggesting that there is no excess ETC capacity over and above that
for oxidative phosphorylation. Thus, electron flow under state 3 respiration is not limited
by mitochondrial complex V or ANT. It is more likely that complex III and/or complex
IV are the rate limiting steps in rat lung mitochondria.
Integrated model sensitivity analysis can reveal important information regarding
rate limiting steps in mitochondrial ETC. A high sensitivity coefficient for a given
parameter indicates that the model output is sensitive to the enzyme whose activity is
described by that parameter. Therefore, an enzyme with a relatively high sensitivity
coefficient is more likely to be the rate limiting step than an enzyme with a low
sensitivity coefficient. Sensitivity analysis results (Figure 2.6) show that mitochondrial
complex I and complex IV have much higher normalized sensitivity coefficients than
complex III. One possible explanation is that with complex I substrates, there is excess
electron transport capacity in ETC, and that mitochondrial electron flow is limited by
complex I activity. However, when complex II substrate is present, electron flow from
complexes I and II exceeds the maximum capacity of complex IV, and thus complex IV
becomes the rate limiting step.
To prove that mitochondrial complex IV is the rate limiting step, maximum
complex IV activity was measured using the complex IV substrate TMPD (artificial
electron donor for complex IV) + ascorbate as direct electron donors. Maximal complex

60
IV activity was measured by adding TMPD along with ascorbate to the medium in the
presence of antimycin A. The measured oxygen consumption rates (OCR) are shown in
Table 2.5, which also shows OCR in the presence of exogenous cytochrome C and
succinate. The results in Table 2.5 show no significant difference between the oxygen
consumption rates measured under state 3 conditions in the presence of succinate and
those measured in the presence of TMPD + ascorbate or TMPD + ascorbate +
cytochrome C. These results are consistent with those reported by Fisher et al. [76, 78].

Table 2.5: Complex IV activity (nmol/min/mg)
Electron donor
OCR (nmol/min/mg)
OCR (nmol/min/mg)
Current study (30 oC)
Fisher et al. [76, 78], 28 oC
65 ± 12 (n = 8)
50 ± 13 (n = 4-7)
TMPD+Ascorbate
73 ± 11 (n = 8)
NA
TMPD+Ascorbate+CytoC
78± 11 (n = 8)
53 ± 9 (n = 4 -7)
SUC+ADP
Values are mean ± SE. OCR, oxygen consumption rate; CytoC, cytrochrome c; TMPD,
tetramethyl-p-phenylenediamine; NA, not available.

These results suggest that maximum complex IV activity is reached when
succinate is used as the metabolic substrate, and that additional oxygen consumption
cannot be stimulated by the addition of an uncoupler or complex I substrates to the
surrounding medium.
Release of cytochrome c due to the relatively leaky mitochondrial outermembrane could be a reason for the apparent low complex IV activity. If so, the addition
of exogenous cytochrome c to the medium should markedly stimulate oxygen
consumption. As shown in Table 2.5, adding exogenous cytochrome c had a small
(12.5%) and insignificant effect (paired t-test, p = 0.11) on the measured rate in the
absence of exogenous cytochrome c in the medium. Considering that a ≤10% increase of
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the cytochrome c stimulated oxygen consumption can be regarded as a sign of intact
outer-membrane in heart and muscle mitochondria [96], a 12.5% increase in oxygen
consumption may suggest a slightly “leaky” mitochondrial outer-membrane.

2.8 Conclusion and model limitations
2.8.1 Conclusions
The proposed integrated bioenergetics model is an important step towards the
development and validation of a comprehensive thermodynamically-constrained
computational model of isolated perfused rat lung tissue bioenergetics that includes
cytosolic processes such as glycolysis. Such a model will be used to evaluate the impact
of ALI- or ARDS-induced changes in one or more mitochondrial or cytosolic processes
on overall lung tissue bioenergetics, and for assessing the impact of targeting specific
processes for mitigating the impact of ALI and ARDS on lung tissue bioenergetics.
2.8.2 Model limitations
Cations such as calcium (Ca2+) and magnesium (Mg2+) play an important role in rat
lung mitochondrial bioenergetics. In this integrated bioenergetics model, all the cation
concentrations are assumed constant. Even though it is known that dehydrogenases are
activated by Ca2+ at nM level (~100-300 nM), Fisher et al. reported that mitochondrial
oxygen consumption rates are inhibited as Ca2+ concentration in mitochondria matrix
increases to µM-mM ranges [76]. However, the detailed mechanism for this biphasic
effect is not known. Therefore, additional studies and data from isolated rat lung
mitochondria are required to incorporate cations into the current model.
Another limitation of the model is that it does not differentiate between the forty
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different cell types in the lung. Endothelial cells, which account for ~50% of all lung
cells, are not rich in mitochondria [86]. However, other lung cell types including
contractile (smooth muscle cells), phagocytic (alveolar macrophages) and epithelial cells
are rich in mitochondria. Thus, the model and the estimated values of model parameters
should be interpreted as a mechanistic description of the average mitochondrial
bioenergetics of all lung cells. Although the question regarding the mitochondrial
bioenergetics of specific lung cell types is important, understanding the bioenergetics of
mitochondria isolated from lung tissue and alteration in those bioenergetics is important
and has functional implications regardless of the lung cell types involved.
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Chapter 3 : Computational Model of the Bioenergetics of
Isolated Perfused Rat Lung
3.1 Introduction
Altered lung tissue bioenergetics plays a key role in the pathogenesis of lung
diseases. A wealth of information exists regarding the bioenergetic processes of
mitochondria isolated from rat lungs, cultured pulmonary endothelial cells, and intact rat
lungs under physiological and pathophysiological conditions [7, 16, 18, 20-24]. However,
the interdependence of those processes makes it difficult to quantify the impact of a
change in a single or multiple process(es) on overall lung tissue bioenergetics. For
instance, although ~85% of cellular ATP is produced in mitochondria under physiological
conditions [18], glycolysis is important for lung tissue bioenergetics since it can partially
compensate for the decrease in lung tissue ATP when mitochondrial ATP generation is
impaired [97].
The objective of Aim 2 was to develop and validate an integrated computational
model of isolated rat lung tissue bioenergetics using existing experimental data. Figure
3.1 shows an overview of an isolated perfused rat lung system. The system allows us to
change ventilation gas and composition of the perfusate.
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Figure 3.1: Structure of isolated perfused rat lung system.

The model of isolated perfused rat lung expands the integrated computational
model of the bioenergetics of mitochondria isolated from rat lungs by accounting for
glucose uptake and phosphorylation, glycolysis, and the pentose phosphate pathway. The
model is used to gain novel insights into how lung tissue glycolytic rate is regulated by
exogenous substrates such as glucose and lactate, and assess differences in the
bioenergetics of mitochondria isolated from lung tissue and those of mitochondria in
intact lungs. The results of Aim 2, including the development and validation of the model
of the bioenergetics of the intact rat lung, are described in an accepted manuscript
(Frontiers in Physiology: Mitochondrial Research).

3.2 Model Development
3.2.1 Model Structure
As shown in Figure 3.2, the proposed model consists of five different regions: the
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reservoir + tubing region, the lung vascular (blood) region, the cytosolic region, intermembrane space (IMS) region, and the mitochondria matrix region. For all regions, the
general forms of the reaction and transport fluxes are identical to those developed for the
integrated computational model of the bioenergetics of mitochondria isolated from rat
lungs [24].
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Figure 3.2: Structure of the isolated perfused rat lung bioenergetics model.
The model consists of five regions: The reservoir + tubing region, the lung vascular
(blood) region, the cytosolic region, the inter-membrane space (IMS) region, and the
mitochondria matrix region. Major reactions include glycolysis, pentose phosphate cycle,
TCA cycle, and electron transport chain reactions. Major biochemical species included
include: GLC: glucose, G6P: glucose 6-phosphate, F6P: fructose 6-phospate, F16BP:
Fructose 1,6-biphosphate, GAP: Glyceraldehyde 3-phosphate, BPG: 1,3Bisposphoglycerate, PEP: Phosphoenolpyruvate, PYR: pyruvate, LAC: lactate. ALA:
alanine. CoA: coenzyme-A, ACoA: acetyl-CoA, OXA: oxaloacetate, CIT: citrate, AKG:
a-ketogluterate, SCoA: succinyl-CoA, SUC: succinate, FUM: fumarate, MAL: malate,
GLU: glutamate, and ASP: aspartate, NAD and NADH: oxidized and reduced form of
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nicotinamide adenine dinucleotide, respectively, FAD and FADH2: oxidized and reduced
form of flavin adenine dinucleotide, respectively, ADP and ATP: adenosine triphosphate
and adenosine diphosphate, respectively, UQ and UQH2: oxidized and reduced form of
ubiquinone, respectively, CtyC3+ and CytC2+: oxidized and reduced form of cytochrome
c, respectively.
Lung tissue is capable of oxidizing a wide range of substrates, including glucose,
fatty acids, amino acids, and lactate [18, 21, 23]. However, glucose is by far the major
substrate under physiological conditions [18]. Alanine, an amino acid, can also be an
importance substrate, especially when glucose is low [23, 98]. Thus, glucose and alanine
utilization and intermediary metabolism are accounted for in the proposed integrated lung
tissue bioenergetics model. The model does not account for glycogen, which is low and
relatively constant in lung tissue [23].
3.2.2 Reaction and transport fluxes
The proposed integrated lung tissue bioenergetics model accounts for 70 state
variables, including the concentrations of key metabolites in the mitochondrial matrix
region and cytosol, as well as the mitochondrial membrane potential. Key reactions in the
glycolytic pathway and pentose phosphate pathway are also included in this model (Table
3.1).

Table 3.1: Reactions in the isolated perfused rat lung model
Reaction number Enzyme
Reference reactions
HK
GLCc+ATPc ⇌ G6Pc+ADPc+Hc
1
PGI
G6Pc ⇌ F6Pc
2
PFK
F6Pc+ATPc ⇌ F16BP+ADPc+H+
3
ALD
F16BPc ⇌ 2GAPc
4
GAPDH
GAPc+Pic+NADc ⇌ BPG+NADHc+Hc
5
PGK
BPGc + ADPc ⇌ PEPc+ATPc
6
PK
PEPc+ADPc+Hc ⇌ PYRc+ATPc
7
LDH
PYRc + NADHc + Hc ⇌ LACc + NADc+
8
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9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

G6PDH
6PGD
GR
GPx
ATPase
AK
AA
PDH
CITS
ICDH
AKGDH
SCAS
NDK
SDH
FUM
MDH
GOT
CI
CII
CIII
CIV
CV

G6Pc + NADPc ⇌ PG6c + NADPHc + Hc
PG6c + NADPc ⇌ R5Pc + NADPHc + Hc + CO2
GSSGc + Hc + NADPH ⇌ 2GSHc + NADPc+
2GSHc + H2O2c ⇌ GSSGc + 2H2O
ATPc ⇌ ADPc + Pic+ Hc
ATPc+ AMPc ⇌ 2ADPc
PYRc ⇌ ALAc
PYRm+CoAm+NADm ⇌ ACoAm+CO2+NADHm+Hm
ACoAm+OXAm ⇌ CITm+CoAm+ 2Hm
CITm+NADm ⇌ AKGm+NADHm+CO2
AKGm+CoAm+NADm ⇌ SCoAm+NADHm+CO2
SCoAm+GDPm+Pim ⇌ SUCm+GTPm+CoAm+Hm
GTPm+ADPm ⇌ GDPm+ATPm
SUCm+FADm ⇌ FUMm+FADH2m
FUMm = MALm
MALm+NADm ⇌ OXAm+NADHm+ Hm
ASPm+aKGm ⇌ GLUm+OXAm
NADHm+UQm+Hm ⇌ NADm+UQH2m+ 4∆H
FADH2+UQm ⇌ FADm+UQH2m
UQH2,m+2CytCo+2Hm ⇌ UQm+2CytCr+ 4∆H
2CytCr+0.5O2+2Hm ⇌ 2CytCo+H2O+2∆H
ADPm+Pim+Hm+3∆H ⇌ ATPm

Thirteen trans-membrane transport processes (Table 3.2) are included in the
model to account for the exchange of key metabolic species between the mitochondrial
matrix and cytosol, and between the blood region and cytosolic region. We used the same
reaction and transport flux expressions as in the isolated rat lung mitochondria [24].

Table 3.2: Transports in the isolated perfused rat lung model
Transport number
Enzyme
Reference reactions
1
GLUT
GLCb ⇌ GLCc
2
PYRT
PYRb + Hb ⇌ PYRc + Hc
3
LACT
LACb + Hb ⇌ LACc + Hc
4
PIT
Pib ⇌ Pic
5
DCC (SUC)
SUCm +Pic ⇌ SUCc+Pim
6
DCC (MAL)
MALm+Pic ⇌ MALc+Pim
7
TCC
MALc+ CITm ⇌ MALm+ CITc
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8
9
10
11
12
13

PYRc + Hc ⇌ PYRm + Hm
Pic + Hc ⇌ Pim + Hm
ADPc + ATPm ⇌ ADPm + ATPc
GLUc+ Hc ⇌ GLUm+ Hm
NADHc + NADm ⇌ NADHm + NADc
Hi ⇌ Hm

PYRH
PIC
ANT
GLUH
MAS
LEAK

Several glycolytic reactions are regulated by specific activators or inhibitors [99]. For
instance, hexokinase (HK) is inhibited by its reaction product glucose-6-phosphate
(G6P), phosphofructokinase (PFK) is known to be activated by cytosolic AMP and
inhibited by cytosolic ATP and citrate [99, 100]. Those reaction fluxes are modified to
account for such regulatory effects as described in Appendix V.
3.2.3 Dynamic mass balance equations
The governing ordinary differential equations describing the dynamic changes in
the concentrations (C) of various chemical species in different regions (total 70 state
variables) were derived based on the principle of mass balance. The changes in the
concentration of species within each of the five regions are given by:

 F  Cb, j  Cr , j 

(3.1)

 F  Cr , j  Cb, j    J bc, j

(3.2)

   c , j J c , j   J b c , j   J c  m , j

(3.3)

Vr

Vb

Vc

dCr , j

dCb, j
dt

dCc, j
dt
Vm

Vi

dt

dCm, j
dt
dCi , j
dt

   m, j J m, j   J c m, j

(3.4)

  i , j J i , j   J i m, j

(3.5)

where Cx,j is the concentration of jth species in region x, F is the flow rate, Jx,j is the jth
reaction flux in region x, and Jx-y,j is the jth transport flux between region x and region y,

69
and Vx is the volume of the region x. Subscripts r, b, c, m, and i denote reservoir region,
blood region, cytosolic region, mitochondrial region, and inter-membrane space region,
respectively. Detailed mass balance equations are included in Appendix VI.
MATLAB function ‘ode15s’ (MathWorks Inc.) was used to solve the system of
governing differential equations.

3.3 Model parameter estimation
The proposed integrated lung tissue bioenergetics model accounts for key
metabolites in the mitochondrial matrix region and cytosol, as well as the mitochondrial
membrane potential. Volumes of each region and general model parameters are listed in
Table 3.3.

Table 3.3: General model parameters for the isolated perfused lung model
Parameter

Value (units)

Source

Volumes
Capillary vascular volume (Vb)
0.66 (ml)
[12]
Total tissue volume (Vc+Vm+Vi)
0.67 (ml)
[12]
Total lung volume
1.33 (ml)
[12]
Lung tissue cytosolic volume (Vc)
0.66 (ml)
[86]*
Mitochondria volume (Vm)
13.12 (μl)
[86]*
Inter-membrane space volume (Vi)
0.95 (μl)
[46]*
Lung wet/dry weight ratio
5.87 ± 0.24
[16]
Average rat lung dry weight
0.227 (g)
[16]**
Metabolic pools
Total flavin adenine dinucleotide
0.7 (mM)
[66]
concentration (FAD + FADH2) in
mitochondria
Total pyridine nucleotide content
1.73 (nmol/mg
[76]
(NAD+ + NADH) in mitochondria
mitochondria)
Cytosolic NAD+ concentration
[98]
340 (M)
* Calculated based on Vm/Vc = 1/50 [86], and Vi/Vm = 0.0724 [46].
** Calculated from lung wet weight based on rat lung wet weight/ dry weight ratio =
5.87;
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For the mitochondria matrix and IMS regions, the values of intrinsic (binding
constants, K’s) and all extrinsic model parameters (Vmaxfs and Tmaxfs), except for the
parameter describing mitochondrial membrane leakiness, were fixed to those estimated
using our model of the bioenergetics of isolated lung mitochondria (Aim 1) [24]. For
these regions, the values of the extrinsic model parameters, expressed in units of
nmol/min/mg mitochondria protein in the model for isolated lung mitochondria, were
converted to nmol/min/lung for the integrated lung model by multiplying each parameter
by total mitochondria protein mass (Mmito) in the rat lung. The value of Mmito along with
those for other unknown model parameters were estimated from the experimental data
described below. For the lung model, the value of Tmaxf,,LEAK was assumed to be equal to
or lower than that estimated for isolated mitochondria [24], since the mitochondria
isolation process could cause damage to mitochondrial membrane. Thus Tmaxf,LEAK was
assumed to be an unknown parameter for the lung model.
For the cytosolic region, the values of the intrinsic model parameters, such as
binding constants of various substrates and products for different enzymes and
transporters, were set to previously published values (see Appendix). The assumption is
that the binding constants are intrinsic model parameters, and hence their values should
be organ-independent [24, 46]. The values of the extrinsic model parameters (i.e., Vmaxfs,
Tmaxfs) in Table 3.3 were estimated by fitting model solution to experimental data Figure
3.3-Figure 3.5 from rat lung tissue bioenergetics using the genetic algorithm (MATLAB
function ‘ga’). The objective function E optimized was:
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1 N  xi , j  X i , j
E   
 X i, j
j 1 N i 1 
M
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(3.6)

where xi , j and X i , j are the model solutions and the corresponding experimental
data at the ith time point and jth data set, respectively. N is the number of data points and
M is the number of data sets used for the parameter estimation. Experimentally measured
maximal enzyme activities were used as initial guesses for the Vmaxfs of corresponding
reactions in the glycolytic pathway [101]. A total of seventeen unknown extrinsic
parameters were estimated from the experimental data in Figure 3.3-Figure 3.5 [16, 18,
20, 21, 23].

Table 3.4: Estimated values of unknown parameters for the lung model (30 °C)
Parameters Definition
Parameter
Experimentally
value
measured value
(nmol/min/lu (nmol/min/lun
ng)
g)
[101]*
Glycolytic pathway reactions
Vmaxf, HK
Maximum forward reaction rate of HK
279
705 ± 93.1
4
Vmaxf, PGI
Maximum forward reaction rate of PGI
3.70×10
4.2×104 ±
3.7×103
Vmaxf, PFK
Maximum forward reaction rate of PFK
1.47×103
8.3×103 ±
1.2×103
Vmaxf, ALD
Maximum forward reaction rate of ALD 1.43×103
5.72×103 ± 146
4
Vmaxf, GAPDH Maximum forward reaction rate of
6.35×10
5.53×103 ± 864
GAPDH
Vmaxf, PGK
Maximum forward reaction rate of PGK 2.00×105
8.15×104 ±
1×104
4
Vmaxf, PK
Maximum forward reaction rate of PK
1.89×10
1.83×104 ± 784
4.74×104 ±
Vmaxf, LDH
Maximum forward reaction rate of LDH 3.92×105
5.6×103
Other parameters
Maximum forward reaction rate of
NA
Vmaxf, G6PDH
2.82×103
G6PDH
Maximum forward reaction rate of
NA
Vmaxf, ATPase
2.54×104
ATPase
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Vmaxf, AA
Tmaxf, GLUT
Tmaxf, PYRT
Tmaxf, LACT
Tmaxf, MAS
Tmaxf, LEAK

Maximum forward reaction rate of AA
409
NA
Maximum transport rate of GLUT
534.12
NA
Maximum transport rate of PYRT
185.08
NA
3
Maximum transport rate of LACT
9.08×10
NA
3
Maximum transport rate of MA shuttle
4.43×10
NA
Maximum rate of passive proton leak
15.98
NA
Average mass of mitochondria protein in
13.12 mg**
Mmito
16.44 mg
rat lungs
*values are converted from µmol/g wet weight/min to nmol/min/lung. **Mitochondrial
protein content is 1mg/1µL mitochondrial volume. NA = Not available.
The following data sets (Figure 3.3–Figure 3.5) were used to estimate the values
of the unknown model parameters (i.e. maximal reaction and transport velocities), related
to the cytosolic reactions and plasma membrane metabolite transporters.

Figure 3.3: Pseudo-steady state reaction fluxes used for parameter estimation.
Panel A. Glucose (GLC) consumption rate [23] and total lactate (LAC) and pyruvate
(PYR) production rates [20] of isolated rat lungs perfused with perfusate containing 5.5
mM glucose. Red symbols are experimental data (mean ± SE, n = 4). Panel B. Pseudosteady state reaction flux of pentose phosphate pathway (PPP) measured at the end of 100
min recirculation time [18]. G6PDH: glucose 6 phosphate dehydrogenase. Red symbol is
experimental data calculated based on [18, 70]. Values are mean ± SE (n = 4). Panel C.
Lung cyanide-sensitive oxygen consumption rate (OCR), calculated as lung OCR in the
absence of potassium cyanide – OCR in the presence of potassium cyanide (complex IV
inhibitor, 2 mM) of atelectatic isolated perfused rat lungs [102]. Values are mean ± SE (n
= 6). For the model, lung OCR was calculated as half of reaction flux of complex IV.
Panel D. Mitochondrial and cytosolic ATP production rate were estimated based on
recovery of catabolic products from glucose [18]. Units were converted from µmol/hr/g
dry weight to µmol/min/g dry weight. In model simulations, pseudo-steady state reaction
fluxes are collected at the end of 100 min simulation time. Blue bars are model fits to the
data.
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For the perfusate glucose concentration of 5.5 mM, Figure 3.3 (panel A) shows
the glucose consumption rate [23], and the production rates of pyruvate and lactate [20].
The data in Figure 3.3 (panel B) show the pseudo-steady state reaction flux of the pentose
phosphate pathway. Audi et al. estimated the reaction flux of mitochondrial complex IV
as the cyanide-sensitive oxygen consumption rate (OCR) calculated as the difference in
isolated rat lung OCR measured in the absence of potassium cyanide (complex IV
inhibitor, 2 mM) and that measured in the presence of potassium cyanide (Figure 3.3,
panel C) [102]. The data in Figure 3.3 (panel D) show rat lung cytosolic ATP production
rate and mitochondrial ATP production rate estimated by Fisher et al. based on glucosecarbon recovery from glucose [18].
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Figure 3.4: Effects of the perfusate GLC or LAC on rat lung GLC consumption and LAC
production. Panel A. Effect of perfusate glucose (GLC) concentrations on rat lung
glucose consumption rate [23]. Lungs were isolated from male Sprague-Dawley rats
(200-260 g) and perfused with different concentrations of D-glucose plus 5-3H-glucose
and U-14C glucose. The labeled glucose, 5-3H-glucose, and U-14C glucose were used to
measure glucose consumption and exogenous lactate production, respectively. The
production rate of 3H2O was used as index of glucose consumption since more than 90%
of 3H from glucose was recovered as 3H2O [23]. Values are mean ± SE (n = 3 or more for
each glucose concentration). Lines are model fits to data. Panels B and C. Lung
exogenous, endogenous, and total lactate (LAC) production rates as a function of
perfusate glucose concentration [23]. Isolated rat lungs were perfused with different
concentrations of D-glucose plus 5-3H-glucose and U-14C glucose. Perfusate samples
were collected every 20 minutes for LAC measurement. Labeled LAC concentrations
were derived from U-14C glucose; unlabeled LAC concentrations were derived from
endogenous substrates such as amino acids [23]. In panel B, total LAC production is
plotted as a function of recirculation time. In panel C, exogenous, endogenous, and total
LAC production rates are plotted separately as a function of buffer GLC concentration.
Values are mean ± SE (n = 6 or more for each GLC concentration). Lines are model fits
to data. Panel D. Effect of perfusate LAC concentrations on lung GLC consumption rate
[21]. Lungs were isolated from male Sprague-Dawley rats (180–220 g) and perfused with
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perfusate containing 10 mM 5-3H-glucose and D-glucose. In addition, different
concentrations of LAC were added to the perfusate before recirculation. 3H2O production
rate was measured as an index of GLC consumption rate. 0.5 mM LAC had no effect on
GLC consumption rate, but as buffer LAC concentrations increased to 2 mM, GLC
consumption rate decreased to half compared to that under baseline conditions (no LAC).
Symbols are mean values from 4–10 lungs, and lines are model fits to data.
Kerr et al. evaluated the effect of perfusate glucose concentrations on the glucose
consumption rate as well as lactate production rate in isolated perfused rat lungs [23]. The
lungs were perfused with different concentrations of D-glucose along with labeled
glucose (5-3H-glucose and U-14C glucose, each with specific activity of 0.1 mCi/mmol).
The labeled glucose were used to measure lung glucose consumption rate, and to
distinguish lactate production rate from glucose added to the perfusate (exogenous
source) from that derived from endogenous substrates such as amino acids and glycogen
[23]. Following the lung uptake of 5-3H-glucose, tritium (3H) is liberated during
glycolysis to form 3H2O. Over 90% of the 3H from glucose was recovered as 3H2O [23].
As such, the production rate of 3H2O was used as a measure of lung glucose consumption
rate [23]. For a given perfusate sample, 3H2O was separated from 5-3H-glucose by
evaporation of the sample [71]. 14C labeled lactate measured in perfusate was derived
from U–14C glucose and is referred to as exogenous lactate since it is derived from
exogenous sources (i.e. glucose added to the perfusate). Lactate derived from U–14C
glucose was separated from U–14C glucose by extraction with ether [23]. Endogenous
lactate in a given perfusate sample was then obtained as the difference between total
lactate in sample, measured enzymatically, and labeled lactate [23]. The resulting data are
shown in Figure 3.4 (panels A–C). The data in Figure 3.4 show the amount of glucose
consumed (panel A) and total lactate produced (panel B) as a function of recirculation
time over a range of perfusate glucose concentrations. The results show a nonlinear
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relationship between the perfusate glucose concentration and the lung rate of glucose
consumption, consistent with the saturability of glucose transporters [23]. The results in
Figure 3.4 (panel C) show that the rate of endogenous lactate production is saturable at
low perfusate glucose concentration, whereas the rate of exogenous lactate production is
relatively linear over the range of perfusate glucose concentrations studied. In the model,
exogenous (LACexo) and endogenous (LACend) lactate production rates were calculated as

LACendo 

J AA
J LACT
J PK  J AA

(3.7)

LACexo 

J PK
J LACT
J PK  J AA

(3.8)

where JAA , JPK and JLACT are the reaction/transport rates of alanine aminotransferase,
pyruvate kinase, and lactate transport between blood and cytosol, respectively.
Fisher and Dodia evaluated the effect of perfusate lactate concentrations on lung
glucose consumption rate in isolated rat lungs perfused with perfusate containing 5-3Hglucose and different D-glucose concentrations [21]. 3H2O production rate was measured
as an index of glucose consumption rate. The data in Figure 3.4 (panel D) show that 0.5
mM lactate had no effect on glucose consumption rate, but as perfusate lactate
concentration increased to 2 mM, glucose consumption rate decreased to half as
compared to that under baseline conditions (zero exogenous lactate). These data suggest
that exogenous lactate has a regulatory effect on rat lung glycolytic rates [21, 103, 104].
In another study, Fisher and Dodia measured the production rates of lactate and
pyruvate in isolated perfused rat lungs as a function of O2 partial pressure (PO2) in lung
ventilation/aeration gas mixture [20]. Gas mixtures containing %PO2 ranging from
0.006% to 95% were used to ventilate the lungs and aerate the perfusate. Perfusate
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samples were then collected for lactate and pyruvate measurements. Figure 3.5 shows
that lactate and pyruvate production rates were not significantly altered when PO2 in gas
mixture was between 0.1% (0.76 mmHg) and 95% (~722 mmHg) [20]. However, as PO2
was dropped to 0.006%, lactate production rate increased by ~ two-fold. These results
suggest that rat lung can maintain normal metabolism for PO2 ≥ 0.1% [20].

A.

B.

C.

D.

E.

F.

Figure 3.5: Effects of lung oxygen partial pressure (PO2) on lung LAC and PYR
production. Lungs were isolated from male Sprague-Dawley rats (200–250 g) and
perfused with 40 ml Krebs-Ringer bicarbonate buffer containing 10 mM glucose (GLC)
and 3% bovine serum albumin [20]. Gas mixtures containing different % oxygen partial
pressures (PO2; ranging from 0.006% to 95%) were used to ventilate the lungs and aerate
the perfusate. Perfusate sample were collected for lactate (LAC) and pyruvate (PYR)
measurements. Rat lung LAC production rate (panels A and D), PYR production rate
(panels B and E), and LAC/PYR ratio (panels C and F) are plotted as a function of %PO2
(top panels) or log (%PO2) (bottom panels) in gas mixture to show the model fit to data at
low %PO2 [20]. Symbols are experimental data [20] and solid lines are model fits.
All of the extrinsic model parameters of the integrated lung tissue bioenergetics
model (Table 3.4) were estimated by simultaneously fitting the model solution to the
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experimental data in Figure 3.3–Figure 3.5 using genetic algorithm (MATLAB function
“ga”). The estimated values of the extrinsic model parameters are shown in Table 3.4

3.4 Model validation
To assess the estimability (existence of model parameters to fit available
experimental data) and identifiability (uniqueness of the model parameters to fit available
experimental data) of the extrinsic parameters of the integrated lung tissue bioenergetics
model, we estimated the parameters’ normalized sensitivity coefficients and a matrix of
correlation coefficients between the estimated model parameters. The normalized
sensitivity coefficients provide information about the contribution of each of the extrinsic
model parameters to the overall model solution. If a given model parameter is
identifiable, its sensitivity coefficient should be relatively large. In addition, a parameter
that has a relatively larger sensitivity coefficient indicates the parameter has more
influence on model outputs. While the correlation coefficient matrix provides
information about the degree of interdependence between the various model parameters.
For a given extrinsic model parameter, the normalized sensitivity coefficient was
determined using (3.9) [57]:
Si 

i  E 


E  i 

(3.9)

where E is the sum of squared difference between experimental data and the integrated
lung tissue bioenergetics model fit, as defined by equation (3.9), and
value of ith extrinsic model parameter.

i

is the estimated

E
was approximated using the central difference
 i
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method with 0.1% change in

i .

The matrix of correlation coefficients between the model parameters was
evaluated at the estimated parameter values in Table 3.4 that best fit the integrated lung
tissue bioenergetics model to the available experimental data. The correlation coefficient
(CCij) between the ith parameter and jth parameter was determined using Equation (3.10)
[85]:
CCij 

HH ij
HH ii  HH jj

for i,j= 1,…,np

(3.10)

where np is the number of model parameters, HH is the inverse of the product of the
transpose of the Jacobian matrix and the Jacobian matrix evaluated at the estimated
values of the model parameters in Table 3.4 that best fit the model to the data in Figure
3.3-Figure 3.5.
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Figure 3.6: Matrix of correlation coefficients between the extrinsic parameters of the
integrated lung tissue bioenergetics model.
Correlation coefficients range between -1 (perfect negative correlation) and +1 (perfect
positive correlation) and are estimated using equation (3.10). A small positive or negative
correlation coefficient between two parameters suggests small interdependence between
those parameters.
Figure 3.7 and Figure 3.6 show the respective normalized sensitivity coefficients
and matrix of correlation coefficients for the extrinsic model parameters. For most of the
extrinsic model parameters, the normalized sensitivity functions are relatively high, and
the correlation coefficients are relatively low, consistent with a tight range of values for
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those parameters that provide a good fit to the data in Figure 3.3–Figure 3.5. This
suggests that the chosen experimental data has enough information to estimate the values
of the unknown model parameters.

Mmito
Tmaxf, LEAK
Tmaxf, MAS
Tmaxf, LACT
Tmaxf, PYRT
Tmaxf, GLUT
Vmaxf, AA
Vmaxf, ATPase
Vmaxf, G6PDH
Vmaxf, LDH
Vmaxf, PK
Vmaxf, PGK
Vmaxf, GAPDH
Vmaxf, ALD
Vmaxf, PFK
Vmaxf, PGI
Vmaxf, HK

0.0

0.1

0.2

2.0

Normalized sensitivity coefficient

Figure 3.7: Normalized sensitivity coefficients of the extrinsic model parameters.
A parameter contribution to the model solution is proportional to its normalized
sensitivity coefficient estimated using equation (3.10).
To validate the integrated lung tissue bioenergetics model, we assessed its ability
to predict published experimental data that were not used for estimating the values of the
unknown model parameters. To that end, we evaluated the ability of the model to predict
the experimental data in Figure 3.8–Figure 3.10 and Table 3.5.
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Bongard et al. measured fractional ATP, ADP and AMP contents as a function of
energy charge (EC)
EC 

ATP  0.5 ADP
ATP  ADP  AMP

(3.11)

in isolated rat lungs following exposure to a single or combination of various treatments,
including rotenone (complex I inhibitor, 20 μM), ubiquinol analog coenzyme Q1
(oxidized artificial electron donor, 50 µM), or antimycin A (complex III inhibitor, 3.6
μM) [16]. These treatments induced different degrees of change in lung EC, adenine
nucleotides contents, and lactate production rates. Figure 3.8 (panel A) shows that lung
ATP content decreased as EC decreased, whereas AMP content increased as EC
decreased. Lung ADP content shows a biphasic behavior as a function of EC. As shown
in Figure 3.8 (panel B), lung lactate production rate increased as lung EC decreased.
However when EC dropped below 0.4, lung lactate production rate did not increase
further. The two glycolytic enzymes HK and PFK require ATP as substrate. Model
simulation shows that when EC falls below 0.4, ATP content becomes too low for these
two enzymes to proceed. Therefore, under such conditions, most of the lactate produced
by rat lung is from endogenous substrate such as alanine. As shown in Figure 3.8, model
predictions using the estimated values of the model parameters in Table 3.4 are in good
agreement with the measured experimental data. For model predictions, mitochondrial
complex I and complex III activities were gradually decreased to simulate the inhibitory
effects of rotenone and antimycin A on EC. Additional model simulations in Figure 3.8C
show that as cytosolic ATP concentration decreases (due to decrease in complex I (CI)
activity), cytosolic phosphate (Pi) concentration as well as cytosolic ADP + AMP
increase. Model simulations in Figure 3.8D show mitochondrial concentration of ATP,
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ADP, and Pi as a function of complex I activity.
The ATP hydrolysis potential, rGATPase, is a measure of the energy released by
ATP hydrolysis and is more thermodynamically relevant than EC [105]. We calculated

rGATPase using the following equation:
 [ ADPc ][ Pic ] 
0
 r GATPase   r GATPase
  RT  ln 

 [ ATPc ] 

(3.12)

where [ATPc], [ADPc] and [Pic] are concentrations of ATP, ADP and inorganic phosphate
(Pi) in the cytosolic region, respectively; rG0ATPase, R and T are the standard Gibbs free
energy of the reaction at pH = 7, gas constant, and temperature, respectively. Model
simulations in Figure 3.8E and F show that decreasing CI activity leads to decrease in
lung EC, decrease in cytosolic rGATPase, decrease in lung O2 consumption rate (OCR),
and increase in lung rate of lactate (LAC) production. The simulations in Figure 7E
suggests a high correlation between EC and rGATPase, consistent with theoretical
calculations by Erecinska et al. [105].
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Figure 3.8: Relationship of lung fractional ATP, ADP and AMP contents, lung lactate
(LAC) production rate, and energy charge. For the data (symbols) in panels A and B,
lungs were isolated from male Sprague-Dawley rats (n = 36) and perfused with perfusate
containing 5.5 mM glucose and 5% bovine serum albumin at 37°C. Isolated perfused rat
lungs were exposed to single or combination of different treatments, including 20 μM
rotenone (complex I inhibitor), 50 µM CoQ1 (reduced to CoQ1H2, an artificial electron
donor), or 3.6 μM antimycin A (complex III inhibitor).These treatments induced different
degrees of change in lung EC, adenine nucleotides contents, and LAC production rates.
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For model predictions (solid lines), mitochondrial complex I activity was incrementally
decreased to simulate the inhibitor effects of rotenone on lung EC. In panel A, lung ATP
amount decreased as EC decreased, while AMP amount increased as EC decreased. Lung
ADP amount showed a biphasic behavior. In panel B, lung LAC production rate
increased as lung EC decreased. Panel C shows model predicted relationships between
CI activity and cytosolic concentrations of ATP, ADP, AMP and Pi. Panel D shows model
predicted relationships between complex I (CI) activity and mitochondrial concentrations
of ATP, ADP, and phosphate (Pi). Panel E shows model predicted relationships between
CI activity and EC and cytosolic ATP hydrolysis potential (rGATPase). Panel F shows
model predicted relationships between CI activity, lung oxygen consumption rate (OCR)
and lung lactate (LAC) production rate.

Bongard et al. also evaluated the effect of complex I inhibitor rotenone (20 µM)
on lung ATP/ADP ratio and on lactate/pyruvate ratio in perfusate recirculated through
isolated perfused rat lungs [16]. As shown in Figure 3.9, model simulations are in good
agreement with the measured experimental data. For model predictions, rotenone
inhibitory effect was simulated by decreasing mitochondrial Complex I activity by 85%,
with the values of all the other model parameters set to those in Table 3.4. CO inhibitory
effect was simulated by decreasing mitochondria complex IV activity by 99.7% at 10
min, with the values of all the other model parameters set to those in Table 3.4.

A

B

C

ROT
ROT

CO

Figure 3.9: Effects of ROT on lung ATP/ADP ratio and LAC, PYR production.
Effect of complex I inhibitor rotenone (ROT, 20 µM) on lung ATP/ADP (Panel A) ratio
and LAC, PYR production rates (Panel B) in perfusate recirculated through isolated
perfused rat lungs [16]. Experimental conditions are the same as those for data in Figure
3.3. For model predictions, ROT effect was simulated by decreasing mitochondrial
Complex I activity by 85% at 10 min, with all other parameters unchanged. Symbols are
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experimental data [16], values are mean ± SE (n = 4). Solid lines are model predictions.
Panel C. Effect of complex IV inhibitor CO (carbon monoxide) on lung LAC, PYR
production rates. In control condition, the lung was ventilated with 95% O2 and 5% CO2.
At 5 min, the ventilation gas was changed to 95% CO and 5% CO2. For model
predictions, CO effect was simulated by decreasing mitochondria complex IV activity by
99.7%. Symbols are experimental data [22] and solid lines are model predictions. LAC
production rate was multiplied by a factor of 2 since LAC production measured in [22] is
50% lower than in [16].
Table 3.5: Model predicted and experimental lung tissue adenine nucleotide
Model
Bongard et al.
Akai et al.
Fisher AB
predicted
[16]
[106]
[107]
0.79
0.83
0.83
ATP/(ATP ADP AMP) 0.78
0.16
0.12
0.12
ADP/(ATP ADP AMP) 0.19
0.04
0.05
0.05
AMP/(ATP ADP AMP) 0.03
6.64
5.66 ± 0.46
6.8 ± 0.5
12.8 ± 0.1
ATP (mole/g dry wt)
1.85
1.17 ± 0.14
0.95 ± 0.05
1.8 ± 0.2
ADP (mole/g dry wt)
0.29
0.31 ± 0.06
0.41 ± 0.02
0.8 ± 0.1
AMP (mole/g dry wt)

Table 3.5 shows experimentally measured [16] and model predicted lung tissue
adenine nucleotide fractions and content under control conditions. Model predictions are
within the range of measured experimental data.
Staniszewski et al. and Sepehr et al. measured lung surface NADH (top panels)
and FAD (middle panels) emission signals in isolated perfused rat lungs by placing a
fiber optic probe against the pleural surface of the right lobe [26, 108]. Signals were first
obtained under resting conditions, and then following the addition of inhibitors to the
recirculating perfusate to induce changes in NADH and FAD redox status, and thus
fluorescence intensities. Lung redox ratios were then calculated as the ratio
(NADH/FAD) of NADH and FAD fluorescence intensities. As shown in Figure 3.10,
rotenone (ROT, complex I inhibitor) caused a 20% increase in NADH intensity and
negligible effect in FAD intensity. Potassium cyanide (KCN, complex IV inhibitor)
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caused 20% increase in NADH intensity as well as a 10% decrease in FAD intensity. The
mitochondrial uncoupler pentachlorophenol (PCP) caused a 20% decrease in NADH
intensity and negligible effect on FAD intensity. For model predictions, the ROT effect
was simulated by decreasing mitochondrial Complex I activity by 85%, KCN effect was
simulated by decreasing mitochondria complex IV activity by 99.7%, and PCP effect was
simulated by increasing the proton leak activity (parameter Tmaxf,leak) by 5 times. As
shown in Figure 3.10, model simulations are in good agreement with the measured
experimental data.

A.

ROT

D.

KCN

G.

PCP

B.

ROT

E.

KCN

H.

PCP

C.

ROT

F.

KCN

I.

PCP

Figure 3.10: Experimental data and model prediction of normalized lung surface NADH
(top panels), FAD (middle panels) and redox ratio (NADH/FAD, bottom panels) [26,
109].
Lungs were isolated from male Sprague-Dawley rats (300-350 g) and perfused with
perfusate containing 5.5 mM glucose and 3% bovine serum albumin at 37°C. NADH and
FAD fluorescence intensities were measured using fluorometer with fiber optic probe
placed against the pleural surface of the right lobe. Signals were first obtained under
resting conditions, and then following the addition of inhibitors to the recirculating
perfusate to induce changes in NADH and FAD redox status and thus fluorescence
intensities. Lung redox ratios were calculated as the ratio (NADH/FAD) of NADH and
FAD fluorescence intensities. For panels A, B, and C, 20 µM rotenone (ROT, complex I
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inhibitor) was added to the recirculating perfusate at 3 min. For panels D E, and F, 2 mM
potassium cyanide (KCN, complex IV inhibitor) was added to the recirculating perfusate
at 3 min. For panels G, H, and I, 3 mM protonophore (PCP, uncoupler) was added to the
recirculating perfusate at 3 min. For model predictions, ROT effect was simulated by
decreasing mitochondrial Complex I activity by 85%, KCN effect was simulated by
decreasing mitochondria complex IV activity by 99.7%, and PCP effect was simulated by
increasing proton leak activity by 5 times. Symbols are experimental data [26, 109], and
solid lines are model predictions.

3.5 Discussion
We have developed and validated the first integrated computational model of the
bioenergetics of isolated rat lungs. This model is an extension of our previously
developed integrated computational model of the bioenergetics of isolated rat lung
mitochondria [24] presented in Chapter 2.
3.5.1 Parameter estimation results and sensitivity analysis
As shown in Figure 3.3–Figure 3.5, the model was able to fit a wide range of
published experimental data collected from isolated perfused rat lungs under various
experimental conditions, including metabolic changes in response to different buffer
glucose concentrations, lactate concentrations, oxygen partial pressures, as well as the
effects of various metabolic inhibitors.
Except for the maximum mitochondria proton leak activity (Tmaxf,leak), the values
of model parameters for the mitochondria matrix and IMS regions were set to those
estimated using our recent model of the bioenergetics of mitochondria isolated from rat
lungs [24]. Our estimate of Tmaxf,leak from isolated mitochondria ranged between ~15
nmol/min/mg and 36 nmol/min/mg mitochondria protein, depending on the quality of
isolated mitochondria since the isolation process could damage the mitochondrial
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membranes [24]. For the whole lung, the value of Tmax,leak would be expected to be equal
to or smaller than that estimated from isolated mitochondria, since mitochondria isolation
process may cause damage to mitochondria membrane [24]. For the lung model, the
estimated value of Tmaxf,leak was ~16 nmol/min/mg mitochondria protein which is close to
the low end of the range of values estimated from isolated mitochondria [24].
For glycolytic enzymes, we used experimentally measured enzyme activities
[101] as initial guesses for the unknown extrinsic model parameters, which significantly
improved the efficiency of the parameter estimation method using genetic algorithm.
Parameter estimation results show that most of the estimated Vmaxfs values that best fit
model solution to the experimental data in Figure 3.3–Figure 3.5 are relatively close to
the measured activities of the corresponding enzymes. This along with the ability of the
model to predict quite well additional experimental data that were not used for model
parameter estimation serve as validation of this integrated isolated rat lung bioenergetics
model.
A parameter with a relatively high normalized sensitivity coefficient is more
likely to be the rate limiting step, since a small change in that parameter will result in
relatively big change in the model output. Model sensitivity analysis revealed key
information regarding the limiting step(s) in glycolysis. Consistent with enzyme studies
in isolated rat lung cells [101], few glycolytic enzyme activities greatly exceeded the
observed rate of glucose utilization. As such, the calculated normalized sensitivity
coefficients are low for the glycolytic enzyme activity model parameters, including
phosphoglucose isomerase (PGI) and phosphoglycerate kinase (PGK). In contrast,
glucose transporter (GLUT), phosphofructokinase (PFK) and hexokinase (HK) have
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relatively high sensitivity coefficients, and hence are probably the glycolysis rate limiting
steps in lung tissue.
Flux control coefficient for a given enzyme or transporter is defined as the
relative change in a pathway’s flux (e.g. glycolysis) with respect to a change in the value
of a model parameter describing the activity of that enzyme or transporter in that pathway
[110]. To gain more insights into the rate limiting step for glycolysis, we calculated the
flux control coefficients [43, 110] for glycolytic enzymes and for the transporters that are
affected by glycolysis (glucose transporter, lactate transporter and pyruvate transporter).
The sum of those flux control coefficients should be one, as predicted by the metabolic
control theory [43]. The results shown in Figure 3.11 (left panel) suggest that under basal
condition, GLUT has the highest flux control coefficient, and hence is the rate limiting
step for glycolysis. However Figure 3.11 (right panel) shows that when lung EC
decreases, the flux control coefficients of the glycolytic enzymes HK and PFK increase
significantly since they use ATP as a substrate, whereas that for GLUT decreases. Thus
under conditions of low EC, HK and PFK are potentially the rate limiting steps for
glycolysis.
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Figure 3.11: model predicted flux control coefficients for glycolytic enzymes and for the
transporters that are affected by glycolysis.
Left panel: model predicted flux control coefficients under basal conditions. Right panel:
flux control coefficients as a function of energy charge (EC, defined in Equation 10). The
flux control coefficient of the glucose transporter (GLUT) decreased as EC decreased,
whereas flux control coefficients of the glycolytic enzymes phosphofructokinase (PFK)
and hexokinase (HK) increased as EC decreased. For model simulations, mitochondrial
complex I activity was incrementally decreased to induce a decrease in EC.

3.5.2 Differences between the bioenergetics of mitochondria isolated from lungs and
mitochondria in intact lungs
The metabolic environment in isolated mitochondrial experiments is different
from that in isolated perfused lung experiments. For instance, the environment in isolated
mitochondria experiments is quite stable since the buffer volume is relatively large as
compared to mitochondrial volume (ratio of mitochondrial volume to buffer volume is
~1/1000) [24, 46]. For intact lungs, bioenergetics are more sensitive to metabolic control
in isolated perfused rat lungs because of the relatively large mitochondria/cytosol volume
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ratio (mitochondria to cytosol volume ratio of ~1/50) [86].
Mitochondrial respiratory substrates can inhibit glycolytic rate via increased
citrate production from mitochondria [21]. For this study, conditions of abundant
mitochondrial respiratory substrates were simulated using the proposed integrated lung
tissue bioenergetics model by elevating cytosolic pyruvate concentration. The simulations
in Figure 3.12 show that the fluxes of three TCA cycle reactions (namely PDH, CITS,
and MDH) increased with increase in cytosolic pyruvate concentration. The fluxes of the
other TCA cycle reactions (ICDH, AKGDH, SCAS and SDH) actually decreased with
increase in cytosolic pyruvate concentration. As a result, excessive mitochondrial citrate
produced by TCA cycle is released to cytosol, which in turn inhibits glycolysis.
Previously we showed that the TCA cycle in mitochondria isolated from rat lung
is functionally incomplete [24], with only half of the TCA cycle reactions (PDH, CITS,
MDH) active while the other reactions are apparently inactive. However as Figure 3.12
shows, a different TCA cycle behavior was observed in simulations generated using the
integrated lung tissue bioenergetics model. For intact lung experimental conditions, the
TCA cycle is complete and all the reactions are running at approximately equal rates.
This difference in TCA cycle activity is potentially due to differences in the
mitochondrial environment of the isolated mitochondrial preparation as compared to that
in isolated perfused lung preparation. For instance in isolated perfused rat lung, the
physiological pyruvate concentration is around 0.1 mM under normal conditions [98].
However, in isolated mitochondrial experiments, the buffer pyruvate concentration used
(~5 mM) is much higher than the physiological pyruvate concentration, to ensure enough
substrate availability for mitochondrial respiration [24, 76, 78, 111].
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Figure 3.12: Model predicted mitochondrial TCA cycle fluxes as functions of cytosolic
pyruvate (PYR) concentration.
When cytosolic PYR concentration is clamped below 0.1 mM, TCA cycle is seen to be
functionally complete (equal fluxes at steady state). As cytosolic pyruvate concentration
increases, TCA cycle becomes increasingly functionally incomplete. PDH: Pyruvate
dehydrogenase, CITS: Citrate synthase, ICDH: Isocitrate dehydrogenase, AKGDH: αketoglutarate dehydrogenase, SCAS: Succinyl-coenzyme A synthetase, SDH: Succinate
dehydrogenase, MDH: Malate dehydrogenase.
Simulations using the lung tissue bioenergetics model provide a potential
explanation for why the TCA cycle is apparently incomplete in isolated mitochondrial
studies, but is complete in isolated perfused rat lung experiments. Higher cytosolic
pyruvate concentration, as that used in isolated mitochondrial studies, results in higher
NADH generation in mitochondria. Isocitrate dehydrogenase (ICDH) is known to be
inhibited by NADH [24, 49], with the ICDH activity decreasing as mitochondrial
NADH/NAD ratio increases. As such, increased amount of citrate is released into cytosol
through the mitochondrial transporter tricarboxylate carrier (TCC) resulting in
incomplete TCA cycle.
Based on the calculated mitochondria volume (13.1 µL), the calculated

94
mitochondria protein mass is around 13.1 mg in intact rat lung. This value is close to the
estimated value using genetic algorithm (16.4 mg). Based on our previous study [5],
mitochondria yield from lung tissue is around 2-3 mg/rat lung. That suggests that 80–
85% of rat lung mitochondria is lost/inactivated during the isolation process.
3.5.3 Lactate regulation of glycolytic rate
Experimental data showed that exogenous lactate has a regulatory effect on
glycolytic rate (Figure 3.4D) [21, 103]. However, the underlying mechanism for such
effect is not well understood. Different hypotheses have been proposed [21], including
through alternations in cellular redox state or cellular energy states. However,
mitochondrial control of the TCA cycle may also be contributing to lactate’s regulation of
glycolytic rate.
In the cytosol, pyruvate is always in equilibrium with lactate since the enzyme
lactate dehydrogenase (LDH) activity is much higher than other glycolytic enzymes.
Thus, increasing exogenous lactate concentration increases pyruvate concentration in
cytosol, which in turn inhibits glycolysis. This is consistent with the data in Figure 3.4
(panel D), which show that exogenous lactate has an inhibitory effect on rat lung
glycolytic rates [21, 103, 104].
Even though glucose utilization rate of rat lung is similar to that of heart and brain
[18], isolated perfused rat lungs produce significantly higher lactate than hearts [18] and
skeletal muscle [61]. 40–50% of glucose consumed by lungs is released as lactate [18].
Thus, a significant fraction of NADH produced in the glycolytic pathway is consumed by
lactate dehydrogenase. Only ~10% of NADH produced by glycolysis is transported into
mitochondria by MA-shuttle [18]. Previous modeling studies have suggested that the
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MA-shuttle may have an important regulatory role on the bioenergetics of skeletal muscle
and heart [46, 61]. However, simulations using the proposed integrated lung bioenergetics
models suggest that the role of MA-shuttle may be less important in isolated rat lung.

3.6 Conclusions and model limitations
In conclusion, we have developed and validated an integrated mechanistic
computational model of isolated perfused rat lung tissue bioenergetics by extending the
model of isolated rat lung mitochondrial bioenergetics in chapter 2. The model was used
to gain insights into how lung tissue glycolytic rate is regulated by exogenous substrates,
such as glucose and lactate, and assess differences in the bioenergetics of mitochondria
isolated from lung tissue and those of mitochondria in intact lungs.
As shown in Figure 3.4 (panels B, C), model simulated endogenous lactate
production underestimate the experimentally measured lactate production [23] when
perfusate glucose concentration is low (0 to 0.5 mM). The model predicts that when
exogenous glucose is low, lung mitochondria diverts more pyruvate from endogenous
substrates (e.g. alanine), thus resulting in lower endogenous lactate production. However,
Figure 3.4C shows the experimentally measured endogenous lactate production [23] is
independent of perfusate glucose concentration. One possible reason for this could be that
experimentally measured endogenous lactate production (Figure 3.4C) [23] is
overestimated since pyruvate and lactate were extracted using ion-exchange
chromatography [23, 71]. This method cannot differentiate between lactate and other
small anions potentially present in the perfusate [71]. It is likely that the production rate
of those small anions is independent of perfusate glucose concentration.
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Another possible reason for the inability of the model to account for the rate of
lactate production under conditions of low perfusate glucose concentration could be that
the activity of the enzyme alanine aminotransferase is dependent on ATP level. The
rationale is that when glucose is low, protein degradation is stimulated in response to
decreased ATP, resulting in more pyruvate formation from alanine. However,
experimental data and model simulation in Figure 3.9 show that pyruvate production is
decreased in the presence of rotenone (complex I inhibitor) which is known to decrease
mitochondrial ATP [16].
Glucose and alanine are considered major metabolic substrates for this rat lung
bioenergetics model. Other substrates such as fatty acids and glycogen are not accounted
for. Under normal conditions, fatty acid production accounts for less than 5% of glucose
consumption in isolated perfused rat lungs [18]. Thus, the contribution of fatty acid is
considered insignificant. However, under low energy conditions, fatty acid could become
a significant alternative energy source. For example, fatty acid oxidation may be
activated by AMPK (AMP-activated protein kinase) when glucose is low [112]. Fatty
acids were not accounted for in the present model due to the scarcity of experimental data
regarding fatty acid as a source of energy in intact lungs.
Another limitation of the lung model is that it does not account for all ATP
consumption processes, including consumption by active transporters, due to the scarcity
of experimental data [7, 18, 20-24]. Instead, the ATP consumption rate is modeled as a
passive process whose rate is only dependent on the concentrations of ATP, ADP, and
inorganic phosphate. Accounting for all ATP consumption processes and their regulatory
effects could improve the ability of the model to simulate experimental data under
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conditions of low glucose concentration.
The model does not account for cation ions. This is a limitation since cation ions
such as Ca2+ and Mg2+ s play an important role in lung tissue bioenergetics. A study by G.
Nicolaysen demonstrated that normal Ca2+ and Mg2+ concentrations are essential for
maintaining capillary barrier [113]. When Ca2+ or Mg2+ concentration in the perfusate
recirculating through isolated rabbit lungs were reduced by added chelators to the
perfusate, edema developed [113]. In addition, as discussed in chapter 2, Ca2+ has
regulatory role on mitochondria bioenergetics. At low concentrations, Ca2+ activates
dehydrogenase enzymes, whereas at high concentrations, Ca2+ inhibits mitochondria
respiration [76]. Therefore, in order to incorporate Ca2+ and other cations into the current
model, additional studies and data about transporters and buffering mechanisms for those
ions, and about the interactions of these ions with other metabolites in the different
regions of the model are required. Such data are not currently available, and collecting
such data is beyond the scope of this dissertation.
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Chapter 4 : Effects of hyperoxia on lung tissue bioenergetics
4.1 Introduction
Normobaric hyperoxia (high O2 concentration) is an essential therapy for patients
with hypoxemia (low blood oxygen partial pressure, PO2) and hypoxia (low tissue
oxygenation) from any cause, including ALI/ARDS, to restore blood oxygen [7].
However, there is ample evidence that sustained exposure to hyperoxia causes lung
injury, and hyperoxic lung injury is a widely accepted animal model of human
ALI/ARDS [5, 7, 11, 107]. The objective of Aim 3 is to use the computational models
developed under Aims 1 and 2 to quantify the impact of previously measured hyperoxiainduced changes in specific mitochondrial processes on lung mitochondrial and tissue
bioenergetics [5, 11, 26, 114-117]. This exercise will help in identifying potential
therapeutic targets for ALI/ARDS.
Previous studies have reported that specific mitochondrial and cytosolic processes
pertinent to lung tissue bioenergetics are significantly altered in hyperoxia-exposed rats,
and have suggested that these processes are important to lung hyperoxic lung injury and
protection from this injury [16, 26, 117] . As described below, the computational models
developed under Aims 1 and 2 allow us to determine the functional impact (e.g. effect on
lung tissue bioenergetics) of changes in one or more of these processes.

4.2 Hyperoxia-induced structural changes in rat lungs
Exposure of rats to >95% oxygen is a well-documented animal model of clinical
ALI/ARDS [11]. In a morphometric study, Crapo et al. observed no structural changes
(cell volume, surface area, etc.) in rats exposed to 100% O2 for up to 40-h [12]. However,
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the lungs of rats exposed to 100% O2 for 60-h showed cellular and functional changes,
including significant loss of capillary endothelial cells and cell surface area, infiltration of
phagocytic leukocytes, and an increase in the thickness of the air-blood barrier [12].
Longer exposure periods resulted in additional loss of endothelial cells, enhanced
microvascular capillary permeability, and severe hypoxemia and death within 64 to 72
hours. For instance, the total number of endothelial cells, which was not changed for
lungs of rats exposed to hyperoxia for up to 40 hours, decreased by ~31% in lungs of rats
exposed to hyperoxia for 60 hours [12].

4.3 Hyperoxia-induced changes in electron transport chain (ETC)
enzymes in rat lungs
Previous studies have demonstrated changes in mitochondrial redox state prior to
evidence of respiratory distress in the pathogenesis of hyperoxia-induced lung injury [26,
117]. For instance, Sepehr et al. used optical fluorometry to detect changes in the redox
status of mitochondrial NADH and FAD at the surface of isolated perfused lungs from
rats exposed to >95% O2 for 48 hours [26]. Those changes were consistent with decrease
in complex I (77%) and complex II (63%) activities in lung homogenates of rats exposed
to >95% O2 for 48 hours [26]. Audi et al. also demonstrated ~50% decrease in complex I
activity in lungs of rats exposed to 85% O2 for 48 hours, but no effect on complex III
activity [25]. Das et al. also reported a ~44% decrease in complex I activity in lungs of
mice exposed to 90% O2 for 48 hours [116]. Bayir and Kagan have suggested that this
decrease in complex I activity could be through the oxidation of cardiolipin [10], which is
important for the function of mitochondrial complexes [26]. Another possible reason
might have to do with the fact that 7 out of the 45 complex I subunits are encoded by
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mtDNA, which are known to be highly sensitive to ROS, which play a key role in the
pathogenesis of ALI/ARDS [26]. Mitochondrial dysfunction can alter lung tissue
bioenergetics and hence key cellular functions since mitochondria is the major site of
ATP production in cells, accounting for 80–85% of ATP in lung tissue [18]. Bongard et
al. demonstrated that inhibition of mitochondria complex I decreased whole lung tissue
ATP level by ~60% and compromised microvascular permeability as measured by an
increase in pulmonary vascular endothelial filtration coefficient (Kf), a sensitive measure
of pulmonary endothelial barrier function by 262% [16]. Moreover, they demonstrated
that the decrease in lung tissue ATP and the increase in Kf can be reversed by adding an
exogenous electron donor (reduced form of the quinone coenzyme Q1) which bypasses
complex I to reduce complex III and restore mitochondrial bioenergetics. These results
suggest that altering mitochondrial bioenergetics can reproduce one of the cardinal
features of ALI, and hence suggest an important role for mitochondrial bioenergetics in
the pathogenesis of ALI. Furthermore, the results suggest complex I as a potential
therapeutic target for ALI/ARDS.

4.4 Experimental data and model simulations of effects of hyperoxia
(isolated mitochondria level)
Hyperoxia-induced changes in the redox state of lung mitochondria are in big part
due to hyperoxia-induced changes in the activities of mitochondrial complexes I and II.
Simulations in Figure 4.1 and Figure 4.2, generated using the computational model of the
bioenergetics of isolated mitochondria, show that changes in the activities of
mitochondrial complexes I and II lead to changes in mitochondria membrane potential
(m), NADH/NAD ratio at state 2, ATP generation capacity and duration of state 3, and
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these changes are substrate dependent. Simulations with complex I substrates pyruvate +
malate and complex II substrate succinate are shown in Figure 4.1 and Figure 4.2,
respectively. For these simulations, model parameters describing the activities of
complexes I and II were decreased from 100% to 20% of those measured in mitochondria
from normoxic lungs. All other model parameters were fixed to those estimated for
mitochondria from normoxic lungs (Table 2.4 in chapter 2) [24]. Figure 4.1 shows that
when using pyruvate + malate as substrates, decreasing complex I activity resulted in a
decrease in m (depolarization) and maximum ATP generation rate, and an increase in
NADH/NAD ratio and duration of state 3 respiration (as indicated by full width at half
maximum (FWHM) of ADP-induced membrane potential depolarization). In contrast,
decreasing complex II activity had little or no effect since NADH is the major electron
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donor to ETC when using pyruvate + malate as metabolic substrates.
A

B

C

D

Figure 4.1: Model predicted effects of decreased complex I (CI) and/or complex II (CII)
activities on mitochondria bioenergetics with PYR+MAL as substrates.
Panel A: membrane potential (m) at state 2; Panel B: NADH/NAD ratio at state 2;
Panel C: maximum ATP production rate at state 3 (ADP = 0.1 mM); Panel D: FWHM of
state 3 (ADP = 0.1 mM). Simulations were generated using the isolated mitochondria
model. Parameters describing the activities of CI and/or CII activities were altered. All
other parameters were set to those estimated from mitochondria isolated from normoxic
lungs (see Table 2.4 in chapter 2). PYR: pyruvate, MAL: malate, FWHM: Full width at
half maximum.

When using succinate (SUC) as metabolic substrate (Figure 4.2), decreasing
complex II activity also resulted in a decrease in m, NADH/NAD ratio and in
maximum ATP generation rate, and an increase in duration of state 3 (as indicated by full
width at half maximum of ADP-induced membrane potential depolarization). In contrast,
decreasing complex I activity had no effect since FADH2 is the major electron donor to
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ETC when using SUC as metabolic substrate.
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Figure 4.2: Model predicted effects of decreased complex I (CI) and/or complex II (CII)
activities on mitochondria bioenergetics with SUC as substrate.
Panel A: membrane potential m) at state 2; Panel B: NADH/NAD ratio at state 2;
Panel C: maximum ATP production rate at state 3 (ADP = 0.1 mM); Panel D: FWHM of
state 3 (ADP = 0.1 mM). Simulations were generated using the isolated mitochondria
model. Parameters describing the activities of CI and/or CII were altered. All other
parameters were set to those estimated from mitochondria isolated from normoxic lungs
(see Table 2.4 in chapter 2). SUC: succinate, FWHM: Full width at half maximum.

4.4.1 Hyperoxia-induced changes in the membrane potential (m)
The mitochondrial membrane potential (Ψm) plays a key role in mitochondrial
ATP synthesis, apoptosis, and other functions [86]. Previously, we quantified Ψm in
mitochondria isolated from normoxic and hyperoxic rat lungs (>95% O2 for 48 hrs) using
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the cationic dye rhodamine 123 (R123) [72]. Figure 4.3 shows that the R123 emission
signal dropped rapidly following the addition of mitochondria in the presence of pyruvate
+ malate (complex I substrates), consistent with uptake and accumulation of R123 into
mitochondria driven by Ψm [72]. Addition of ADP (state 3) stimulated transient and
reversible efflux of R123 from mitochondria consistent with partial depolarization of
Ψm [72]. Addition of the mitochondrial uncoupler carbonyl cyanide-4(trifluoromethoxy) henylhydrazone (FCCP) depolarized Ψm resulting in efflux of R123
from mitochondria. Similar results were obtained with succinate (Figure 4.3, panel B), a
complex II substrate [72]. One measure of the kinetics of ADP-stimulated Ψm
polarization is the full width half maximum time (FWHM) for R123 return to baseline
(state 2) [72]. Table 4.1 shows that rats exposed to hyperoxia (>95% O2 for 48 hrs)
increased FWHM by 67%. This suggests that Ψm recovery from ADP-induced
depolarization in mitochondria from hyperoxic lungs was substantially slower than that in
normoxic lungs, which is consistent with hyperoxia-induced decreases in lung tissue
complex I (77%) and II (64%) activities [26, 72]. What is not clear from the experimental
results is whether the hyperoxia-induced changes in complexes I and II activities are
sufficient to account for the measured hyperoxia-induced changes in Ψm as measured by
the changes in FWHM from the R123 data. As shown below, the computational model of
the bioenergetics of isolated mitochondria allows us to address this important question.

105

A

B

FWHM
ADP
0.1 mM

ADP
0.05 mM

FCCP

ADP
0.1 mM

ADP
0.05 mM

FCCP

Figure 4.3: Averaged R123 emission signal in mitochondria isolated from lungs of
normoxia and hyperoxia (>95% O2 for 48 hrs).
Panel A: PYR + MAL; Panel B: SUC. 0.1 mM ADP and 0.05 mM ADP were added at 3
min and 12 min, respectively. Uncoupler FCCP was added at 15 min [118]. One measure
of the kinetics of ADP-stimulated m depolarization and repolarization is the full width
at half maximum time (FWHM) for R123 return to baseline (state 4). PYR: pyruvate,
MAL: malate, SUC: succinate.

To evaluate the effect of a decrease in complexes I and II activities on
mitochondrial membrane potential, simulations were performed with parameters
describing complex I (Figure 4.4) or complex II (Figure 4.5) activities set at values
ranging between 20% and 100% of those estimated from mitochondria isolated from
normoxic lungs (Table 2.4 in chapter 2). Model simulations in Figure 4.4 and Figure 4.5
show the effect of the addition of 0.1 mM and 0.05 mM ADP to buffer at 6 min and 14
min, respectively, and FCCP at 15 min on R123 concentration in medium and on m.
As shown in Figure 4.4, when using PYR + MAL as metabolic substrates for
mitochondria, decreasing complex I activity leads to a proportional decrease
(depolarization) in the steady state m at state 2 and state 4 (panel A), and a
proportional increase in the duration of state 3 (panel B). When using SUC as metabolic
substrate, decreasing complex I activity has little or no impact on m (panel C) or the
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duration of state 3 (panel D).
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Figure 4.4: Model simulated effect of decreased complex I (CI) on m and R123
dye concentration in buffer in the presence of PYR + MAL (panels A and B) or SUC
(panels C and D). Simulations were performed using the isolated mitochondria model
with parameter describing the activity of complex I activity set at 100%, 60% or 20% of
that estimated for complex I activity in mitochondria from normoxic lungs. The values of
other parameters were fixed to those estimated from mitochondria isolated from
normoxic lungs. PYR: pyruvate; MAL: malate; SUC: succinate.
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Figure 4.5: Model simulated effect of decreased complex II (CII) on m and R123
dye concentration in buffer in the presence of PYR + MAL (panels A and B) or SUC
(panels C and D). Simulations were performed using the isolated mitochondria model
with parameter describing the activity of complex II activity set at 100%, 60% or 20% of
that estimated for complex II activity in mitochondria from normoxic lungs. The values
of other parameters were fixed to those estimated from mitochondria isolated from
normoxic lungs. PYR: pyruvate; MAL: malate; SUC: succinate.

Similarly, as shown in Figure 4.5, when using SUC was the substrate, decreasing
complex II activity resulted in a proportional decrease (depolarization) in the steady state
m at state 2 and state 4 (panel C), and a proportional increase in the duration of state 3
(panel D). No effect was observed in the presence of PYR + MAL (panels A and B).
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Table 4.1: Measured and simulated membrane recovery time following ADP-induced
depolarization in mitochondria isolated from lungs of rats exposed to normoxia or >95%
O2 for 48 hrs
Group
FWHM (min), FWHM (min), Model predicted Model predicted
PYR+MAL
SUC
FWHM (min),
FWHM (min),
PYR + MAL
SUC
Normoxia
1.98 ± 0.18
1.75 ± 0.16
1.50
1.76
(n=7)
(n=7)
48-h
3.3 ± 0.26 *
2.7 ± 0.32 *
3.10
3.88
hyperoxia
(n=6)
(n=6)
Values are mean ± SE for experimental results [118]. FWHM indicates full width at half
maximum for 0.1 mM ADP-stimulated depolarization of membrane potential. *different
from normoxia. Model predicted FWHM times for normoxia and hyperoxia conditions
were generated using the computational model for the bioenergetics of mitochondria
isolated from rat lungs with the values of model parameters set to those in Table 2.4 for
normoxia condition. For simulation of 48-h hyperoxia, the values of the parameters
describing activities of complexes I and II were 77% and 64% lower than those for
normoxia conditions. The values of the remaining parameters were set to those estimated
for normoxia conditions (Table 2.4) [24].

Sepehr et al. reported 77% and 64% decreases in the activities of complexes I and
II, respectively, in lung homogenates of rats exposed to > 95% O2 for 48 hrs as compared
to lung homogenates from normoxic rats [26]. Simulations in Figure 4.6 using the model
of bioenergetics of isolated mitochondria, along with the pharmacokinetic model of R123
disposition in isolated mitochondria, show the effects of simultaneously decreasing the
values of model parameters describing complexes I and II activities by 77% and 64%,
respectively, on m and the duration of ADP-induced state 3 as measured by the
FWHM time. All other model parameters were fixed to those estimated from
mitochondria isolated form normoxic lungs [24]. The results in Table 4.1 show that
hyperoxia-induced changes in FWHM can be accounted for by hyperoxia-induced
changes in complexes I and II activities. For succinate, model simulated FWHM increase
is higher than experimentally measured FWHM after exposure to hyperoxia, could be
because hyperoxia induced injury to complex II is less than 64% in isolated

109
mitochondria.
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Figure 4.6: Experimental data (panels A and B) and model predicted (panels (C-F)
hyperoxia induced changes in mitochondria membrane potential.
Simulations were generated using the isolated mitochondria model. For model-simulated
hyperoxic conditions, parameters describing complex I (CI) and complex II (CII)
activities were decreased by 77% and 64%, respectively, as compared to those estimated
for mitochondria isolated from lungs of normoxic rats (Table 2.4 in chapter 2). All other
parameters was set to those estimated from mitochondria isolated from lungs of normoxic
rats (Table 2.4) [24]. Panels A and B show experimentally measured R123 dye
concentration calculated from R123 fluorescence intensity. Panels C and D show model
simulated R123 dye concentrations in normoxic (control) lung and hyperoxic lung using
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isolated mitochondria model along with a pharmacokinetic model of R123 disposition in
isolated mitochondria. Panels E and F show model simulated mitochondria membrane
potential.
4.4.2 Hyperoxia-induced changes in mitochondrial oxygen consumption rates
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0.05 mM
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Figure 4.7: Model-simulated mitochondrial oxygen consumption kinetic data and rates in
mitochondria isolated from lungs of normoxic and 48-hr hyperoxic rats.
Simulations were generated using the isolated mitochondria model, with malate +
glutamate as metabolic substrates. For model-simulated hyperoxia condition, parameters
describing complex I (CI) and complex II (CII) activities (Table 2.4) were decreased by
77% and 64%, respectively, as compared to those estimated from mitochondria isolated
from lungs of normoxic rats (Table 2.4 in chapter 2). All other parameters wet set to those
estimated from mitochondria isolated from lungs of normoxic rats (Table 2.4) [24]. Panel
A shows simulated oxygen concentration in the buffer. ADP was added into the buffer at
1 min. Panel B shows calculated oxygen consumption rate (OCR) at state 2 and state 3.

Simulations using the isolated mitochondria model were performed to evaluate
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the effect of decreased activities of complexes I and II on mitochondrial oxygen
consumption rate. As shown in Error! Reference source not found., hyperoxic c
onditions were simulated by decreasing mitochondria complex I and complex II activities
by 77% and 64%, respectively. Hyperoxia resulted in slower state 2 and state 3 oxygen
consumption rate. RCI (calculated as state 3 OCR divide by state 2 OCR) decreased
from 2.65 to 1.83. This result is consistent with our previously measured OCR data in
mitochondria isolated from normoxic lungs (RCI = 2.58 ± 0.06 (SE), n = 4) [24], and
unpublished results from 48-hr hyperoxic rats (RCI =1.84 ± 0.18, n=4) with malate +
glutamate as substrates.
The simulations of membrane potential in Figure 4.6, OCR in Error! Reference s
ource not found. and FWHM values in Table 4.1 demonstrate that the effect of
hyperoxia on lung mitochondria membrane potential and oxygen consumption rate
observed in isolated mitochondrial experiments can be accounted for by hyperoxiainduced changes in the activities of complexes I and II. This is consistent with
mitochondrial complexes I and II being potentially primary sites of hyperoxia-induced
changes in lung tissue mitochondria.

4.5 Experimental data and model simulations of effects of hyperoxia
(intact lungs)

4.5.1 Hyperoxia-induced changes in rat lung NADH and FAD surface fluorescence
signals (redox status)
Sepehr et al. evaluated the effect of rat exposure to hyperoxia (>95% O2 for 48
hrs) on lung surface fluorescence signals (and hence redox status) of mitochondrial
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NADH and FAD in the presence of rotenone (complex I inhibitor), potassium cyanide
(complex IV inhibitor), and/or the mitochondrial uncoupler pentachlorophenol [26].
Experimental results (Table 4.2) show that rotenone- and cyanide-induced decrease in
lung NADH signal was significantly smaller (63% for rotenone and 58% for cyanide) in
hyperoxic lungs as compared to that in normoxic lungs. These results are consistent with
hyperoxia-induced decrease in complex I activity (77%) in lung tissue homogenate [26].
Neither inhibitor had a significant effect on %FAD in hyperoxic lungs as compared to
normoxic lungs. However in the presence of the uncoupler pentachlorophenol (PCP),
which fully oxidized the ETC, potassium cyanide effects on NADH and FAD surface
signals were 65% and 55% lower respectively in hyperoxic as compared to normoxic
lungs (Table 4.2). According to Sepehr et al., this is consistent with a more reduced ETC
upstream from complexes I and II in hyperoxic lungs as compared to that in normoxic
lungs, and with hyperoxia-induced decrease in complexes I and II activities in lung tissue
homogenates [26].

Table 4.2: The effects of inhibitors on lung NADH and FAD signals [26].
Inhibitor/Uncoupler

FAD % change
NADH % change
Normoxic
Hyperoxic
Normoxic
Hyperoxic
ROT
0.2 ± 0.2
-0.3 ± 0.3
20.2 ± 2.3
7.5 ± 1.0*
KCN
-6.8 ± 1.6
-5.2 ± 0.5
21.7 ± 2.5
9.2 ± 1.2*
PCP
1.7 ± 0.8
-2.3 ± 1.4*
-19.7 ±2.1
-20.8 ±1.2
PCP + KCN
-9.3 ± 1.0
-4.2 ± 0.7*
25.7 ± 2.6
9.0 ± 1.0*
Values are mean ± SE. *significantly different from the corresponding normoxic value (ttest, P<0.05). ROT: Rotenone; KCN: Potassium cyanide; PCP: Pentachlorophenol.
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Figure 4.8: Experimental data and model simulated effect of hyperoxia on lung tissue
NADH change in response to inhibitors.
Experimental data and model simulated effect of hyperoxia on lung tissue NADH change
in response to rotenone (ROT, panels A, B) and potassium cyanide (KCN, panels C, D).
Inhibitor (ROT or KCN) was added at 3 min. Symbols are experimental data of NADH
signal from normoxic lungs (red symbols) and hyperoxic lungs (blue symbols).
Simulations were generated using the intact lung model under normal conditions (values
of model parameters fixed to the values in Table 3.4), or with the value of the model
parameter describing complex I activity at 80%, 50% or 23% of the value under
normoxic conditions (Table 3.4).

Simulations were performed using the isolated rat lung model under the same
experimental conditions as in Figure 3.10. For simulations of normoxic conditions, all
parameters were fixed to the values in Table 3.4. For 48-hr hyperoxic conditions,
parameters describing the activities of mitochondrial complexes I and II were decreased
to evaluate their effects on total (mitochondrial + cytosolic) NADH and mitochondrial
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FAD signals.
Model simulations in Figure 4.8 show that the ROT and KCN induced less
changes in NADH signal in hyperoxic lungs than in normoxic lungs, suggesting that at
normal condition (no inhibitor) NADH is more reduced in hyperoxic lungs. Simulations
in Figure 4.9 show that PCP induced more changes in NADH signal, consistent with a
more reduced NADH in hyperoxic lungs. Figure 4.8C and D show that PCP had no effect
on FAD signal, and KCN induced a ~5% decrease in FAD signal.

Normoxic lung NADH
A

Hyperoxiclung NADH (CI)

Hyperoxiclung NADH (CII)
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KCN

PCP
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Figure 4.9: Experimental data and model simulated effect of decreased CI and CII on
NADH and FAD signals in response to inhibitos.
Experimental data and model simulated effect of decreased CI (B, E) or CII (C, F) on
lung tissue NADH and FAD redox status in response to pentachlorophenol (PCP) and
potassium cyanide (KCN). Symbols are experimental data of NADH and FAD signal for
normoxic lungs (red) and hyperoxic lungs (blue). Simulations were generated using the
intact lung model under normal conditions (A, D, values of model parameters fixed to the
values in Table 3.4), or with the value of the model parameter describing complex I
activity (B, E) fixed at 80%, 50% and 23% of the value under normoxic conditions (Table
3.4), or with the value of the model parameter describing complex II activity (C, F) fixed
at 80%, 50% and 20% of the value under normoxic conditions (Table 3.4).
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Model simulation in Figure 4.8 and Figure 4.9 show that experimental data of
NADH signal are more consistent with a 20% decrease in CI (i.e., 80% of CI activity in
normoxic lung), much less than the 77% decrease in CI activity measured in lung
homogenates by Sepehr et al. For simulations with 77% decreased CI activity, adding
KCN after PCP failed to increase NADH signal (blue dash lines in Figure 4.9B, C). In
contrast, as shown in Figure 4.9C and E, model simulations show that decreased CII from
80% to 20% had little or no effect on lung NADH and FAD signals. This observation
indicates that for the intact lung, NADH is the major electron donor for ETC, while the
contribution of FADH2 is low compared with NADH.
4.5.2 Hyperoxia-induced changes in lung tissue glycolytic rates
Since injury to the ETC enzymes impairs the ability of mitochondria to generate
ATP, one would expect lung cells under such conditions to rely more on glycolytic ATP
production. Fisher et al. reported 61% increase in lactate production rate, an index of
glycolytic ATP production, in lungs of rats exposed to >95% O2 for 48 hours [107].
Another study reported a 52% increase in the rate of glucose utilization and 99% increase
in rate of lactate + pyruvate production in lungs of rats exposed to 100% O2 for 24 hours
[115]. In addition, Bassett et al in [115] show that lung ATP content was not significantly
altered following rat exposure to 100% O2 for 24 hours, which suggests that stimulation
of glycolytic ATP production can compensate for the diminished mitochondrial ATP
generation due to rat exposure to hyperoxia for 24 hrs.
Model simulations were generated using the isolated perfused rat lung model to
further understand the impact of decreased complexes I and II on lung tissue
bioenergetics. As shown in Figure 4.10, lung glucose consumption (as indicated by
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GLUT, panel A) and lactate production (as indicated by LACT, panel B) increase in
response to decreased mitochondrial complex I, but no change is observed in response to
complex II. This simulation suggests that even though complex II is important for
mitochondria respiration in isolated mitochondria experiments when using SUC as
substrate, it does not affect bioenergetics in the intact lungs. In contrast, decreased
mitochondrial complex I resulted in decreased lung ATP/ADP and NADH/NAD ratios,
which leads to stimulation of glycolysis in the cytosol to compensate for the impaired
mitochondrial ATP generation capacity.

A

B

C

D

Figure 4.10: Simulated effect of decreased CI and CII activities on lung tissue
bioenergetics.
Simulations were generated using the isolated rat lung model, with decreased CI and CII
activities (range from 20% to 100% of activity under normoxic conditions). Other
parameters were fixed to the values estimated for normoxic lungs (Table # in chapter 3).
Panel A: Lung glucose (GLUT) utilization; Panel B: Lung lactate (LACT) production
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rate; Panel C: Lung ATP/ADP ratio; Panel D: Lung NADH/NAD ratio.

Figure 4.11: Effects of hyperoxia on GLC consumption and PYR, LAC production of
isolated perfused rat lung.
Symbols in the figure are data of effect of 24-h hyperoxia exposure on lung glucose
consumed (A) and PYR+LAC produced (B) in 100 minutes. Experiment data is compare
with model simulation using whole lung model of control condition (red solid line), and
decreasing complex I (CI) activity by 25% (solid blue line) and 50% (dash blue line),
respectively.

Fisher et al. [115] reported the effect of hyperoxia duration on lung pyruvate and
lactate production rates, and lung ADP and ATP amount. As shown in Figure 4.12A,
lactate and pyruvate production rate were measured in rat lungs after exposure to
hyperoxia for 0 hours (control, normoxic), 18, 24 and 48 hours. Hyperoxia exposure
significantly stimulated lactate production rate but had no effect on pyruvate production
rate. This result is consistent with model simulation with increasingly decreased complex
I activity from 100% to 50% (Figure 4.12B). By comparing Figure 4.12A and Figure
4.12B, experimental data of 48-h hyperoxia rat lung lactate production are consistent with
a ~50% decrease in complex I activity.
Data and simulations in Figure 4.12 suggest that hyperoxia-induced injury to
mitochondrial enzyme activity is proportional to the duration of the exposure period, and
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that CI is an early and major injury site. Even though mitochondrial ATP generation
capacity is impaired experimental data [115] (Figure 4.4C) and model simulation show
that (Figure 4.4D) lung ATP content can be maintained for up to 48 hours. However
glycolytic ATP production is stimulated to compensate for the diminished mitochondrial
ATP generation due to rat exposure to hyperoxia.

A

B

C

D

Figure 4.12: Effect of hyperoxia exposure on lung lactate, pyruvate production and ATP,
ADP. Lactate and pyruvate production rates (Panel A) and ATP, ADP amounts (Panel C)
were measured in rat lung isolated after 0, 18, 24, 48 hours of hyperoxia exposure. Model
simulations were performed with increasingly decreased complex I activity.
Aconitase, a TCA cycle enzyme that catalyzes the isomerization of citrate to
isocitrate, was also suggested to be altered early in the pathogenesis of hyperoxia-induced
lung injury. For instance, Gardner et al. [119] reported a 73% decrease in aconitase
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activity in rat lung after 24 hours of exposure to hyperoxia. However, as shown in chapter
2, most of the generated citrate in TCA cycle is released into buffer. Therefore,
decreasing aconitase activity has no effect on lung mitochondria bioenergetics.

4.7 Discussion and conclusions
Mitochondria electron transport chain is a primary and early target of injury
during hyperoxia exposure (100% O2 for 48 hrs) as reflected by significant decreases in
complexes I and II activities [26]. Longer membrane potential repolarization time [118]
and slower oxygen consumption rates were observed in rat lungs after exposure to
hyperoxia. Model simulations using isolated mitochondria model suggest that the
changes in mitochondria membrane potential and oxygen consumption rates at states 2
and 3 can be accounted for by a 77% decrease in complex I and a 64% decrease in
complex II activities.
At the isolated mitochondria level, model simulations suggest that hyperoxiainduced changes in mitochondria complexes I and II activities can account for most
observed hyperoxia-induced changes in mitochondrial bioenergetics. Decreasing complex
I and complex II activities resulted in slower respiration in isolated mitochondria
experiments when using pyruvate + malate, or succinate as substrates, respectively.
Moreover, simulations in Figure 4.6 show that decreasing complex I results in higher
FWHM value of ADP induced depolarization. Similarly, when using SUC as substrate,
decreasing complex II resulted in slower repolarization. This indicates that both
complexes I and complex II are essential to mitochondria respiration in isolated
mitochondria, depending on the metabolic substrates used.
In intact lungs, however, the impact of a hyperoxia-induced decrease in complex
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II activity might be less important to lung bioenergetics as compared to that with a
decrease in complex I activity. Simulations using isolated perfused rat lung model
(Figure 4.10) show that lung ATP/ADP ratio and NADH/NAD ratio are altered in
response to a change in mitochondria complex I activity, but not to a change in complex
II activity. Thus, complex I activity appears to be more important than complex II in
intact lungs, and hence might be a potential therapeutic target for hyperoxia-induced lung
injury.
In addition, simulations using isolated perfused rat lung model suggest that the
hyperoxia-induced decrease in complex I activity might be less than that measured in the
isolated mitochondrial preparation. Both NADH/FAD simulations and glycolytic rate
simulations show that a smaller decrease in complex I activity (20% - 50%) than the 77%
reported by Sepher et al. is needed to account for the hyperoxia-induced changes in lung
surface NADH/FAD and glycolytic rate. Simulations in Figure 4.8 and Figure 4.9 show
that NADH and FAD signal changes measured in hyperoxic lungs are consistent with
model simulations with only a 20%-50% decrease in mitochondria complex I.
Simulations in Figure 4.12 also show that hyperoxia-induced increase in lactate
production after 48 hours is consistent with ~50% decrease in complex I activity. One
possible explanation of this inconsistency between isolated mitochondria and intact lungs
is that complex I activity is reduced more in lung homogenates than in intact lungs.
Another explanation is that in intact lungs, other pathways changes, such as energetic
compensation by glycolysis after complex I damage.
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Chapter 5: Summary, conclusions and future directions
5.1 Summary and conclusions
A key outcome of this dissertation is the development and validation of two
thermodynamically constrained integrated models of the bioenergetics of rat lung
mitochondria and the bioenergetics of an intact rat lung. These models incorporate major
metabolic pathways/components in rat lung mitochondrial/tissue bioenergetics, including
glycolysis and pentose phosphate pathway in cytosol, and TCA cycle, electron transport
chain, ATP phosphorylation in mitochondria. This resulted in the estimation of kinetic
parameters describing those pathways, including intrinsic parameters (binding constants)
and extrinsic parameters (Vmaxs/Tmaxs) for various enzymes and transporters. For each
model, the same set of model parameters were able to fit well a wide range of new and
existing data from isolated rat lung mitochondria and/or isolated perfused rat lungs,
including mitochondrial oxygen consumption, TCA cycle metabolites
consumption/production, lung glucose consumption rate, and lactate/pyruvate production
rates. For validation, each model was capable of predicting well experimental data not
used for the estimation of the model parameters. As such, these two models provide a
basic structure for building more complex model, and for integration and interpretation of
experimental data collected at different levels of biological organization, including
isolated enzyme data, isolated mitochondria data and isolated perfused lung data. Such
models can also allow us to predict the functional impact of a change in one or more of
mitochondrial or cytosolic processes on bioenergetics under pathophysiological
conditions such as rat exposure to hyperoxia. Simulations using these models provided
important insights into the bioenergetics of lung mitochondria and lung tissue, and how
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they differ from those of other organs. For instance, citrate production is much higher in
isolated lung mitochondria than in cardiac mitochondria. The high citrate production
results in an incomplete TCA cycle, since no enough intermediates are left for the TCA
cycle reactions. Thus, only half of TCA cycle reactions are active in isolated rat lung
mitochondria. Additional simulations in our whole lung model show that completeness of
TCA cycle in rat lung mitochondria is dependent on substrate concentrations.
The developed models can also be used to test hypotheses with respect to the
regulation of metabolic pathways. For example, the models were used to evaluate how
substrates concentration (PYR, LAC, etc) regulate glycolysis and TCA cycle.
Moreover, the developed models can be used to evaluate the effect of altered
enzyme activities on lung bioenergetics. For example, the effect of the overexpression of
a specific enzyme or transporter can be simulated by increasing the value of the
Vmax/Tmax parameter that describe the activity of that enzyme or transporter. The effect
gene knockout or injury to a specific enzyme or transporter can be simulated by
decreasing the value of the Vmax/Tmax parameter that describe the activity of that enzyme
or transporter. Using these two models, we were able to evaluate the impact of hyperoxiainduced-decreases in the activities of mitochondrial ETC enzymes on mitochondrial
membrane potential, coenzymes NADH and FAD redox status, lung glucose
consumption, and lung lactate and pyruvate production rates. Both isolated mitochondria
model and isolated lung model suggest that hyperoxia-induced decreases in mitochondria
complexes I and II are sufficient to account for experimentally measured changes in
mitochondrial membrane potential, and the redox status of the coenzymes NADH and
FAD. These results are consistent with the experimental results of Bongard et al. in which
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they showed that 1) inhibition of mitochondria complex I decreased whole lung tissue
ATP level and comprised microvascular permeability as measured by an increase in
pulmonary vascular endothelial filtration coefficient (Kf), a sensitive measure of
pulmonary endothelial barrier, and 2) that the decrease in lung tissue ATP and the
increase in Kf can be reversed by adding an exogenous electron donor (reduced form of
the quinone coenzyme Q1) which bypasses complex I to reduce complex III and restore
mitochondrial bioenergetics [16].

5.2 Future directions
As mentioned in the limitation sections in chapters 2 and 3, cations such as Ca2+
and Mg2+ are not included in the current bioenergetics models, even though they play an
important regulatory role in rat lung bioenergetics [76]. It is known that dehydrogenases
are activated by Ca2+ at nM level (~100–300 nM). However, Fisher et al. reported that
mitochondrial oxygen consumption rates are inhibited as Ca2+ concentration increases to
µM–mM ranges [76]. In addition, high mitochondria matrix Ca2+ concentration is known
to stimulate permeability transition pore (PTP) opening, allowing small molecules (such
as TCA intermediates and NADH) in mitochondria matrix to pass across mitochondria
inner-membrane, resulting in loss of mitochondrial intermediates and membrane potential
depolarization [120]. This provides a possible explanation for the inhibitory effect of high
Ca2+ on respiration [120]. Besides the inhibitory effect of Ca2+, Fisher et al. also observed
a loss of free NAD(P)H (drop from 2.3 nmol/mg to 0.3 nmol/mg) in the presence of high
Ca2+ (0.2 mM) [76]. This observation is consistent with the hypothesis of PTP opening.
However, in order to account for Ca2+ in the computational models, additional studies and
data from isolated rat lung mitochondria are required to identify the threshold Ca2+
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concentration and kinetics behavior for PTP opening. In a computational study, ChapaDubocq et al. recently developed a mitochondrial model of PTP to study Ca2+ induced
mitochondria swelling in cardiac cells [121]. In order to include Ca2+ into the current
computational model, two aspects of Ca2+ effects need to be considered. At low
concentrations, Ca2+ is important for ion homeostasis, and Ca2+ stimulates mitochondrial
respiration by activating dehydrogenase enzymes. Computational models of Ca2+
transportation and buffering in mitochondria developed by Dash and coworkers [31, 122,
123] need to be integrated into current models. At high concentrations, Ca2+ stimulates
PTP opening and induces mitochondrial dysfunction. Mathematical equations describing
PTP opening need to be included.
Mitochondrial Ca2+ influx and increased ROS production are early events in the
pathogenesis of ALI/ARDS [124]. In addition, increased mitochondrial ROS production
or oxidative stress plays a key role in the pathogenesis of other lung diseases [125, 126].
Mitochondria are not only the key site of ROS production, but also the key sites for ROS
detoxification, and hence a primary target of oxidative stress (excess ROS production
with low ROS detoxification capacity). Both the computational models developed here
do not account for ROS production and scavenging under physiological or
pathophysiological conditions, and the impact of ROS on the activities of key cellular
processes. Therefore, one future direction for this work is to include ROS production into
current bioenergetics models. There is a wealth of data about ROS production and
scavenging in isolated mitochondria [127-131]. In cardiac cells, mitochondria complex I
and complex III are major sites for mitochondrial ROS production. Computational
models that account for ROS production have been develop for complex I [131] and
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complex III [130]. Similarly in a series of studies, Dash and colleagues have developed
detailed kinetics/mechanistic models of mitochondrial ROS scavenging by the
glutathione and thioredoxin ROS scavenging systems [127-129].
For rat lung tissue, mitochondria complex II might also be an important source of
ROS production [132]. Using Amplex red and optical imaging, Audi et al. showed that
complex II accounted for 76% of the rate of H2O2 production in the isolated perfused rat
lung [132]. In addition, they showed that lung ventilation with high O2 gas mixture (acute
hyperoxia) increased H2O2 production from non-mitochondrial source, potentially via
NADPH oxidase, but did not increase mitochondrial H2O2 production. Incorporating the
ROS production data in lung tissue into the two computational models of lung tissue
mitochondrial bioenergetics along with ROS scavenging would help in furthering our
understanding of the interrelationship between lung tissue and mitochondrial ROS
production, oxidative stress, and hyperoxia-induced ALI/ARDS.
Another future direction is to look at lung bioenergetic changes due to another rat
model of clinical ALI, namely lipopolysaccharide (LPS)-induced lung injury, a model of
clinical sepsis which is one of the main causes of ALI/ARDS. LPS-induced lung injury
and hyperoxia induced lung injury share common pathways, including injury to capillary
endothelium and cell apoptosis [11]. In order to evaluate the effect of LPS on
mitochondrial bioenergetics, mitochondria membrane potential data and NADH/FAD
fluorescence need to be collected in LPS-exposed rat lungs, and simulations using the
two computational models developed under Aims 1 and 2 can be used to further our
understanding of the role of lung tissue and mitochondrial bioenergetics in the
pathogenesis of LPS-induced ALI.
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Appendix I: Glossary
Terms
Subscript r
Subscript b
Subscript c
Subscript m
Subscript i
Species
ADP
ATP
ALA
ACoA
ASP
AKG
BPG
CoA
CIT
CytCr
CytCo
DHAP
F16BP
F6P
FUM
FAD
FADH2
GAP

Description
Reservoir region
Lung vascular (blood) region
Cytosolic region
Mitochondria matrix region
Inter-membrane space
Description
Adenosine diphosphate
Adenosine triphosphate
Alanine
Acetyl-coenzyme A
Aspartate
α-ketoglutarate (2-oxoglutarate)
1,3-Bisphosphoglyceric acid
Coenzyme A
Citrate
Reduced form of cytochrome c
Oxidized form of cytochrome c
Dihydroxyacetone phosphate
Fructose 1,6- bisphosphate
Fructose 6-phosphate
Fumarate
Oxidized form of flavin adenine dinucleotide
Reduced form of flavin adenine dinucleotide
Glyceraldehyde 3-Phosphate
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GDP
G6P
GTP
GLC
GLU
MAL
OXA
PYR
PG6
PEP
Pi
SUC
SCoA
UQH2
UQ
Cytosolic
Reactions
AA
AK
ALD
HEX
GAPDH
G6PDH
GSR
GPx
LDH
PFK
PGI
PGK
PK

Guanidine diphosphate
Glucose-6-phosphate
Guanidine triphosphate
Glucose
Glutamate
Malate
Oxaloacetate
Pyruvate
6-phosphogluconolactone
Phosphoenolpyruvic acid
Inorganic phosphate
Succinate
Succinyl-coenzyme A
Reduced form of ubiquinone
Oxidized form of ubiquinone
Description

Mitochondrial
Reactions
AKGDH
CITS
CITDH
CI
CII
CIII
CIV
CV
FH
GOT

Description

Alanine Aminotransferase
Adenylate kinase
Lumped reaction of Aldolase and triose phosphate isomerase
Hexokinase
Glyceraldehyde 3-phosphate dehydrogenase
Glucose-6-phosphate dehydrogenase
Glutathione reductase
Glutathione peroxidase
Lactate dehydrogenase
Phosphofructokinase
Phosphoglucose isomerase
Phosphoglycerate kinase
Pyruvate Kinase

α-ketoglutarate dehydrogenase
Citrate synthase
Lumped reaction of aconitase and isocitrate dehydrogenase
Complex I
Complex II
Complex III
Complex IV
Complex V
Fumarate hydratase
Glutamate oxaloacetate (or Aspartate aminotransferase)
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MDH
NDK
PDH
SCAS
SDH
Transporters
ANT
DCC
GAE
GLUH
GLCT (b-c)
LACT (b-c)
LEAK
OME
PYRT (b-c)
PIC (c-m)
PIT (b-c)
PYRH
TCC
MAS

Malate dehydrogenase
Nucleoside diphosphokinase
Pyruvate dehydrogenase
Succinyl-coenzyme A synthetase
Succinate dehydrogenase
Description
Adenine nucleotide translocase
Dicarboxylate carrier
Glutamate-aspartate exchanger
Glutamate-hydrogen co-transporter
Glucose transporter between blood and cytosol
Lactate transporter between blood and cytosol
Passive proton leak from inter-membrane space to mitochondria matrix
α-ketoglutarate (2-oxoglutarate) malate exchanger
Pyruvate transporter between blood and cytosol
Inorganic phosphate carrier (cytosol to mitochondria)
Inoganic phosphate-Na cotransporter (blood to cytosol)
Pyruvate-hydrogen co-transporter
Tricarboxylate carrier
Malate Aspartate Shuttle

145

Appendix II: Derivation of the generalized metabolic reaction and
transport flux equations:

One-substrate one-product enzymatic reactions
E

SP

The general scheme for a reversible one-substrate one-product enzymatic reaction
[133] is shown in Figure A1,

ES
ESP

E

EP

Figure A1. General scheme for one substrate and one product enzymatic reactions
where E is the enzyme, S is the substrate, P is the product, and ESP is a hypothetical
enzyme-substrate-product complex that binds both substrate and product, KS is the
dissociation constant of ES complex, and KP is the dissociation constant of EP. For
simplicity and to reduce the number of unknown parameters, two assumptions were made
to derive the general flux equations. First, we assumed rapid equilibrium conditions, i.e.,
all the enzymatic complex dissociation reactions are considered extremely rapid
compared to the interconversion of ES and EP, which is the only rate limiting reaction
step. Second, we assumed that the binding of S does not affect the binding of P.
Under the above assumptions, the flux equation for the reversible one-substrate oneproduct enzymatic reaction is given by
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k p  ES   k p  EP 
J k p  ES   k p  EP 


Et
Et
 E    ES    EP   ESP

(C.13)
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max r
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J

S   P S   P
  S    P  
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1 
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KS KP KS KP
K
KP 
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(C.14)

Vmax f

S  V

 P

max r

where Et is the total concentration of the enzyme, and Vmaxf = kp.Et and Vmaxr = k-p.Et are
the maximum forward and reverse reaction velocities, respectively. The denominator of
Eq (C.13)reflects all four species in this system, namely E, ES, EP, and ESP. However,
under the assumption that both the substrate and product do not bind to the enzyme at the
same time, the ESP complex does not form, and hence [ESP] = 0. Under this assumption,
the flux equation for the reversible one-substrate one-product enzymatic reaction can be
reduced to:
Vmax f
J

S  V

 P

max r

KS
KP
 S    P
1
KS KP

(C.15)

We note here that the flux expression (C.15) for a reversible one-substrate oneproduct enzymatic reaction contains two intrinsic model parameters (enzymatic complex
dissociation constants KS and KP; also referred to as binding constants), and two extrinsic
model parameters (forward and reverse reaction maximal velocities Vmaxf and Vmaxr). The
intrinsic parameters are assumed to be independent of tissue source of enzymatic
reaction, while the extrinsic model parameters are assumed to be dependent on tissue
source of enzymatic reaction. Specifically, the extrinsic model parameters are assumed to
be dependent on the activity of the enzyme in a particular tissue, which is dependent on
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several cellular factors, such as enzyme expression, concentration, post-translational
modifications, physiological state of the tissue, etc.
Two-substrates two-products enzymatic reactions
E

S1  S2  P1  P2

Figure A2. General scheme for two substrates two products enzymatic reactions

The general scheme (a random rapid-equilibrium binding scheme) for a reversible
two-substrate two-product enzymatic reaction is shown in Figure A2. With the similar
assumptions, as described for a reversible one-substrate one-product enzymatic reaction,
the flux equation for a reversible two-substrate two-product enzymatic reaction can be
derived as:
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Vmax f

J

 S1  S2   V

 P1  P2 

max r

K S1K S 2
K P1 K P 2
 S   S   P   P   S  P   S  S 
1 1  2  1  2  1 2  1 2
K S1 K S 2 K P1 K P 2 K S1 K P 2 K S1 K S 2


 P1  P2    S2  P1    S1  P1    S2  P2    S1  S2  P1 



 S1  S2  P2    S1  P1  P2    S2  P1  P2    S1  S2  P1  P2 

K P1 K P 2

K S 2 K P1

K S1K S 2 K P 2

K S 1 K P1

K S 1 K P1 K P 2

KS 2KP2

K S 2 K P1 K P 2

(C.16)

K S 1K S 2 K P1

K S 1 K S 2 K P1 K P 2


 S1  S2   V  P1  P2  
 Vmax f

max r
K S1K S 2
K P1 K P 2 

J
  S1    S2    P1    P2  
1 
1 
1 
 1 

 K S1  K S 2  K P1  K P 2 
Considering that

and

share the same binding site on the enzyme, and

(C.17)

and

share a different binding site on the enzyme, as usually is the case for reaction cofactors
(such as NADH and NAD+, ATP and ADP, GTP and GDP, etc.), the flux equation can be
modified to exclude the contributions of [ ][ ] or [ ][ ] product terms:


 S1  S2   V  P1  P2  
 Vmax f

max r
K S1K S 2
K P1 K P 2 

J
  S1   P1    S2   P2  


1 
1 

K
K
K
KP2 
S
1
P
1
S
2



(C.18)

The flux expression (C.18) for a reversible two-substrate two-product enzymatic
reaction contains four intrinsic model parameters (binding constants KS1, KS2, KP1 and KP2)
and two extrinsic model parameters (forward and reverse reaction maximal velocities Vmaxf
and Vmaxr), having the similar tissue-independent and tissue-dependent characteristics, as
described above for the one-substrate one-product enzymatic reaction.
Multi-substrates multi-products enzymatic reactions
For more complex enzymatic reactions that contain multiple substrates and
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multiple products, we write the generalized reaction as:
Ns

 S
i

NP

  j Pj

i

i 1

(C.19)

j 1

where Si is ith substrate, Pj is jth product, NS and NP are number of substrates and products
in the reaction, respectively, and αi and βj are the corresponding stoichiometric
coefficients. The general form of the reaction flux J is given by

 i 1 Si 

i

Ns

Vmaxf
J


Si  i
Ns 

 i1 1  K i
Si


P 
j 1  j 
Np

K j
j 1 Pj

Np

 Vmaxr

 i1K Si i
Ns

j






 P  j

Np
j
   j 1 1    j


K Pj








(C.20)

where KSi and KPj are the binding constants (intrinsic model parameters) corresponding to
substrates and products, respectively, and Vmaxf and Vmaxr are the forward and reverse
reaction velocities (extrinsic model parameters).
Thermodynamic constraints for enzymatic reactions:
To maintain the thermodynamic consistency of an enzymatic reaction, the
forward and reverse reaction velocities are constrained by the Haldane relationship [46].
At equilibrium, the net reaction flux is zero (J = 0), which gives the following
thermodynamic constraint for a NS-substrate NP-product enzymatic reaction:

Vmaxf  j p1K Pj
N

j

Vmaxr  i s1K Si i
N





Np



[ Pj ]eqj

j 1
Ns

[ S ]i
i 1 i eq

 K eq

(C.21)

where K eq is the apparent equilibrium constant for the reaction, which is the value of the
reaction equilibrium-state quotient (i.e. ratio of product of product concentrations over
product of substrate concentrations) at specified thermodynamic conditions (i.e.
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temperature, ionic strength, and pH). The apparent equilibrium constant at pH = 7 (

K eq0  K eq (pH  7)) is calculated as:
K eq0  eΔr G

0

/ RT

(C.22)

where Δ r G0 , R and T are the standard Gibbs free energy of the reaction at pH = 7, gas
constant, and temperature, respectively. The standard Gibbs free energy of reactions in
the mitochondrial bioenergetics model was obtained from references [46, 56, 68], and are
listed in Part C.
0
With the Haldane constraint (C.21), Vmaxr can be calculated from Vmaxf and K eq to

reduce the number of unknown model parameters. Thus, the reaction flux expression for
multi-substrate and multi-product enzymatic reaction becomes:
j
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(C.23)

Under the assumption that the substrate and product representing a co-factor pair
bind with a given enzyme at the same binding site, one can show that the resulting
reaction flux equation does not include the corresponding substrate and product terms.
Since in the proposed integrated bioenergetics model all the co-factor pairs (e.g.
NADH/NAD+, ATP/ADP/Pi, GTP/GDP/Pi and CoA/ACoA/SCoA) are assumed to bind
to a given enzyme at the same binding site, the reaction flux equation for the enzyme is
modified accordingly.
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Metabolite transporters
Most of the metabolite transporters in the proposed integrated bioenergetics
model involve the transport of two different metabolites or a metabolite and an ion. In
general, there are two different types of such transporters: a co-transporter (symporter)
that transports two different substances from one side to the other side of the inner
mitochondrial membrane (IMM), and an antiporter (exchanger) that transports two
different substances across the IMM in the opposite directions [133]. There are also
uniporters, which transport one substance across the IMM, such as a Ca2+ uniporter,
which is not considered in the present integrated bioenergetics model.
For generality, a random-ordered rapid-equilibrium binding mechanism is
assumed for all the transporters, i.e., the transporter can bind to the two substrates in an
arbitrary order, similar to that described for a reversible two-substrate two-product
enzymatic reactions. Thus, the transport flux equations for various transporters can be
derived similarly.
The general scheme for a co-transporter is shown below in Figure A3:

Figure A3. General scheme for a co-transporter
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Here

𝑖

and

𝑖

are two distinct substrates at side i of the membrane (i =1, 2). The

free transporter (E) binds to the two substrates in an arbitrary order before undergoing
conformational changes. All association and dissociation processes are assumed to be
reversible and rapid-equilibrium reactions. The rate limiting steps are the conformational
changes in the substrate-bound transporters resulting in the transport of the substrates
across the membrane.
Assuming rapid equilibrium, the general flux equation for a co-transporter is
given by
Tmax f

J co 

 A1  B1   T

 A2  B2 

max r

K A1 K B1
K A2 K B 2
 A   A   B   B   A  B   A  B 
1 1  2  1  2  1 1  2 2
K A1 K A2 K B1 K B 2 K A1 K B1 K A 2 K B 2

(C.24)

where Tmaxf and Tmaxr are the maximum forward and reverse transport rates, respectively.
The general scheme for an anti-porter is shown below in Figure A4:

Figure A4. General scheme for an anti-porter

The anti-porters bind to the substrates from both sides of the membrane. The
general flux equation for an anti-porter is similarly given by:
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Tmax f

J anti 

 A1  B2   T

 A2  B1 

max r

K A1 K B 2
K A2 K B1
 A   A   B   B   A  B   A  B 
1 1  2  1  2  1 2  2 1
K A1 K A 2 K B1 K B 2 K A1K B 2
K A 2 K B1

(C.25)

For all the metabolite transporters, the internal and external binding constants are
assumed to be equal (KA1 = KA2 and KB1 = KB2). Therefore:
Tmax f 
 A2  B2  
  A1  B1  

K AKB 
K eq 
J co 
 A   A   B   B   A  B   A  B 
1 1  2  1  2  1 1  2 2
KA
KA
KB
KB
K AKB
K AKB

J anti

Tmax f 
 A2  B1  
  A1  B2  

K AKB 
K eq 

 A   A   B   B   A  B   A  B 
1 1  2  1  2  1 2  2 1
KA
KA
KB
KB
K AKB
K AKB

(C.26)

(C.27)

For non-electrogenic transporters, Tmaxf =Tmaxr and Keq = 1. For electrogenic
transporters, such as the glutamate-aspartate exchanger (GAE) and the adenine nucleotide
translocase (ANT), equilibrium constants are dependent on membrane potential,
determined based on the Nernst equation. Detailed transport flux expressions for such
transporters are described in Part C.
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Appendix III: Flux expressions for metabolic reactions and transport
processes for the isolated mitochondria model
In the proposed mitochondrial bioenergetics model, metabolic reaction and
transport flux equations are derived based on thermodynamically-constrained enzymatic
reaction and transport kinetic mechanisms [75, 133]. As described below, the intrinsic
model parameters, such as binding constants (K’s), were either determined using
previously published isolated enzyme and transporter kinetic data or set to wellestablished published values. Most of the enzyme kinetic data were measured using
isolated mitochondrial enzymes purified from the heart or liver tissue, as no such kinetic
data are available for lung tissue. The assumption is that differences in the intrinsic
properties of the mitochondrial enzymes, such as binding constants (K’s), between the
heart, liver and lung are relatively small [75], under fixed experimental conditions
(temperature, pH, and ionic strength). With the intrinsic model parameters K’s known,
the extrinsic model parameters, such as the maximum reaction and transport velocities
(Vmaxs and Tmaxs), of the integrated bioenergetics model for isolated lung mitochondria
were then estimated using previously published and newly measured experimental data
from isolated rat lung mitochondria as described in the Results section of the main paper.
The extrinsic model parameters are assumed to be dependent on the activities of the
enzymes and transporters in a particular tissue, which is dependent on several cellular
factors, such as enzyme and transporter expressions, concentrations, post-translational
modifications, and physiological state of the tissue. Particularly the mitochondrial
enzyme and transporter activities in non-excitable lung tissue is expected to be
significantly different from that in excitable cardiac and skeletal muscle tissues.
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In what follows, we provide the flux expressions for different enzymes and
transporters used in the proposed integrated bioenergetics model. These flux expressions
are determined based on the generalized flux expressions derived in the previous section.
These flux expressions are then fitted to available experimental data on the kinetics of
specific enzymes and transporters to estimate the associated parameter values (i.e. K’s,
Vmax’s, Tmax’s). This is done using the “fmincon” algorithm in the MatLab optimization
toolbox. Kinetic parameters for some of the enzymes and transporters are fixed at the
well-established published values for which suitable kinetic data could not be identified.
Only the values (estimated or fixed) of the intrinsic model parameters, such as binding
constants K’s, are used in the integrated bioenergetics model. All extrinsic model
parameters, such maximal reaction and transport velocities (Vmax’s and Tmax’s), were reestimated based on fittings of the integrated bioenergetics model to available and new
experimental data from isolated rat lung mitochondrial experiments.
Reaction 1: Pyruvate dehydrogenase (PDH)
PYRm + CoAm + NADm ⇌ ACoAm + CO2 + NADHm + Hm+
For this reaction, the reactant concentrations are denoted as A =
C=

[ PYRm ] , B = [CoAm ] ,

[ NADm ] , D = [ ACoAm ] , E = [CO2,m ] , F = [ NADH m ] . CO2 concentration is set at

1.32×10-5 M based on Henry’s law and is assumed to be constant. The participating cofactor pairs in the above reaction are NADH/NAD and CoA/ACoA. Thus, the overall
reaction flux equation,

J PDH , is given by
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J PDH

(C.28)

The above PDH-catalyzed reaction involves the generation of one proton. Thus, the
pH-dependent apparent equilibrium constant for this reaction is defined as:
  eΔr GPDH / RT 10 pHm 7
Keq
'0

where

(C.29)

0 is the transformed Gibbs free
pH m is pH in the mitochondrial matrix, and r GPDH

energy of the reaction catalyzed by PDH at pH = 7. Since the CO2 concentration is
assumed constant, the factor 1  E / K E  in the denominator reduces to a constant value.
Figure A5 shows the PDH reaction flux measured in isolated enzyme over a range
of PYR, CoA, or NAD concentrations [134]. The model parameters (Table A4) were
estimated by simultaneously fitting the solution of equation (C.28) to all the data in
Figure A5 using the MATLAB “fmincon” optimizer. The solid lines in Figure A5 are the
fits of equation (C.28) to the data.
Even though the binding constant of PYR for PDH is estimated to be ~25 M in
isolated enzyme experiments (as shown in Figure A5 and Table A1), the experimental
data at the whole mitochondria level show that the apparent binding constant of PYR for
PDH is around ~3-5 mM. This apparent inconsistency is caused by the enzyme pyruvate
dehydrogenase kinase (PDK) [75]. PDH is known to be inhibited by the PDK, and PDK
is inhibited by PYR. Thus, the apparent binding constant of PYR for PDH is affected by
PDK. Therefore, for simplicity, only the apparent binding constant of PYR for PDH is
used for the simulations of the integrated bioenergetics model in the main paper.
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Parameters
Vmaxf

KA
KB

KC
KD
KF
'0
Δr GPDH

Table A1: PDH model kinetic parameters
Definition
Value
Source
Maximum forward
96.8
Estimated using data
reaction rate
nmol/min/mg
in Figure A5
enzyme
PYR binding
Estimated using data
2.52 105 M
constant in isolated
in Figure A5
PDH*
CoA binding
Estimated using data
1.49 105 M
constant
in Figure A5
NAD binding
Estimated using data
3.50 105 M
constant
in Figure A5
ACoA binding
Assumed to be the
1.49 105 M
constant
same as KB
NADH binding
Assumed to be the
3.50 105 M
constant
same as KC
Gibbs free energy of
[68]
-38.64 kJ/mol
the reaction (pH=7)

*The binding constant of PYR for PDH is affected by the enzyme pyruvate dehydrogenase kinase
(PDK). Thus only the apparent binding constant is used for the model simulations in the main
paper.

Figure A5: Symbols: Reaction fluxes of pyruvate dehydrogenase (PDH) measured in
isolated PDH in reference [134]. In these experiments, around ~16–20 µg PDH enzyme
was used to catalyze the reaction. Reaction fluxes are plotted with three substrates
varying at the concentrations as shown in the figures. (A) PYR concentration was varied
from 0 to 0.6 mM, with CoA concentration fixed at 0.2 mM (red), 0.1 mM (blue), 0.07
mM (green), or 0.05 mM (cyan), respectively; NAD concentration was fixed at 0.05 mM.
(B) CoA concentration was varied from 0 to 0.3 mM, with NAD concentration fixed to
0.5 mM (red), 0.25mM (blue), 0.1 mM (green), or 0.05 mM (cyan), respectively; PYR
concentration was fixed at 0.25mM. (C) NAD concentration was varied from 0 to 0.6
mM, with PYR concentration fixed at 0.5 mM (red), 0.25 mM (blue), 0.1 mM (green), or
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0.05 mM (cyan), respectively; CoA concentration was fixed at 0.1 mM. The solid lines
are the fits of equation (C.28) to the data.
Reaction 2: Citrate synthase (CITS)
ACoAm+OXAm ⇌ CoAm+ CITm +2Hm+
For this reaction, the reactant concentrations are denoted as A =

[ ACoAm ] , B =

[OXAm ] , C = [CoAm ] , D = [CITm ] . Since CoA and ACoA are co-factor pairs, the overall
reaction flux equation, J CITS , is given by,

J CITS

Vmaxf 
CD 
 AB 

K AKB 
K eq 


A
C 
B 
D 

1 
1 
1 

 K A KC   K B  K D 

(C.30)

The reaction catalyzed by CITS generates two protons. Thus, the pH-dependent
apparent equilibrium constant for this reaction is defined as:
  eΔr GCITS / RT 102 pHm 14
Keq
'0

(C.31)

Figure A6 shows the CITS reaction flux measured in isolated enzyme over a range of
ACoA, OXA, CIT, or CoA concentrations [48]. The model parameters in Table A5 were
estimated by simultaneously fitting the solution of equation (C.30) to all the data in
Figure A6 using the MATLAB “fmincon” optimizer. The solid lines in Figure A6 are
model fits to the data.
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ACoA

OXA

CIT

CoA

Figure A6: (A) Forward flux as a function of substrates ACoA and OXA. The
concentrations of OXA was 2.5 μM (green), 5.0 μM (blue), or 10 μM (red). (B) Forward
reaction flux as a function of substrates OXA and ACoA. ACoA concentration was
2.5μM (green), 5.0μM (blue), or 10μM (red). (C) Reverse reaction flux as a function of
CoA and CIT. CoA concentration was 20 μM (green), 33 μM (cyan), 50 μM (blue), or
100 μM (red). (D) Reverse reaction flux as a function of concentrations of CoA and CIT.
CIT concentration was 1.0 mM (green), 2.0 mM (cyan), 4.0 mM (blue), or 10 mM (red).
This reaction was fit using data from reference [48] on forward reaction fluxes (Figure
A6A and A6B) and reverse reaction fluxes (Figure A6C and A6D). The solid lines are the
fit of equation A18 to the data. All data were obtained at 28°C, pH = 8.1.

Parameters
Vmaxf
KA
KB
KC

Table A 2: CITS model kinetic parameters
Definition
Value
Source
Maximum forward
243
Estimated using data in Figure
reaction rate
nmol/min/mg
A6
enzyme
ACoA binding
Estimated using data in Figure
3.90 106 M
constant
A6
6
OXA binding
Estimated using data in Figure
4.53 10 M
constant
A6
6
CoA binding
Estimated using data in Figure
57.9 10 M
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KD
'0
Δr GCITS

constant
CIT binding
4.30 103 M
constant
Gibbs free energy of
-36.61kJ/mol
the reaction (pH=7)

A6
Estimated using data in Figure
A6
[68]

Reaction 3: Aconitase and Iso-citrate dehydrogenase (CITDH)
The reactions catalyzed by aconitase and isocitrate (ISOCIT) dehydrogenase are:
Aconitase: CIT ⇌ ISOCIT + H2O
Isocitrate dehydrogenase: ISOCIT +NAD + H2O ⇌ AKG + NADH +
CO2
Under the assumption that the reaction catalyzed by aconitase is rapidly equilibrating,
the reactions catalyzed by aconitase and isocitrate can be lumped into the following
reaction
CITm +NADm ⇌ AKGm + NADHm +CO2
For this reaction, the reactant concentrations are denoted as A =

[CITm ] , B =

[ NADm ] , C = [ AKGm ] , D = [ NADH m ] , and E = [CO2, m ] , which is assumed to be
constant.

J CITDH

Vmaxf 
CDE 
 AB 

K AKB 
K eq 


A 
C 
B
D 
E 

 1 
1 
 1 
1 

 K A   KC   K B K D  K E 

(C.32)

The production of CO2 results in the generation of bicarbonate ions and one
proton. Thus, the equilibrium constant for this reaction is defined as:
  eΔr GCITDH / RT 10 pHm 7
Keq
'0

(C.33)

Figure A7 shows the CITDH reaction flux measured in isolated enzyme over a range
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of NAD or NADH concentrations. The model parameters in Table A6 were estimated by
simultaneously fitting the solution of equation (C.32) to the data in Figure A7 using the
MATLAB “fmincon” optimization program package.

Figure A7: Symbols are reaction fluxes of isocitrate dehydrogenase measured in isolated
enzyme experiments from reference [49]. Reaction fluxes are plotted with NAD and
NADH concentrations varying at the concentrations shown in the figure. (A) Enzyme
activity as a function of NAD in the absence (blue, triangle) or presence of 0.039 mM
NADH (red, asterisk). (B) Inhibition effect of NADH on enzyme activity. Percent
inhibition was calculated as 100(v0-v)/v0, where v0 and v are the enzyme flux rates in the
absence or presence of NADH, respectively. The solid lines are model fits of (C.32) to
the data.
Table A3: CITDH model kinetic parameters
Parameters Definition
Value
Source
Vmaxf
Maximum forward 3.6 106 nmol
Estimated using data in Figure
reaction rate
A7
/min/mg
enzyme
KA
CIT binding
Estimated using data in Figure
1.30 103 M
constant
A7
6
KB
NAD binding
Estimated using data in Figure
500 10 M
constant
A7
6
KC
AKG binding
Estimated using data in Figure
3.50 10 M
constant
A7
6
KD
NADH binding
Estimated using data in Figure
4.70 10 M
constant
A7
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'0
Δr GCITDH

Gibbs free energy
of the reaction
(pH=7)

2.81 KJ/mol

[68]

Reaction 4: AKG dehydrogenase (AKGDH)
AKGm + CoAm + NADm ⇌ SCoAm+NADHm+CO2
For this reaction, the reactant concentrations are denoted as A = [ AKGm ] , B =

[CoAm ] , C = [ NADm ] , D = [SCoAm ] , E = [ NADH m ] , and F = [CO2 ] . The participating
co-factor pairs in the above reaction are CoA/ACoA, and NADH/NAD. Thus, the overall
reaction flux equation

J AKGDH is given below.

DEF 
 ABC 

K A K B KC 
K eq 


C
E 
B
D 
A 


1 
1 
1 

 KC K E   K B K D  K A 
Vmaxf

J AKGDH

(C.34)

Since the CO2 produced results in the generation of a bicarbonate ion and one
proton, the equilibrium constant for this reaction is defined as
  eΔr GAKGDH / RT 10 pHm 7
Keq
'0

(C.35)

Figure A8 shows the AKGDH flux measured in isolated enzyme over a range of
AKG, COA or NAD concentrations. The model parameters in Table A4 were estimated
by simultaneously fitting the solution of equation (C.34) to the data in Figure A8 using
the MATLAB “fmincon” optimization program package. The solid lines are model fits
the data.
Table A4: AKGDH model kinetic parameters
Parameters Definition
Value
Source
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Vmaxf
KA
KB
KC
KD
KE
'0
Δr GAKGDH

Maximum forward
reaction rate

1.07 103

Estimated using data in Figure
nmol/min/mg
A8
enzyme
AKG binding constant
Estimated using data in Figure
85.9 106 M
A8
Estimated using data in Figure
CoA binding constant 1.63 106 M
A8
Estimated using data in Figure
NAD binding constant 46.6 106 M
A8
SCoA binding
Assumed the same as KB
1.63 106 M
constant
NADH binding
Estimated using data in Figure
7.14 106 M
constant
A8
Gibbs free energy of
-37.08
[68]
the reaction (pH=7)
KJ/mol

NAD and AKG

NAD and CoA

AKG and CoA

NADH

Figure A8: AKGDH activity as a function of substrate and product concentrations. (A)
Forward reaction fluxes as a function of AKG concentration as shown at x axis. And
concentrations of NAD and CoA were set to 0.033 mM and 0.005 mM (cyan), 0.066mM
and 0.01 mM (blue), 0.133 mM and 0.02 mM (green), 0.333 mM and 0.05 mM (red). (B)
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Forward reaction fluxes as a function of CoA concentration shown on the x axis. The
concentrations of AKG and NAD were set to 0.025 mM and 0.02 mM (cyan), 0.05 mM
and 0.04 mM (blue), 0.1 mM and 0.08 mM (green), 0.5 mM and 0.4 mM (red). (C)
Forward reaction fluxes as a function of NAD concentration shown on the x axis. The
concentrations of AKG and CoA were set to 0.05 mM and 0.005 mM (cyan), 0.1 mM and
0.01mM (blue), 0.2 mM and 0.02 mM (green), 0.5 mM and 0.05 mM (red). (D) Net
reaction fluxes as a function of NAD concentration shown on the x axis. AKG and CoA
concentrations were fixed to 0.5 mM and 0.05 mM, respectively. The NADH
concentration was set to 0 mM (red), 0.01 mM (green), 0.02 mM (blue), 0.05 mM (cyan).
The symbols are experimental data [135] and solid lines are model fits to the data.
Reaction 5: SCoA synthetase (SCAS)
SCoAm + GDPm + Pim ⇌ SUCm + GTPm + CoAm + Hm+
For this reaction, the reactant concentrations are denoted as A =

[SCoAm ] , B =

[GDPm ] , C = [ Pim ] , D = [SUCm ] , E = [GTPm ] , and F = [CoAm ] . The participating cofactor pairs in this reaction are SCoA/CoA, ADP/ATP, ATP/Pi, and SCoA/SUC.
Therefore, the overall reaction flux equation

J SCAS is given by:


DEF 
 ABC 

K A K B KC 
K eq 


A
D
F
DF  
B
C
E
BC 







1 
 1 
 K A K D K F K D K F  K B KC K E K B KC 
Vmaxf

J SCAS

(C.36)

This reaction involves the generation of one proton, thus, the equilibrium constant
for this reaction is defined as
  eΔr GSCAS / RT 10 pHm 7
Keq
'0

(C.37)

Figure A9 shows the SCAS flux measured in isolated enzyme over a range of
GTP, GDP or SCA concentrations. The model parameters in Table A5 were estimated by
simultaneously fitting the solution of equation (C.36) to the data in Figure A9 using the
MATLAB “fmincon” optimization program package. The solid lines in Figure A9 are
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model fits to the data.
Table A5: SCAS model kinetic parameters
Parameters Definition
Value
Source
Vmaxf
Maximum forward
50.6
Estimated using data in Figure
reaction rate
nmol/min/mg
A9
enzyme
KA
SCoA binding
12.5 106 M Estimated using data in Figure
constant
A9
6
KB
GDP binding
5.70 10 M Estimated using data in Figure
constant
A9
3
KC
Pi binding constant
2.10 10 M Estimated using data in Figure
A9
6
KD
SUC binding
45110 M Estimated using data in Figure
constant
A9
6
KE
GTP binding constant 23.110 M Estimated using data in Figure
A9
6
KF
CoA binding constant 17.7 10 M Estimated using data in Figure
A9
'0
Gibbs free energy of 1.26 KJ/mol
Δ r GSCAS
[68]
the reaction (pH=7)
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GTP
SUC

CoA

SUC

Figure A9: SCAS activity as a function of substrate and product concentrations [50]. (A)
Reverse reaction fluxes as a function of GTP concentration shown on the x axis. SUC
concentrations were fixed at 0.4 mM (red), 1 mM (green), 10 mM (blue), 50 mM (cyan),
while CoA was fixed to 0.1 mM. (B) Forward reaction fluxes as a function of GDP
concentration as shown at x axis. The concentrations of GTP was set to 0 mM (red), 0.05
mM (green) and 0.1 mM (blue), while inorganic phosphate (Pi) concentration fixed at 50
mM and SCoA concentration fixed at 0.1mM. (C) Forward reaction fluxes as a function
of SCoA concentration shown on the x axis. The concentrations of CoA were set to 0 mM
(red), 0.02 mM (green), 0.04 mM (blue). (D) Forward reaction fluxes as a function of
SCoA concentration shown on the x axis. SUC concentration were fixed to 0 mM (blue),
0.5 mM (green), 2 mM (red). While phosphate concentration and GDP concentrations are
fixed at 1 mM and 0.05 mM, respectively.
Reaction 6: Nucleoside diphosphokinase (NDK)
GTPm+ADPm ⇌ GDPm+ATPm
For this reaction, the reactant concentrations are denoted as A = [GTPm ] , B =
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[ ADPm ] , C = [GDPm ] , and D = [ ATPm ] , and the overall reaction flux equation is given by:

J NDK

Vmaxf 
CD 
 AB 

K AKB 
K eq 


A
C 
B
D 


1 
1 

 K A KC   K B K D 

(C.38)

Table A6: NDK model kinetic parameters
Definition
Value
Source
6
GTP binding constant
[46]
11110 M
6
ADP binding constant
[46]
100 10 M
GDP binding constant
[46]
260 106 M
6
ATP binding constant
[46]
278 10 M
'0
Gibbs free energy of the 0 KJ/mol
Δr GNDK
[68]
reaction (pH=7)
Parameters in this reaction do not affect the simulations in the main paper since the
Parameters
KA
KB
KC
KD

reaction is rapidly equilibrating.
Reaction 7: Succinate Dehydrogenase (SDH)
SUCm + FADm ⇌ FUMm + FADH2,m,
For this reaction, the reactant concentrations are denoted as A =

[SUCm ] , B = [

FADm ], C = [ FUM m ] , and D = [ FADH 2,m ] , and the participating co-factor pairs are
FAD and FADH2. The overall reaction flux equation is given by:

J SDH

Vmaxf 
CD 
 AB 

K AKB 
K eq 


A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 

(C.39)

Figure A10 shows reaction fluxes for different concentrations of SUC and the
exogenous electron acceptor phenazine methosulphate. The model parameters in Table
A7 were estimated by simultaneously fitting the solution of equation (C.39) to the data in
Figure A10 using the MATLAB “fmincon” optimization program package. The solid
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lines in Figure A10 are the fits of equation (C.39) to the data.

Figure A10: SDH activity as a function of succinate and electron acceptor (phenazine
methosulphate) concentrations [136]. Succinate concentration is indicated on the x axis,
and electron acceptor concentrations are 0.067 (red), 0.10 (blue), 0.167 (yellow), 0.30
(cyan), and 2 mM (black), respectively.
Table A7: SDH model kinetic parameters
Parameters Definition
Value
Source
6
1.20

10

/
min
Vmaxf
Maximum forward
Estimated using
600
reaction rate
data in Figure
A10
3
KA
SUC binding
Estimated using
1.80 10 M
constant
data in Figure
A10
6
KB
FAD mimic binding
Estimated using
140 10 M
constant
data in Figure
A10
3
KC
FUM binding
Assumed the
1.80 10 M
constant
same as KA
6
KD
FADH2 binding
Estimated using
2.45 10 M
constant
data in Figure
A10
'0
Gibbs
free
energy
of
-3.62
KJ/mol
Δr GSDH
[68]
the reaction (pH=7)
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Reaction 8: Fumarate Hydratase (FH)
FUMm + H2O ⇌ MALm
For this rapidly equilibrating reaction, the reactant concentrations are denoted as A =

[ FUM m ] , and B = [MALm ] . The reactant H2O is ignored in this reaction since its
concentration is assumed to be constant.

J FUM

Vmaxf 
B 
 A 

K AKB 
K eq 


A 
B 
1 
1 

 K A  K B 

(C.40)

Table A8: FH model kinetic parameters
Parameters Definition
Value
KA
FUM binding constant
1.8 103 M
KB
MAL binding constant
1.8 103 M
'0
Gibbs free energy of the
-3.6 KJ/mol
Δ r GFH
reaction (pH=7)

Source
fixed
fixed
[68]

Reaction 9: Malate Dehydrogenase (MDH)
MALm + NADm ⇌ OXAm + NADHm + Hm+
For this reaction, the reactant concentrations are denoted as A =

[ NADm ] , B =

[MALm ] , C = [OXAm ] , D = [ NADH m ] , the participating co-factor pairs are NADH/NAD,
and MAL is known to be competitive inhibitor of OXA [137]. Thus, the overall reaction
flux equation is given by:

J MDH

Vmaxf 
CD 
 AB 

K AKB 
K eq 


B
C 
A
D 


1 
1 

 K B KC   K A K D 

(C.41)
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The above reaction involves the generation of one proton, thus, the equilibrium
constant for this reaction is defined as
  eΔr GMDH / RT 10 pHm 7
Keq
'0

(C.42)

Figure A11 shows reaction fluxes over different concentrations of NAD, OXA,
and NADH. The model parameters in Table A9 were estimated by simultaneously fitting
the solution of equation (C.41) to the data in Figure A11 using the MATLAB “fmincon”
optimization program package. The solid lines in Figure A11 are the fits of equation
(C.41) to the data.

NADH

MAL

MAL

Figure A11: MDH activity [137] as a function of substrate and product concentrations
(A) Forward reaction flux as a function of NAD and MAL. NAD concentrations are
indicated on the x axis. MAL concentrations are fixed to 0.33 mM (green), 0.5 mM
(magenta), 0.67 mM (cyan), 1 mM (yellow), 2 mM (blue), 4 mM (red). Product
concentrations are set to zero. (B) Reverse reaction flux as a function of OXA and NADH
concentrations. NADH concentrations are fixed at 0.0067 mM (cyan), 0.015 mM (blue),
0.02 mM (green), 0.05 mM (red). (C) Reverse reaction flux as a function of NADH and
MAL. NADH concentrations are indicated on the x axis and MAL concentrations were
fixed to 0 mM (red), 1.5 mM (magenta), 3 mM (cyan), 4.5 mM (yellow), and 6 mM
(blue).

Parameters
Vmaxf
KA

Table A9: MDH model kinetic parameters
Definition
Value
Source
Maximum forward
170 nmol/min/mg
Estimated using
reaction rate
enzyme
data in Figure A11
MAL binding constant

155 106 M

Estimated using
data in Figure A11
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KB

NAD binding constant

1.10 103 M

KC

OXA binding constant

3.38 106 M

KD

NADH binding
constant
Gibbs free energy of
the reaction (pH=7)

36.1106 M

'0
Δ r GMDH

28.83 KJ/mol

Estimated using
data in Figure A11
Estimated using
data in Figure A11
Estimated using
data in Figure A11
[68]

Reaction 10: Glutamate oxaloacetate transaminase (GOT)
ASPm +AKGm ⇌ GLUm + OXAm
For this reaction, the reactant concentrations are denoted as A =

[ ASPm ] , B =

[ AKGm ] , C = [GLU m ] , D = [OXAm ] , and the overall reaction flux equation is given by:

J GOT

Vmaxf 
CD 
 AB 

K AKB 
K eq 


A 
B 
C 
D 
 1 
1 
1 
 1 

 K A  K B   K C   K D 

(C.43)

The equilibrium constant for this reaction is:
  eΔr GGOT / RT
Keq
'0

(C.44)

Table A 10: GOT model kinetic parameters
Parameters Definition
Value
Source
KA
ASP binding constant 3.9 103 M
[46]
6
KB
ΑKG binding constant 430 10 M
[46]
KC
GLU binding constant 8.9 103 M
[46]
6
KD
OXA binding constant 88 10 M
[46]
'0
Gibbs free energy of
-1.31KJ/mol
Δr GGOT
[68]
the reaction (pH=7)

Reaction 11: Complex I (CI)
NADHm + UQm + Hm ⇌ NADm + UQH2m + 4ΔH
The above reaction catalyzed by complex I involves pumping four protons (ΔH)
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from the mitochondria matrix into the inter-membrane space. Thus, this reaction flux is
dependent on proton motive force defined as GH  F   RTln [ Hi ] / [ H m ] , where F
is the Faraday’s constant and  is the mitochondrial membrane potential. To take this
dependency into account, the kinetic parameters was modified to be dependent on
membrane potential [74, 138].
For this reaction, the reactant concentrations are denoted as A =

[ NADH m ] , B =

[UQm ] , C = [ NADm ] , D = [UQH 2m ] , and the participating co-factor pairs in this
reaction are NAD/ NADH, and UQ/UQH2. Thus, the overall reaction flux equation is
given by:

J CI 



  CI (4GH  Δ r GCI'0 ) 
exp



 AB
RT
Vmaxf 





'0
K AKB 
   CI  1 (4GH  Δ r GCI ) 

 CD 
 exp 
RT





A
C 
B
D 


1 
 1 

 K A KC   K B K D 

(C.45)

The model parameters in
Table A11 were estimated by simultaneously fitting the solution of equation (C.45) to
the data in Figure A11 using the MATLAB “fmincon” optimization program package. The
solid lines in Figure A11 are the fits of equation (C.45) to the data.
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UQ

NAD

UQH2

NAD

Figure A12: CI activity [131] as a function of substrate and product concentrations (A)
NADH concentrations are varied as shown on the x axis. UQ concentrations was set to 25
µM (cyan), 50 µM (blue), 100 µM (green), 200 µM (red). Product concentrations are set
to zero. (B) NADH concentrations are varied as shown on the x axis. UQ concentration
was set to 100 µM and NAD concentration was fixed to 0 µM (red), 200 µM (green), 400
µM (blue), 600 µM (cyan). (C) NADH concentrations are varied as shown on the x axis.
UQ concentrations was set to 100 µM and UQH2 concentrations were set to 0 µM (red),
100 µM (blue), 200 µM (green). (D) UQ concentrations are varied as shown on the x
axis. NADH concentration was fixed to 10 µM and NAD concentration was set to 0 µM
(red), 400 µM (blue), 600 µM (green).
Table A11: CI model kinetic parameters
Parameters

Definition
Maximum forward
reaction rate

Value
9.8 pmol/min/mg
enzyme

KA

NADH binding constant

1.50 106 M

KB

UQ binding constant

58.1106 M

KC

NAD binding constant

428 106 M

Vmaxf

Source
Estimated using data
in Figure A12
Estimated using data
in Figure A12
Estimated using data
in Figure A12
Estimated using data
in Figure A12
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KD
βCI

Δr GCI'0

UQH2 binding constant
Complex I free energy
barrier
Gibbs free energy of the
reaction (pH=7)

519 106 M

Estimated using data
in Figure A12

0.5

Fixed

-69.37KJ/mol

[68]

Reaction 12: Complex II (CII)
FADH2,m + UQm ⇌ FADm + UQH2,m
For this reaction, the reactant concentrations are denoted as A = [ FADH 2,m ] , B =

[UQm ] , C = [ FADm ] , D = [UQH 2,m ] , and the participating co-factor pairs are FAD/
FADH2, and UQ/UQH2. Thus, the overall reaction flux equation is given by:

J CII

Vmaxf 
CD 
 AB 

K AKB 
K eq 


A
C 
B
D 


1 
1 

 K A KC   K B K D 

(C.46)

Table A12: CII model kinetic parameters
Parameters Definition
Value
Source
FADH2 binding
Assume the same as NADH
KA
1.50 106 M
constant
binding constant in CI
UQ binding
Assume the same as UQ binding
KB
58.1106 M
constant
constant in CI
FAD binding
Assume the same as NAD
KC
428 106 M
constant
binding constant in CI
UQH2 binding
Assume the same as UQH2
KD
519 106 M
constant
binding constant in CI
Gibbs free
'0
energy of the
-1.31 KJ/mol [68]
Δ r GCII
reaction (pH=7)
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Reaction 13: Complex III (CIII)
UQH2m + 2CytCo + 2Hm ⇌ UQm + 2CytCr + 4ΔH
For this reaction, the reactant concentrations are denoted as A = [UQH 2,m ] , B =
[CytCo] , C =

[UQm ] , D = [CytCr ] , and the participating co-factor pairs are

UQm/UQH2,m, and CytCr/CytCo. In addition, the above reaction catalyzed by complex III
involves pumping four protons from mitochondria matrix into inter-membrane space.
Thus, the overall reaction flux equation is given by:

J CIII

'0



 4GH 2 F  Δ r GCIII
  2


 exp  CIII 

  AB
RT
RT  
Vmaxf 

 RT


2 
'0
K AKB 

 4GH 2 F  Δ r GCIII
 
2
 exp  CIII  1 


  CD 

RT
RT  

 RT



2
2

A
C 
B
D 

1 
1  2  2 
 K A KC   K B K D 

The model parameters in M (red).

(C.47)
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Table A13 were estimated by simultaneously fitting the solution of equation (C.47) to the
data in Figure A13 using the MATLAB “fmincon” optimization program package. The
solid lines are model fits to the data.

B

A

CytCr

UQH2

C

D

CytCr

CytCo

Figure A13: CIII activity [130] as a function of substrate and product concentrations as
indicated in the figures. (A) Oxidized form of cytochrome c concentrations were varied
as shown on the x axis. UQH2 concentrations were set to 25 µM (cyan), 15 µM (blue), 10
µM (green), 7 µM (red). Product concentrations are set to zero. (B) Oxidized form of
cytochrome c concentrations were varied as shown on the x axis. Reduced form of
cytochrome c concentrations were set to 0 µM and 10 µM, respectively. UQ
concentration was fixed to 20 µM. (C) UQH2 concentrations were varied as shown on the
x axis. Reduced form of cytochrome c concentrations were set to 0 µM (cyan), 5 µM
(blue), 10 µM (green), 15 µM (red). (D) UQH2 concentrations are varied as shown on the
x axis. Oxidized form of cytochrome c concentrations were fixed to 7 µM (cyan), 12 µM
(blue), 20 µM (green), 30 µM (red).
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Parameters
Vmaxf
KA
KB
KC
KD
βCIII
'0
Δ r GCIII

Table A13: CIII model kinetic parameters
Definition
Value
Source
Maximum forward
32 µmol/s/mg Estimated using data in Figure
reaction rate
enzyme
A13
6
UQH2 binding
Estimated using data in Figure
4.66 10 M
constant
A13
6
CytCo binding
Estimated using data in Figure
3.76 10 M
constant
A13
6
UQ binding constant
Estimated using data in Figure
4.08 10 M
A13
6
CytCr binding
Estimated using data in Figure
4.9110 M
constant
A13
Complex III free
0.5
Fixed
energy barrier
Gibbs free energy of
-32.53KJ/mol
[68]
the reaction (pH=7)

Reaction 14: Complex IV (CIV)
2CytCr+0.5O2+2Hm ⇌ 2CytCo+H2O+2ΔH
For this reaction, the reactant concentrations are denoted as A = [CytCr ] , B =

[O2 ]

, C = [CytCo] , and the participating co-factor pair is CytCr/CytCo. In addition, two protons
arepumped from the matrix side to the inter-membrane space. Another two protons are
consumed in the matrix side. The overall reaction flux equation is given by:

J CIV

'0

  2GH 2 F  Δ r GCIV
  2 0.5 
exp





 IV 
 A B
RT
RT  
Vmaxf 
  RT


2
0.5 
'0
K AKB 

 2GH 2 F  Δ r GCIV   2 
 exp   IV  1 


 C

RT
RT   

 RT


(C.48)

A2 C 2 
B 0.5 
1  2  2 1  0.5 
 K A KC   K B 

The model parameters in Table A14 were estimated by simultaneously fitting the solution
of equation (C.48) to the data in Figure A14 using the MATLAB “fmincon” optimization
program package. The solid lines in Figure A14 are the fits to the data.
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Figure A14: CIV activities as a function of the substrate cytochrome c and membrane
potential (A), or oxygen (B) [139, 140]. In Figure 14A, CIV enzyme turnover numbers
were measured under different fractions of reduced cytochrome c and membrane
potentials. In Figure 14B, CIV reaction fluxes were measured under different oxygen
concentrations.
Table A14: CIV model kinetic parameters
Parameters
Definition
Value
Source
Maximum forward
3.8 µmol/s/mg Estimated using data in
Vmaxf
reaction rate
enzyme
Figure A14
Estimated using data in
KA
CytCr binding constant
680 106 M
Figure A14
Estimated using data in
KB
Oxygen binding constant 5.4 106 M
Figure A14
KC
CytCo binding constant
Assumed the same as KA
680 106 M
Complex IV free energy
βCIV
0.5
Fixed
barrier
Gibbs free energy of the
'0
-122.94KJ/mol [68]
Δ r GCIV
reaction (pH=7)

Reaction 15: Complex V (CV)
ADPm + Pim +3Hi + Hm+ ⇌ ATPm + 3Hm+
For this reaction, the reactant concentrations are denoted as A =
=

[ ADPm ] , B = [ Pim ] , C

[ ATPm ] , and the participating co-factor pair is ADP/ATP. Thus, the overall reaction
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flux equation is given by:

J CV

'0


 3V (GH  Δ r GCV
)
exp



 AB
RT
Vmaxf 





'0
K AKB 
 3  V  1 (GH  Δ r GCV )  
 C 
 exp 
RT

 



A
C 
B 

1 
1 

 K A KC   K B 

Parameters
KA
KB
KC
𝛽𝐶𝑉
'0
Δ r GCV

(C.49)

Table A15: CV model kinetic parameters
Definition
Value
ADP binding constant
10 106 M
Pi binding constant
0.5 103 M
ATP binding constant
1103 M
Complex V free energy barrier
0.5
Gibbs free energy of the
36.03KJ/mol
reaction (pH=7)

Source
Fixed
Fixed
Fixed
Fixed
[68]

Metabolic Transport Fluxes across the Mitochondrial Inner Membrane:
Transport 1: Pyruvate-Hydrogen Cotransporter (PYRH)
PYRe + He+ ⇌ PYRm + Hm+

J PYRH

 [ PYRe ][ H e ] [ PYRm ][ H m ] 
Tmax 


K PYR K H
K PYR K H 


[ PYRe ] [ PYRm ] [ H e ] [ H m ] [ PYRe ] [ H e ] [ PYRm ] [ H m ]
1





K PYR
K PYR
KH
KH
K PYR K H
K PYR K H
Table A16: PYRH model kinetic parameters
Parameters Definition
Value
KPYR
PYR binding constant
0.24 103 M
KH
H+ binding constant
1 × 10 7 M

Transport 2: Glutamate-Hydrogen Cotransporter (GLUH)
GLUe + He+ ⇌ GLUm + Hm+

Source
[141]
Fixed

(C.50)
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J GLUH

 GLU e  H e  GLU m  H m  
Tmax 


KGLU K H
KGLU K H 

(C.51)

GLU e  GLU m   H e   H m  GLU e  H e  GLU m  H m 

1





KGLU
KGLU
KH
KH
K GLU K H
K GLU K H

Table A17: GLUH model kinetic parameters
Parameter Definition
Value
KGLU
GLU binding constant
0.5 103 M
KH
Proton binding
1107 M
constant

Source
Fixed
Fixed

Transport 3&4: Dicarboxylate Carrier (DCC)
DCC (SUC): Pie + SUCm ⇌ Pim + SUCe
DCC (MAL): Pie + MALm ⇌ Pim + MALe

J DCC ( MAL )

J DCC ( SUC )

  Pi  MALm   Pim  MALe  
Tmax  e


K Pi K MAL
K Pi K MAL 


  Pim   Pie   MALm   MALe   SUCm   SUCe  





 
1 
K
K
K
K
K
K
Pi
Pi
MAL
MAL
SUC
SUC


  MAL  Pi   MAL  Pi   SUC  Pi   SUC  Pi  
e
m
m
e
e
m
m
e





K MAL K Pi
K SUC K Pi
K SUC K Pi 
 K MAL K Pi
  Pi  SUCm   Pim  SUCe  
Tmax  e


K
K
K Pi K SUC 
Pi
SUC


  Pim   Pie   MALm   MALe   SUCm   SUCe  





 
1 
K Pi
K Pi
K MAL
K MAL
K SUC
K SUC


  MAL  Pi   MAL  Pi   SUC  Pi   SUC  Pi  
e
m
m
e
e
m
m
e





K MAL K Pi
K SUC K Pi
K SUC K Pi 
 K MAL K Pi

Parameter
KPi
KMAL
KSUC

Table A18: DCC model kinetic parameters
Definition
Value
Pi binding constant
0.93 103 M
MAL binding constant 1.17 103 M
SUC binding constant
1103 M

Source
[141]
[141]
Fixed

(C.52)

(C.53)
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Transport 5: Tricarboxylate Carrier (TCC)
TCC is non-electrogenic, only 𝐻𝐶𝐼𝑇 and 𝑀 𝐿 are accepted as transport species of
TCC. One proton must bind to CIT for transport process to occur.
HCITe + MALm ⇌ HCITm + MALe
The flux equation for this antiporter is:
  MALe  H m CITm   MALm  H e CITe  
Tmax 


KCIT K H K MAL
K CIT K MAL K H


J TCC 
CIT
H
CIT
H
MAL
MAL
 m  m    e  e    e    m 
1
KCIT K H
K CIT K H
K MAL
K MAL


Parameter
KCIT
KMAL
KH

(C.54)

CITm  H m  MALe   CITe  H e  MALm 
KCIT K H K MAL

K CIT K H K MAL

Table A19: TCC model kinetic parameters
Definition
Value
CIT binding constant
1103 M
MAL binding constant
0.25 103 M
Proton binding constant
1107 M

Source
Fixed
[141]
Fixed

Transport 6: AKG-MAL Exchanger (OME)
AKGe + MALm ⇌ AKGm + MALe

J OME

  MALm  AKGe   AKGm  MALe  
Tmax 


K AKG K MAL
K AKG K MAL 


  MALm   MALe   AKGm   AKGe  



1 

K MAL
K MAL
K AKG
K AKG 


 AKGm  MALe    MALm  AKGe  
 

K AKG K MAL
K AKG K MAL



(C.55)

Table A20: OME model kinetic parameters
Parameter Definition
Value
Source
3
KAKG
AKG binding constant
[141]*
0.24 10 M
3
KMAL
MAL binding constant
[141]*
110 M
KH
Proton binding constant
Fixed
1107 M
*External binding constant and internal binding constant for AKG are reported to be 0.31
mM and 0.17 mM, respectively [141]. For simplicity, internal binding constant and
external binding constant are assumed the same in this model. So an average value of
0.24 mM is used. Similarly, external binding constant and internal binding constants are
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1.36 mM and 0.71 mM, respectively. Thus an average value of 1 mM is used as MAL
binding constant.

Transport 7: ASP-HGLU Exchanger (GAE)
ASPe + HGLUm ⇌ ASPm + HGLUe

J GAE


 0.5F   [ ASPe ][ H m ][GLU m ] 
exp  RT 

K ASP K H K GLU




Tmax 

 exp  0.5F   [ ASPm ][ H e ][GLU e ] 




 RT  K ASP K H K GLU

 H GLU e    H m GLU m    ASPm    ASPe 
1 e
K H K GLU
K H KGLU
K ASP
K ASP


(C.56)

GLU e  H e  ASPm   GLU m  H m  ASPe 
K GLU K H K ASP

K GLU K H K ASP

Table A21: GAE model kinetic parameters
Parameter Definition
Value
KASP
ASP binding constant
0.12 103 M
KGLU
GLU binding constant
0.25 103 M
KH
Proton binding constant
1107 M

Source
[141]
[141]
Fixed

Transport 8: ATP-ADP Anti-Transporter (Adenine Nucleotide Translocase, ANT):
ADPe + ATPm ⇌ ADPm + ATPe
Free ATP carries four negative charges while free ADP carries three negative
charges. Therefore, the transport process catalyzed by ANT is affected by membrane
potential. The flux equation was modified based on [46] to account for the effect of
membrane potential. The transport flux ATP vs. ADP via ANT is given by:
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J ANT



  ANT F    ADPe  ATPm 
exp 


RT

 K ADP K ATP


Tmax 

 exp  (  ANT  1) F    ADPm  ATPe  

 K K


RT


ADP ATP



  ADPm   ATPm 

  F  

exp  ANT
1 

K ADP
K ATP
RT




(C.57)

  ADPe   ATPe 
 (   1) F   

exp  ANT
1 

K ADP
K ATP
RT



Parameters
KADP
KATP
βANT

Table A22: ANT model kinetic parameters
Definition
Value
ADP binding constant
10 106 M
ATP binding constant
10 106 M
ANT free energy barrier 0.6

Source
[141]
[141]
[46]

Transport 9: Inorganic Phosphate Carrier (PIC)
Pie + He+ ⇌ Pim + Hm+

J PIC

 [ Pi ][ H e ] [ Pim ][ H m ] 
Tmax  e


K Pi K H
K Pi K H 


[ Pi ] [ Pi ] [ H  ] [ H  ] [ Pi ] [ H e ] [ Pim ] [ H m ]
1 e  m  e  m  e

K Pi
K Pi
KH
KH
K Pi K H
K Pi K H

Table A23: PIC model kinetic parameters
Parameters Definition
Value
KPi
Pi binding constant
9.4 103 M
KH
H+ binding constant
1107 M

(C.58)

Source
[141]
Fixed

Transport 10: Passive Proton Leak [46]

J HLEAK 

Tmax  
 F  
 F   

   H m  exp  

  H i  exp 
KH 
 2 RT 
 2 RT  

Table A24: Proton leak model kinetic parameters
Parameters Definition
Value
Source
7
KH
H+ binding constant
Fixed
110 M

(C.59)
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Appendix IV: Governing mass balance equations for the isolated
mitochondria bioenergetics model
Buffer region:

d [ Pie ]
  J PIC  J DCC ( MAL )  J DCC ( SUC )
dt
d [ ADPe ]
Ve
  J ANT
dt
d [ ATPe ]
Ve
 J ANT
dt
d [ PYRe ]
Ve
  J PYRH
dt
d [ MALe ]
Ve
  J OME  J DCC ( MAL )  JTCC
dt
d [CITe ]
Ve
  JTCC
dt
d [ AKGe ]
Ve
  J OME
dt
d [ SUCe ]
Ve
  J DCC ( SUC )
dt
d [GLU e ]
Ve
  J GLUH  J GAE
dt
d [ ASPe ]
Ve
  J GAE
dt
d [ H e ]
0
dt
Inter-membrane space region:
Ve

d [ H i ]
0
dt
d [CytCo ]
Vi
 2 J CIII  2 J CIV
dt
d [CytCo ]
d [CytCr ]

dt
dt
Mitochondrial matrix region:

Vm

d [GLU m ]
 J GOT  J GAE  J GLUH
dt

(C.60)
(C.61)
(C.62)
(C.63)
(C.64)
(C.65)
(C.66)
(C.67)
(C.68)
(C.69)
(C.70)

(C.71)
(C.72)
(C.73)

(C.74)
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d [ ASPm ]
  J GOT  J GAE
dt
d [ PYRm ]
Vm
  J PDH  J PYRH
dt
d [OXAm ]
Vm
 J MDH  J CITS  J GOT
dt
d [CITm ]
Vm
  J CITS  J CITDH  JTCC
dt
d [ AKGm ]
Vm
 J CITDH  J AKGDH  J GOT  J OME
dt
d [SCAm ]
Vm
 J AKGDH  J SCAS
dt
d [ SUCm ]
Vm
 J SCAS  J SUCDH  J DCC ( SUC )
dt
d [ FUM m ]
Vm
 J SDH  J FH
dt
d [MALm ]
Vm
 J FH  J MDH  J DCC ( MAL )  JTCC  J OME
dt
d [ FADH 2,m ]
Vm
 J SDH  J CII
dt
d [ FADH 2,m ]
d [ FADm ]
Vm
 Vm
dt
dt
d [ NADH m ]
Vm
  J PDH  J CITDH  J AKGDH  J MDH  J CI
dt
d [ NADm ]
d [ NADH m ]
Vm
 Vm
dt
dt
d [ ATPm ]
Vm
  J ANT  J NDK  J CV
dt
d [ ADPm ]
d [ ATPm ]
Vm
 Vm
dt
dt
d [GTPm ]
Vm
 J SCAS  J NDK
dt
d [GDPm ]
d [GTPm ]
Vm
 Vm
dt
dt
d [ ACoAm ]
Vm
 J PDH  J CITS
dt
d [CoAm ]
Vm
  J PDH  J CITS  J SCAS  J AKGDH
dt
d [ Pim ]
Vm
 J PIC  J SCAS  J CV  J DCC ( MAL )  J DCC ( SUC )
dt

Vm

(C.75)
(C.76)
(C.77)
(C.78)
(C.79)
(C.80)
(C.81)
(C.82)
(C.83)
(C.84)
(C.85)
(C.86)
(C.87)
(C.88)
(C.89)
(C.90)
(C.91)
(C.92)
(C.93)
(C.94)
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 J HLEAK  J GAE  JTCC  2 J PIC  J GLUH  (1  2) J PDH 


d [ H m ]
2.303
Vm

Cm, H   2 J CITS  J AKGDH  J SCAS  J MDH   4  1 J CI
 (C.95)
dt
 mit


 2 J CIII  4 J CIV   3  1 J CV

d [UQm ]
(C.96)
Vm
  J CI  J CII  J CIII
dt
Vm

d [UQH 2 m ]
d [UQm ]
 Vm
dt
dt

(C.97)

Mitochondria membrane potential:

d 
1

 4 JCI  2 JCIII  4 J CIV  3J ANT  J HLEAK  J ANT 
dt
Cimm
where

(C.98)

Cimm is capacitance of the inner mitochondrial membrane.

Oxygen consumption:
For membrane potential experiments, the chamber is open to the atmosphere, and
oxygen concentration is assumed to be constant. Therefore,
d [O2 ]
0
dt

(C.99)

For oximetry experiments, the chamber is a closed system, and oxygen is consumed
by the mitochondria at complex IV. Therefore,

Vm  Ve  Vi 

d [O2 ]
 0.5 J CIV
dt

(C.100)
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Appendix V: Flux expressions for transport process and reactions for
the isolated rat lung bioenergetics model
Cytosolic region
Reaction 1: Hexokinase (HK)
GLCc + ATPc ⇌ G6Pc+ ADPc + Hc
For this reaction, the reactant concentrations are denoted as A =
[ ATPc ] ,

C=

[G6 Pc ] ,

D=

[ ADPc ] ,

[GLCc ] ,

B=

and ATP/ADP is considered a co-factor pair. In

addition, this enzyme is known to be inhibited by its product, G6P [61, 99]. The flux
equation is modified based on [61] to account for the inhibitor effect. The overall reaction
flux is given by

J HK 

Vmaxf  KiC  
CD 

  AB  ' 
K A K B  KiC  C  
K eq 

A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 

(C.101)
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Table A25: HK model kinetic parameters
Parameter
Definition
Value
Source
KA
GLC binding constant
1×10-4 M
[142]
-4
KB
ATP binding constant
1.16×10 M
[142]
KC
G6P binding constant
1×10-4 M
Assumed the same as
KA
KD
ADP binding constant
1.26×10-4 M
[142]
KiC
G6P inhibition constant
27.8×10-3 M
[61]
Gibbs free energy of the
[143]
'0
-24.41 kJ/mol
Δ r GHK
reaction (pH=7)
Reaction 2: Phosphoglucose isomerase (PGI)
G6Pc ⇌ F6Pc
For this reaction, the reactant concentrations are denoted as A = [G6 Pc ] , B =
[ F 6 Pc ] .

The overall reaction flux equation is given by

J PGI

Parameter
KA
KB
'0
Δ r GPGI

Vmaxf 
B 
 A  ' 
KA 
K eq 


A 
B 
1 
1 

 K A  K B 

(C.102)

Table A26: PGI model kinetic parameters
Definition
Value
G6P binding constant
0.59 103 M
F6P binding constant
0.095 103 M
Gibbs free energy of the
3.18 kJ/mol
reaction (pH=7.4)

Source
[144]
[144]
[143]

Reaction 3: Phosphofructokinase (PFK)
F6Pc + ATPc ⇌ F16BPc+ADPc+H+
The reactant concentrations are denoted as A =
[ F16 BPc ] ,

D=

[ F 6 Pc ] ,

B=

[ ATPc ] ,

C=

[ ADPc ] .

PFK is the key regulatory enzyme for glycolysis. It follows sigmodial kinetics
with respect to F6P. ATP allosterically inhibits PFK by decreasing its affinity for F6P
(i.e. increasing binding constant of F6P), whereas AMP and ADP compete for the
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allosteric site and reverse the inhibitory action of ATP [99]. In addition, PFK is inhibited
by cytosolic citrate [61, 99].
Thus, the reaction flux equation is modified to account for the regulatory effects
of ATP, ADP, AMP and citrate based on [145]. The proportion of PFK in active state (R
state) is given by
p

1
1 L

(C.103)

where

ATPc
1 
 K i , ATP

n

n

 
CITc 
 1 

Ki ,CIT 


L
n
n
 F 6 Pc F16 BPc  
AMPc  
ADPc

 1 
1 
 1 
KA
KC   K a , AMP   K a , ADP






n

(C.104)

Even though fructose 2,6-bisphosphate is also an activator of PFK, its
physiological concentration (30 µM) is sufficient to fully activate PFK (half maximal
activation occurs at ~2µM) [100]. Thus, its effect is not considered in this model.
The overall reaction flux equation

J PFK is

given by

Vmaxf 
CD 
 AB  ' 
K AKB 
K eq 


A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 
p

J PFK

(C.105)

The activation constants or inhibition constants were estimated based on available
data from rat lung PFK shown in Figure A15. In Figure A15, symbols are experimental
data obtained from [100] and [146] and solid lines are model flux (C.105) fits to the data
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Figure A15: (A) Effect of citrate concentration on normalized enzyme activities measured
in isolated adult rat lung. Symbols are experimental data obtained from [146] and solid
lines are model fits of Equation (C.105) to the data. (B) Effect of ATP concentration on
apparent S0.5 of F6P measured in rat lung. S0.5 is defined as the concentration by which
half maximal velocity is achieved. (C) Effect of AMP and ADP inhibition on normalized
enzyme activity. Symbols in (B) and (C) are experimental data obtained from [100] and
solid lines are model fits. (D) Predicted cooperative feature of PFK with respect to F6P
under different ATP concentrations.

Parameter
KA
KB
KC
KD
KiCIT
KiATP
KaAMP
KaADP
n
'0
Δr GPFK

Table A27: PFK model kinetic parameters
Definition
Value
Source
3
F6P binding constant
[147]
0.032 10 M
3
ATP binding constant
[147]
0.020 10 M
F16BP binding constant 0.032 103 M
Assumed the same as KA
3
ADP binding constant
Assumed the same as KB
0.020 10 M
3
CIT inhibition constant
Estimated from Figure A15
5.5 10 M
6
ATP inhibition constant
Estimated from Figure A15
4.9 10 M
6
AMP activation constant 1.75 10 M
Estimated from Figure A15
6
ADP activation constant 3.5 10 M
Estimated from Figure A15
Hill coefficient
2.3
Estimated from Figure A15
[143]
Gibbs free energy of the -23.24 kJ/mol
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reaction (pH=7)

Reaction 4: Aldolase and triose phosphate isomerase (ALD)
F16BPc ⇌ 2GAPc
This is a lumped reaction of F16BP aldolase and triose phosphate isomerase
F16BP Aldolase: F16BP ⇌ GAP + DHAP
Triose phosphate isomerase: DHAP ⇌ GAP
The reactant concentrations are denoted as A =
overall reaction flux equation

J ALD

'0
Δr GALD

B=

[GAPc ] .

The

is given by

J ALD

Parameter
KA
KB

[ F16 BPc ] ,

Vmaxf 
B2 
 A  ' 
KA 
K eq 


A 
B2 
1

1



2 
 K A  K B 

(C.106)

Table A 28: ALD model kinetic parameters
Definition
Value
Source
6
F16BP binding constant
[148]
1.7 10 M
6
GAP binding constant
Assumed
the same as KA
1.7 10 M
Gibbs free energy of the
[143]
30.7 kJ/mol
reaction (pH=7)

Reaction 5: Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH)
GAPc + Pic + NADc ⇌ BPGc + NADHc + Hc
The reactant concentrations are denoted as A =
=

[ BPGc ] ,

[GAPc ] ,

B=

[ Pic ] ,

C = [ NADc ] , D

E = [ NADH c ] . NAD/NADH are considered cofactor pairs. The overall

reaction flux equation

J GAPDH

is given by
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J GAPDH

Parameter
KA
KB
KC
KD
KE
'0
Δr GGAPDH

Vmaxf 
DE 
 ABC  ' 
K AKB 
K eq 


A 
C
E 
B 
D 

 1 
1 
 1 
1 

 K A   KC K E   K B  K D 

(C.107)

Table A29: GAPDH model kinetic parameters
Definition
Value
Source
6
GAP binding constant
[149]
20.7 10 M
3
Pi binding constant
Set to initial concentration
2.9 10 M
6
NAD binding constant
[149]
17.8 10 M
6
BPG binding constant
Assumed
the same as KA
20.7 10 M
6
NADH binding constant
Assumed the same as KC
17.8 10 M
Gibbs free energy of the
[143]
-1.21 kJ/mol
reaction (pH=7)

Reaction 6: Phosphoglycerate Kinase (PGK)
BPGc + ADPc ⇌ PEPc + ATPc
The reactant concentrations are denoted as A =
,D=

[ ATPc ] .

equation

[ BPGc ] ,

B=

[ ADPc ] ,

C = [ PEPc ]

ADP/ATP is considered a cofactor pair. Thus, the overall reaction flux

J PGK is

given by

J PGK

Vmaxf 
CD 
 AB  ' 
K AKB 
K eq 


A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 

(C.108)

Table A30: PGK model kinetic parameters
Parameter
Definition
Value
Source
3
KA
BPG binding constant
[150]
0.0110 M
KB
ADP binding constant
Assumed the same as KD
0.4 103 M
3
KC
PEP binding constant
Assumed the same as KA
0.0110 M
3
KD
ATP binding constant
[150]
0.4 10 M
Gibbs
free
energy
of
the
[143]
'0
-5.85 kJ/mol
Δr GPGK
reaction (pH=7)
Reaction 7: Pyruvate Kinase (PK)
PEPc + ADPc + Hc ⇌ PYRc + ATPc
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The reactant or regulator concentrations are denoted as A =
C = [ PYRc ] , D =

[ ATPc ] .

[ PEPc ] ,

B=

[ ADPc ] ,

E= [ F16BPc ] .ADP/ATP is considered a cofactor pair. The

enzyme is known to be strongly activated by low concentration of F16BP [151, 152].
The overall reaction flux equation

J PK 

Parameter
KA
KB
KC
KD
KaE
'0
Δ r GPK

J PK

is given by

Vmaxf  E  
CD 

  AB  ' 
K A K B  K aE  E  
K eq 

A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 

(C.109)

Table A31: PK model kinetic parameters
Definition
Value
Source
PEP binding constant
[151]
0.26 103 M
3
ADP binding constant
[151]
0.40 10 M
3
PYR binding constant
Assume the same as KA
0.26 10 M
ATP binding constant
Assume the same as KB
0.40 103 M
6
F16BP activation constant
[151]
110 M
Gibbs free energy of the
[143]
-28.89 kJ/mol
reaction (pH=7)

Reaction 8: Lactate Dehydrogenase (LDH)
PYRc + NADHc + Hc ⇌ LACc + NADc+
The reactant concentrations are denoted as A =
[ LACc ] ,

D=

[ NADc ] .

reaction flux equation

[ PYRc ] ,

B=

[ NADH c ] ,

C=

NAD/NADH is considered a cofactor pair. Thus, the overall
J LDH is

given by

J LDH

Vmaxf 
CD 
 AB  ' 
K AKB 
K eq 


A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 

(C.110)
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Parameter
KA
KB
KC
KD
'0
Δr GLDH

Table A32: LDH model kinetic parameters
Definition
Value
Source
3
PYR binding constant
[153]
0.052 10 M
6
NADH binding constant
Fixed to initial
0.68 10 M
concentration
LAC binding constant
[153]
4.934 103 M
6
NAD binding constant
Fixed to initial
340 10 M
concentration
Gibbs free energy of the
[143]
-23.9 kJ/mol
reaction (pH=7)

Reactions 9 and 10: Pentose phosphate pathway reactions (PPP)
6-Phosphogluconate Dehydrogenase (6PGDH)
G6Pc + 2NADPc ⇌ R5Pc + 2NADPHc+ 2Hc+ CO2;
R5Pc ⇌ 5 G6Pc ;
6

Δ r G '0 =-34.23

Δ r G '0

=-20.66 kJ/mol

kJ/mol

Overall equation for the pentose phosphate pathway:
1
'0
=-54.89 kJ/mol
G6Pc +2NADPc ⇌ CO2 +2NADPHc +2Hc ; Δ r GPPP
6

The reactant concentrations are denoted as A =
D=

[G6 Pc ] ,

B=

[ NADPc ] ,

C = [CO2 ] ,

[ NADPH c ] .

 1/6 2 CD 2 
 A B  ' 
K A1/6 K B2 
K eq 


A1/6 C  B 2 D 2 
1




1 

1/6
KC   K B2 K D2 
 KA
Vmaxf

J PPP

Parameter
KA
KB
KC
KD
'0
Δ r GPPP

Table A33:PPP model kinetic parameters
Definition
Value
G6P binding constant
36 106 M
NADP binding constant
4.8 106 M
PG6 binding constant
36 106 M
NADPH binding constant
4.8 106 M
Gibbs free energy of the
-54.89 kJ/mol
reaction (pH=7)

(C.111)

Source
[154]
[154]
[154]
[154]
[155]
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Reaction 11: Glutathione reductase (GSR)
GSSGc + Hc + NADPHc ⇌ 2GSH + NADPc+

J GSR

Vmaxf 
BC 
 A  ' 
KA 
K eq 


A
B 
C 


1 
 1 
 K A K B  KC 

(C.112)

Table A34: GSR model kinetic parameters
Definition
Value
Source
GSSG binding constant
[156]
61106 M
6
NADPH binding constant
[156]
7.6 10 M
6
GSH binding constant
Assumed
the same as KA
6110 M

Parameter
KA
KB
KC
KD

NADP binding constant

7.6 106 M

Assumed the same as KB

Keq'0 ,GSR

Equilibrium constant (pH=7)

0.075

[157]

Reaction 12: GSH Peroxidase (GPx)
2GSHc + H2O2,c ⇌ GSSGc + 2H2O
The reactant concentrations are denoted as A =
[GSSGc ] .The

equation

[ H 2O2 ] ,

C=

given by

J GPx

'0
Δ r GGPx

B=

reactant H2O is ignored for this reaction. Thus, the overall reaction flux

J GPx is

Parameter
KA
KB
KC

[GSH c ] ,

Vmaxf  2
C 
A
B



K A2 K B 
K eq' 


A2 C 
B 
1  2 
1 

 K A KC   K B 

(C.113)

Table A35: GPx model kinetic parameters
Definition
Value
Source
3
GSH binding constant
[158]
3 10 M
6
H2O2 binding constant
[158]
110 M
GSSG binding constant
Assumed the same as KA
3 103 M
Gibbs free energy of the
reaction (pH =7)

-275.7 kJ/mol

[143]
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Reaction 13: ATPase
ATPc ⇌ ADPc + Pic+ Hc+

J ATPase

Parameter
KA
KB
KC
'0
Δr GATPase

Vmaxf 
BC 
 A  ' 
KA 
K eq 


A
B 
C 


1 
 1 
 K A K B  KC 

Table A36: ATPase model kinetic parameters
Definition
Value
ATP binding constant
1103 M
ADP binding constant
100 106 M
Pi binding constant
1103 M
Gibbs free energy of the reaction
(pH=7)

-36.03 kJ/mol

(C.114)

Source
Fixed
Fixed
Fixed
[143]

Reaction 14: Adenylate kinase (AK)
AMPc + ATPc ⇌ 2ADPc

J AA

Parameter
KA
KB
KC

Vmaxf 
B 
 A  ' 
KA 
K eq 


A 
B 
1 
1 

 K A  K B 

Table A37: AK model kinetic parameters
Definition
Value
ATP binding constant
1103 M
AMP binding constant
10 106 M
ADP binding constant
100 106 M

(C.115)

Source
[112]
[112]
[112]

Gibbs free energy of the
[143]
-0.475 kJ/mol
reaction (pH=7)
For this rapidly equilibrating reaction,Vmaxf was set to be 1e7 nmol/min/lung.
'0
Δ r GAK

Reaction 15: Alanine Aminotransferase (AA) [61]
ALAc ⇌ PYRc
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J HK 

Parameter
KA
KB
'0
Δ r GAA

Vmaxf  KiC  
CD 

  AB  ' 
K A K B  KiC  C  
K eq 

A 
C 
B
D 

 1 
1 
 1 

 K A   KC   K B K D 

Table A38: AA model kinetic parameters
Definition
Value
ALA binding constant
1103 M
PYR binding constant
100 106 M
Gibbs free energy of the reaction (pH=7)

-20 kJ/mol

(C.116)

Source
[61]
[61]
[61]

Mitochondrial reactions
For the mitochondrial regions, the reaction flux equations are the same as those in our
integrated model of the bioenergetics of mitochondria isolated from rat lungs [24].
Values of pertinent parameters were set to those estimated for our mitochondria model
[24]. Detailed reaction fluxes are listed in
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Appendix III: Flux expressions for metabolic reactions and transport processes for
the isolated mitochondria model.
Transport Fluxes
Transport 1: Glucose transporter (GLUT)
Glucose transport between blood and cytosol is controlled by AMPK (AMPactivated protein kinase). As energy charge falls, glucose transport is activated by
AMPK. Thus, the flux equation is modified to account for the cytosolic AMP effect on
glucose transport.
GLCb ⇌ GLCc

J GLUT

Parameter
KGLC


  [GLCb ] [GLCc ] 
AMPc
Tmax f 



K a , AMP  AMPc   KGLC
KGLC 


[GLCb ] [GLCc ]
1

KGLC
KGLC

(C.117)

Table A 39:GLUT model kinetic parameters
Definition
Value
Source
[23]
GLC binding constant
3.4 103 M
Fixed to AMP initial

Ka, AMP

AMP activation
constant

0.21103 M

concentration

Transport 2: Pyruvate transporter (PYRT)
This transport process is catalyzed by the enzyme monocarboxylate transporter
(MCT). Km for pyruvate and lactate are 0.1 mM and 0.7 mM, respectively [159].
PYRb + Hb+ ⇌ PYRc + Hc+

J PYRT

 [ PYRb ][ H b ] [ PYRc ][ H c ] 
Tmax f 


K PYR K H
K PYR K H 


[ PYRb ] [ PYRc ] [ H b ] [ H c ] [ PYRb ] [ H b ] [ PYRc ] [ H c ]
1





K PYR
K PYR
KH
KH
K PYR K H
K PYR K H

(C.118)
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Parameters
KPYR

Table A40: PYRT model kinetic parameters
Definition
Value
PYR binding constant

0.1103 M

Source
[159]

Transport 3: Lactate transporter (LACT)
LACb + Hb+ ⇌ LACc + Hc+

J LACT

 [ LACb ][ H b ] [ LACc ][ H c ] 
Tmax f 


K LAC K H
K LAC K H 


[ LACb ] [ LACc ] [ H b ] [ H c ] [ LACb ] [ H b ] [ LACc ] [ H c ]
1





K LAC
K LAC
KH
KH
K LAC K H
K LAC K H

Parameters
KLAC

Table A 41: LACT model kinetic parameters
Definition
Value
LAC binding constant

0.7 103 M

(C.119)

Source
[159]

Transport 4: Phosphate transporter (PIT)
Phosphate is co-transported with sodium ions (Na+) between blood and cytosol.
Na+ concentration is assumed to be constant in this model. Therefore, the flux equation is
simplified to

J PIT

Parameters
KPi

 [ Pi ] [ Pi ] 
Tmax f  b  c 
K Pi 
 K Pi

[ Pi ] [ Pi ]
1 b  c
K Pi
K Pi

Table A42: PIT model kinetic parameters
Definition
Value
Pi binding constant

2 103 M

(C.120)

Source
Fixed

Transport 5-11 are the same as in the mitochondria model.
Transport 12: Malate-Aspartate Shuttle (MAS)
Four reactions and two transport fluxes are involved in Malate-aspartate shuttle,
namely cytosolic MDH (MDH1), mitochondrial MDH (MDH2), cytosolic GOT and
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mitochondrial GOT, OME and GAE. For simplicity and in order to reduce number of
unknown parameters, the overall process is treated as one transporter.
NADHc + NADm+ ⇌ NADHm + NADc+
The transporter GAE is driven by membrane potential. In addition, the
equilibrium constants of MDH is affected by pH. Therefore, the apparent equilibrium
constant for MA shuttle is

 F  m 
Keq ,MA  Keq ,GAE Keq ,MDH 1Keq , MDH 2  exp 
10 pH m  pHc

 RT 

(C.121)

The overall flux equation is defined as


 NADH m  NADc  
  NADH c  NADm  

K NADH K NAD 
K eq'


  NADH c  NADm   NADH m  NADc  

1 

K NADH K NAD
K NADH K NAD


Tmax f

J MAS

Parameters
KNADH KNAD

Table A43: MAS model kinetic parameters
Definition
Product of NADH binding constant and NAD
binding constant

(C.122)

Value
1106 M

Transport 13: Passive Proton Leak [46], is the same as the mitochondria model

Appendix VI: Governing mass balance equations for the lung tissue
bioenergetics model
Reservoir region:
d [GLCr ]
 F  [GLCb ]  [GLCr ]
dt
d [ PYRr ]
Vr
 F  [ PYRb ]  [ PYRr ]
dt
d [ LACr ]
Vr
 F  [ LACb ]  [ LACr ]
dt
d [ Pir ]
Vr
 F  [ Pib ]  [ Pir ]
dt
Vr

Vr

d [ H r ]
 F  [ H b ]  [ H r ]
dt

(C.123)
(C.124)
(C.125)
(C.126)
(C.127)
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where F is the perfusion flow rate of isolated perfused rat lung system.
Vascular region
d [GLCb ]
 F  [GLCr ]  [GLCb ]  J GLUT
dt
d [ PYRb ]
Vb
 F  [ PYRr ]  [ PYRb ]  J PYRT
dt
d [ LACb ]
Vb
 F  [ LACr ]  [ LACb ]  J LACT
dt
d [ Pib ]
Vb
 F  [ Pir ]  [ Pib ]  J PIT
dt

(C.128)

d [ H b ]
 F  [ H r ]  [ H b ]  J LACT  J PYRT
dt

(C.132)

Vb

Vb

(C.129)
(C.130)
(C.131)

Cytosolic region
Vc
Vc

Vc
Vc

Vc
Vc
Vc
Vc
Vc
Vc
Vc
Vc
Vc
Vc

d [GLCc ]
 J GLUT  J HK
dt
d [G6 Pc ]
5
 J HK  J PGI  (1  ) J PPP
dt
6
d [ F 6 Pc ]
 J PGI  J PFK
dt
d [ F16 BPc ]
 J PFK  J ALD
dt
d [GAPc ]
 2  J ALD  J GAPDH
dt
d [ BPGc ]
 J GAPDH  J PGK
dt
d [ PEPc ]
 J PGK  J PK
dt
d [ PYRc ]
 J PK  J LDH  J PYRT  J PYRH
dt
d [ LACc ]
 J LDH  J LACT
dt
d [ PG 6c ]
0
dt
d [ MALc ]
  J DCC ( MAL )  JTCC
dt
d [ PEPc ]
 J PGK  J PK
dt
d [ PYRc ]
 J PK  J LDH  J PYRT  J PYRH
dt
d [ LACc ]
 J LDH  J LACT
dt

(C.133)
(C.134)
(C.135)
(C.136)
(C.137)
(C.138)
(C.139)
(C.140)
(C.141)
(C.142)
(C.143)
(C.144)
(C.145)
(C.146)
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Vc
Vc
Vc
Vc
Vc

Vc
Vc

Vc
Vc

Vc
Vc

Vc
Vc

Vc
Vc

Vc

d [CITc ]
 JTCC
dt
d [ SUCc ]
  J DCC ( SUC )
dt
d [GLU c ]
  J GLUH
dt
d [ ASPc ]
0
dt
d [ Pic ]
 J PIT  J PIC  J DCC ( SUC )  J DCC ( MAL )  J GAPDH  J ATPase
dt
d [ AMPc ]
  J AK
dt
d [ ADPc ]
 J HK  J PFK  J PGK  J PK  2  J AK  J ATPase  J ANT
dt
d [ ATPc ]
  J HK  J PFK  J PGK  J PK  J AK  J ATPase  J ANT
dt
d [ NADH c ]
 J GAPDH  J LDH  J MAS
dt
d [ NADc ]
d [ NADH c ]
 Vc
dt
dt
d [ NADPH c ]
 2  J PPP  J GSR
dt
d [ NADPc ]
d [ NADPH c ]
 Vc
dt
dt
d [GSSGc ]
  J GSR  J GP
dt
d [GSH c ]
 2 J GSR  2 J GP
dt
d [ H 2O2,c ]
0
dt
d[ H c ]
0
dt

(C.147)
(C.148)
(C.149)
(C.150)
(C.151)
(C.152)
(C.153)
(C.154)
(C.155)
(C.156)
(C.157)
(C.158)
(C.159)
(C.160)
(C.161)
(C.162)

Mitochondria region
The ordinary differential equations in mitochondria are the same as in the
mitochondria model, for completeness, the equations are listed as below
d [GLU m ]
 J GOT  J GLUH
dt
d [ ASPm ]
Vm
  J GOT
dt
d [ PYRm ]
Vm
  J PDH  J PYRH
dt
d [OXAm ]
Vm
 J MDH  J CITS  J GOT
dt
Vm

(C.163)
(C.164)
(C.165)
(C.166)
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Vm
Vm
Vm
Vm
Vm
Vm
Vm

d [CITm ]
  J CITS  J ICDH  JTCC
dt
d [ AKGm ]
 J ICDH  J AKGDH  J GOT
dt
d [ SCAm ]
 J AKGDH  J SCAS
dt
d [ SUCm ]
 J SCAS  J SDH  J DCC ( SUC )
dt
d [ FUM m ]
 J SDH  J FH
dt
d [ MALm ]
 J FH  J MDH  J DCC ( MAL )  JTCC
dt
d [ FADH 2,m ]
 J SDH  J CII
dt

(C.167)
(C.168)
(C.169)
(C.170)
(C.171)
(C.172)
(C.173)

Vm

d [ FADH 2,m ]
d [ FADm ]
 Vm
dt
dt

(C.174)

Vm

d [ NADH m ]
 J MAS  J PDH  J ICDH  J AKGDH  J MDH  J CI
dt

(C.175)

Vm

d [ NADm ]
d [ NADH m ]
 Vm
dt
dt

(C.176)

d [ ATPm ]
  J ANT  J NDK  J CV
dt
d [ ADPm ]
d [ ATPm ]
 Vm
dt
dt
d [GTPm ]
 J SCAS  J NDK
dt
d [GDPm ]
d [GTPm ]
 Vm
dt
dt
d [ ACoAm ]
 J PDH  J CITS
dt
d [CoAm ]
  J PDH  J CITS  J SCAS  J AKGDH
dt
d [ Pim ]
 J PIC  J SCAS  J CV  J DCC ( MAL )  J DCC ( SUC )
dt

(C.177)

Vm
Vm

Vm
Vm

Vm
Vm

Vm

 J HLEAK  J GAE  JTCC  2 J PIC  J GLUH 


d [ H m ]
2.303
 (1  2) J PDH  2 J CITS  J AKGDH  J SCAS 
Vm

C 
dt
 mit m, H   J MDH   4  1 J CI  2 J CIII  4 J CIV 


   3  1 J

CV



d [UQm ]
  J CI  J CII  J CIII
dt
d [UQH 2 m ]
d [UQm ]
Vm
 Vm
dt
dt
Vm

(C.178)
(C.179)
(C.180)
(C.181)
(C.182)
(C.183)

(C.184)

(C.185)
(C.186)
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d 
1

 4 JCI  2 JCIII  4 J CIV  3J CV  J HLEAK  J ANT  J MAS 
dt
Cimm

(C.187)

Oxygen consumption:
Oxygen concentration was assumed constant in the isolated perfused rat lung
experiments.
d [O2 ]
0
dt

(C.188)

